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Zusammenfassung 
Ein Methicillin resistenter Staphylococcus aureus (MRSA), hat sich in den letzten Jahren 
unter den Drogenabhängigen der Region Zürich ausgebreitet, der nur eine sehr geringe 
Methicillin Resistenz mit einem heterogenen Resistenzprofil exprimiert. Im Jahre 2003 
konnten 25 % aller identifizierten MRSA Isolate am Institut für Medizinische Mikrobiologie der 
Universität Zürich diesem endemischen Klon zugeordnet werden. Die Methicillin Resistenz 
wird in diesem sich verbreitenden Klon durch das mecA Gen, welches für PBP2a kodiert, 
und das auf einem neuartigen staphylococcal cassette chromosome mec (SCCmec) Element 
liegt, verursacht. Dieser Resistenzphänotyp führte ursprünglich zu Fehlidentifikation und des 
weiteren zu Behandlungsversagen. Um seine diagnostische Identifikation zu vereinfachen 
wurde das SCCmec eines repräsentativen „Drogen-Klons“ kartiert und teilweise sequenziert. 
Viele Faktoren die das Methicillin Resistenzniveau und die heterogene/homogene 
Expression in klinischen MRSA Isolaten bestimmen, sind noch immer unbekannt. Bei der 
Suche nach der Ursache der niedrigen Methicillin Resistenz des „Drogen-Klons“, wurde eine 
Punktmutation in der mecA Promoter Region gefunden, welche die mecA Transkription 
vermindert. Die Untersuchung der mecA Promoter Region, mecA-Transkription und PBP2a 
Menge ergab jedoch, dass das Resistenzniveau in diesem MRSA hauptsächlich durch den 
chromosomalen Hintergrund bestimmt wird und nur zu einem geringen Mass durch die mecA 
Promoter Mutation, welche die mecA Transkription beeinflusst. 
Die mecA-Induktion wird durch den Repressor und Sensor MecI/MecR1 reguliert, jedoch 
wird angenommen, dass zusätzliche Faktoren darin involviert sind. Durch ein Screening von 
Proteinen die an den mecA Promoter binden, wurde ein bis anhin uncharakterisiertes DNA-
bindendes Protein, mit einem typischen helix-turn-helix Motiv herausgefiltert, das am 5’ Ende 
der mecA kodierenden Sequenz bindet. In verschiedenen MRSA Stämmen mit heterogener 
Methicillin Resistenz resultierte die Deletion dieses DNA-bindenden Proteins 
interessanterweise in erhöhter Methicillin Resistenz. Da weder mecA-Induktion, -
Transkription noch PBP2a Menge in den Deletionsmutanten verändert war, muss die 
modifizierte Resistenzhöhe auf die Regulation von unbekannten chromosomalen Faktoren 
zurückgeführt werden.  
Um chromosomale Faktoren, die für die Methicillin Resistenzhöhe verantwortlich sind zu 
identifizieren, wurde von diesem „Drogen-Klon“ mittels zufälliger Integration eines 
Transposons eine Bibliothek erstellt und nach Mutanten mit veränderter Methicillin 
Resistenzhöhe gesucht. Aus 8064 Mutanten wurden 17 Gene identifiziert, die 8 
verschiedenen Funktionsklassen zugeteilt werden konnten, und zu einer mehrheitlich 
reduzierten Methicillin Resistenz führten. Um ihre Funktion in Bezug auf Methicillin Resistenz 
zu verstehen, sind weitere Untersuchungen nötig. 
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Summary 
Increasing numbers of a methicillin resistant Staphylococcus aureus (MRSA) clone were 
detected in the intravenous drug user community in the area of Zurich. In 2003 25% of all 
MRSA isolates identified at the Institute of Medical Microbiology, University of Zurich, 
belonged to this endemic clone. Although this successful clone carries mecA encoding 
PBP2a, which confers methicillin resistance, it expresses very low heterogeneous methicillin 
resistance causing misidentification and treatment failure. The novel staphylococcal cassette 
chromosome mec (SCCmec) of this strain has been mapped and partially sequenced to 
simplify its diagnostic detection.  
Many factors influencing methicillin resistance levels and its heterogeneous/homogeneous 
expression in clinical MRSA isolates are still unknown. A search for the reason for the 
extremely low level methicillin resistance of this particular clone, revealed a point mutation in 
the mecA promoter region reducing mecA transcription. However, characterisation of the 
mecA promoter region, mecA transcription and PBP2a amounts, showed that resistance 
levels of MRSA were mainly determined by the chromosomal background and only to a small 
extent by mecA promoter mutations affecting levels of mecA transcription.  
Since factors involved in the pathway of mecA induction have not yet been completely 
identified, and it has been postulated that another factor, in addition to MecI/MecR1 is also 
involved, a screen for proteins binding to the mecA promoter region was performed. This 
allowed the identification of a previously uncharacterised DNA-binding protein, with a 
characteristic helix-turn-helix motif, binding to the 5’ end of the mecA coding sequence. 
Deletion mutants in different genomic backgrounds of heterogeneously resistant MRSA, 
exhibited increased methicillin resistance levels. As no interference with mecA induction, 
transcription or translation was detected, the modified resistance levels have to be ascribed 
to unknown chromosomal factors controlled by this DNA-binding protein. 
Construction of a random transposon mutant library, using this low level methicillin resistant 
clone, allowed identification of a set of new genes affecting methicillin resistance levels. 
Seventeen new orfs belonging to eight different functional classes were confirmed to alter 
methicillin resistance levels upon their inactivation. Their relative functions in respect to 
methicillin resistance still need to be characterised. 
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1. Introduction 
1.1 Staphylococcus aureus 
Staphylococcus aureus is a member of the family micrococcaceae, it is a Gram-positive, 
non-motile, low G-C, facultatively anaerobic coccus, that can behave as both a commensal 
and a harmful human pathogen. Twenty five to 30 % of healthy people are colonised by 
opportunistic S. aureus in their nasal passages, and on skin and mucous membranes (4, 42). 
Typical distinguishing features of S. aureus include the production of coagulase, clumping 
factor, catalase and β-hemolysis. In general, the most common diseases caused by S. 
aureus are skin- and soft-tissue infections, impetigo, abscesses, pneumonia, sepsis and 
foreign body associated infections (70). Two main factors are responsible for the widespread 
pathogenic success of S. aureus, the first is its large range of virulence factors causing a 
wide range of serious diseases and the second is its strong persistence in hospital settings 
due to the acquisition of antibiotic resistance determinants especially methicillin resistance, 
which confers resistance to virtually all β-lactams and their derivatives (4).   
 
1.2 Antibiotics 
Antibiotics are substances produced by bacteria or fungi, or synthetic compounds, which at 
low concentrations have the ability to kill or inhibit the growth of other bacteria/fungi. 
Antibiotics generally interfere with a much higher affinity to pathways or structures of the 
bacteria than to target homologues found in the eukaryotic host; thus killing the bacteria 
while causing no, or little harm to the eukaryotic host. Modification of existing antibiotics can 
improve their host range, efficacy, and pharmacokinetics. A broad spectrum of antibiotics is 
available for treatment of all kinds of infections caused by diverse bacteria (121).  
Antibiotics can be classified into two categories, according to their bacteriostatic or 
bactericidal activity in vitro. This classification strongly depends on conditions, such as the 
bacterial growth rate, bacterial killing kinetics, duration of exposure to the antibiotic, bacterial 
density, and the organism targeted. However, as the bacteriostatic/bactericidal activity is 
determined in vitro, the actual efficacy can differ in vivo depending on the growth stage (86). 
Antimicrobial potency also depends on the bacterial growth conditions. Free growing, 
planctonic bacteria are affected more easily by bactericidal antibiotics than sessile bacteria 
that persist within a biofilm. Increased tolerance to antibiotics in sessile bacteria might be 
partially caused by restricted access of the antibiotic to the cells, as they are enclosed within 
an extracellular matrix, but is mostly attributed to their slower growth rate, reduced antibiotic 
up take due to decreased metabolic activity and their altered gene expression. Other factors 
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suggested to influence resistance in biofilms are oxygen-/nutrient-limitation, pH, and the 
accumulation of toxic metabolites (17, 26, 94, 103).  
Main targets of antibiotics include bacterial peptidoglycan synthesis, DNA replication, 
transcription, protein synthesis, and folate coenzyme biosynthesis (Figure 1) (122).  
Bacteria have, however, struck back by evolving several resistance strategies. Their high 
mutation rate of 1:107 and their ability to easily take up new resistance determinants, 
combined with antibiotic selection pressure, drive the emergence of resistant clones (25, 
121). The speed and frequency with which resistance arises and spreads varies between 
different bacterial species and different antibiotics (14). Three main resistance strategies 
have been identified: 
I) Antibiotic exclusion, by active efflux or decreased permeability. 
II) Antibiotic inactivation, by enzymatic degradation or modification through phosphorylation, 
thiol transfer, acylation, glycosylation, nucleotidylation, or ribosylation. 
III) Target alteration, by modification of the target site via mutation, or amplification of the 
target, or acquisition of new resistant targets (108, 121, 128). 
Pathogens, using several of these strategies, are accumulating more and more resistances 
and their multi-resistance is causing treatment failures. To delay resistance emergence four 
key strategies have been proposed. First, to determine the optimal use of antibiotics and 
prevent treatment with subinhbitory concentrations; second, to limit and control the use of 
antimicrobials; third the rotational use of antibiotics; and finally, application of combination 
therapy to reduce mutation frequencies (80, 108). But there is still a strong need for the 
development of new antimicrobial substances to ensure continued treatment options for the 
growing number of multiresistant microorganisms. 
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Figure 1.  
Schematic overview of antibacterial targets. a, Peptidoglycan biosynthesis. b, Protein biosynthesis. c, DNA and 
RNA replication. d, Folate metabolism, synthesis of the essential DNA component thymine. Targets of antibiotics 
are indicated by red lines. Taken from (122). 
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1.2.1 Cell wall 
Cell wall synthesis is a major antibacterial drug target. The cell wall of S. aureus consists of 
20-50 networked peptidoglycan layers, is ~ 40 nm thick (75) and determines the cell shape 
and provides the high stability necessary to overcome environmental pressures while 
maintaining a high flexibility.  
The major subcomponent of the staphylococcal peptidoglycan consists of alternating N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acid (MurNAc) forming a β-1,4-linked 
disaccharide, with a pentapeptide L-Ala-D-iGln-L-Lys-D-Ala-D-Ala (stem peptide) attached to 
the MurNAc. The majority of glycan chains have a length of 3 to 10 disaccharide units 
whereas a small minority of 10-15 % can reach a length of more than 26 disaccharides (12).  
In the cytoplasmic steps of peptidoglycan synthesis, fructose-6-phosphate is converted by 
GlmS, GlmM and GlmU to glucosamine-6-phosphate, glucosamine-1-phosphate and UDP-
GlcNAc, respectively. This is followed by the synthesis of UDP-MurNAc from UDP-GlcNAc in 
two steps by MurA and MurB (Figure 2). The amino acids of the stem peptide are 
sequentially added to the carboxyl group of UDP-MurNAc by MurC (L-Ala), MurD (D-Glu), 
MurE (L-Lys), and MurF (D-Ala2). The α-carboxyl group of the D-Glu is amidated in an ATP- 
and ammonia-dependent reaction resulting in D-iGln (112). Proteins thought to be involved in 
the amidation step are GlnA, glutamine synthetase, and its regulator GlnR, as interruption of 
glnR resulted in reduced amidation (43). In the next step MraY transfers the UDP-MurNAc-
pentapeptide to the membrane acceptor (undecaprenylphosphate) generating the lipid I 
precursor. GlcNAc, added by MurG, completes the peptidoglycan monomer subunit called 
lipid II. Five glycines are then sequentially added at the ε-amino group of lysine by FmhB, 
FemA and FemB using glycyl-tRNA as donor (56). FmhB is essential and responsible for the 
incorporation of the first glycine (98), FemA attaches the 2nd and the 3rd glycines and FemB 
the 4th and the 5th (113). Translocation of the lipid II precursor with its accessory pentaglycine 
chain to the outside of the membrane is catalysed by a translocase or flippase that has not 
yet been identified (104).  
The disaccharides on the outside of the cell membrane are polymerised by 
transglycosylation, and the stempeptides are crosslinked by pentaglycine chains connecting 
L-Lys of the first stem peptide with D-Ala at position 4 of a neighbouring peptidogylcan 
strand, by transpeptidation (39, 64, 132). It is the cleavage of the terminal D-Ala during 
transpeptidation that provides the energy necessary to crosslink the stem peptides (64, 104). 
The pentaglycine is able to crosslink stem peptides of different peptidoglycan strands 
resulting in a three-dimensional peptidoglycan network with an extremely high crosslinkage 
degree of 80 - 90% (32, 130, 131). 
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Transpeptidation and transglycosylation are catalyzed by penicillin binding proteins (PBPs); 
D,D-acyltransferases all belonging to the serine acetyltransferase group I family. Group II 
and III members are acetyltransferases with diverse functions, which are either not involved 
or indirectly involved in peptidoglycan synthesis, or are penicillin-resistant L,D-
acetyltransferases, respectively. There are three motifs that are characteristic for the group I 
family, SxxK, SxN (SxD) and KTG (KSG). S. aureus possesses four known group I PBPs; 
PBP1-3 are classified as high molecular weight (HMW) and PBP4 as a low molecular weight 
(LMW) PBP. HMW PBPs are subdivided into class A and B. PBPs of group A are bifunctional 
enzymes and have a non-penicillin binding domain (nPBD) with transglycosylase activity, 
which is linked to a penicillin-binding domain (PBD) with transpeptidase activity. Group B 
PBPs also have a PBD as well a nPBD, but the function/activity of this nPBD is still unknown 
(15, 38, 131). 
PBP1 is a class B HMW protein, has a size of approximately 87-kDa, is encoded by pbpA 
and is composed of a domain of unknown function and a transpeptidase domain. It is located 
at the division site and was shown to be essential for growth and cell division but has no 
major role in peptidoglycan crosslinking (35, 87, 120). 
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Figure 2.  
Peptidoglycan biosynthesis pathway. I, assembly of the lipid II precursor, with MurA as the first catalytic enzyme; 
II, synthesis of the pentaglycine interpeptide at the lipid II precursor; III, after translocation of the peptidoglycan 
subunit to the surface, polymerisation of the disaccharide units takes place and IV, crosslinking of the stem 
peptides via pentaglycines. Adapted from Rohrer and Schneider et al. (97, 105, 112, 124). 
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PBP2 is a bifunctional 79-kDa HMW, class A PBP encoded by pbpB. It is subdivided into a 
C-terminal transpeptidase domain, and an N-terminal transglycosylase domain which are 
connected by a small linker. The membrane anchor is attached at the N-terminal 
transglycosylase domain as shown in Figure 3. These two domains enable polymerisation of 
the disaccharides and crosslinking of the stem peptides (71, 81, 88). PBP2 has been shown 
to be localised at the division septum, where cell wall synthesis takes place, and to be 
essential for cell growth in S. aureus (90, 92). 
Interruption of pbpC, expressing PBP3, a 75-kDa protein, led to a decreased autolytic rate 
but no other phenotype. Due to its similarity to PBP1, both are class B HMW PBPs with a 
transpeptidase motif, it was suggested that PBP1 could functionally substitute for PBP3, 
explaining the lack of a phenotype associated with peptidoglycan composition or 
crosslinking. Possible functions it could be involved in are septum formation and cell 
separation (35, 89). 
PBP4, encoded by pbpD is the only LMW PBP (45-kDa) in S. aureus. PBP4 has a C-terminal 
membrane anchor, and was shown to have D,D-carboxypeptidase, transpeptidase and β-
lactamase activity (35, 36, 62). As the transpeptidase activity was found to be nonessential, it 
is described as a transpeptidase with secondary cross linking activity (131). Peptidoglycan 
subunits are crosslinked to form up to 17mer multimers; further crosslinking to a higher 
degree is then executed by PBP4, as interruption of PBP4 results in a reduction in the 
proportion of highly crosslinked peptidoglycan chains (31, 67, 111). The second activity of a 
D,D-carboxypeptidase is cleavage of the terminal D-Ala of the stem peptide via hydrolysis, 
preventing further cross linking of the peptidoglycan chains (132). 
 
 
       
       Figure 3. 
Structure of the bifunctional PBP2. The 
transpeptidase domain, the linker and the 
transglycosylase domain are coloured in green, 
yellow and in blue, respectively. The putative 
location of the membrane anchor is also indicated 
in blue. Active sites are indicated by red spheres. 
Copied from (71). 
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1.2.2 β-lactam resistance 
1.2.2.1 History 
Penicillin, discovered by Sir Alexander Fleming in 1929, was introduced in 1941 to treat life 
threatening infections caused by S. aureus. Only 1 to 2 years later penicillinase resistant  
S. aureus arose in the hospital environment. The prevalence of penicillinase resistant strains 
increased rapidly within a few years and shortly after penicillin resistant strains also 
appeared in the community (14, 72, 96). Subsequently, in 1959 the semisynthetic, 
penicillinase resistant, β-lactam, methicillin was developed. However, the first methicillin 
resistant S. aureus (MRSA) was already detected in 1961 (55) and this new resistance 
mechanism conferred cross resistance to all β-lactam antibiotics and their derivatives. 
 
1.2.2.2 β-lactam mode of action   
β-lactams, including penicillins, cephalosporins, monobactams, and carbapenems, disrupt 
the balance between peptidoglycan synthesis and degradation thus causing cell lysis (64, 
114). β-lactams all have the β-lactam ring structure in common, which is composed of D-
valine, L-cysteine and a carbonic acid. Recognition of β-lactams by PBPs is due to the 
structural analogy between β-lactams and D-Ala-D-Ala of the stem peptide. 
The transpeptidase function of native PBPs is blocked by β-lactams which bind to the active 
site serine. PBPs and β-lactams initially form a reversible noncovalent Michaelis complex, 
which can either dissociate or undergo acylation to form a stable, covalent acyl-PBP 
intermediate whose breakdown/deacylation is generally very slow and therefore prevents 
peptidoglycan crosslinking. In contrast the D-Ala-D-Ala of the stem peptide, the real 
substrate of the PBPs, is rapidly acylated and deacylated, making the PBPs available for 
further cross linking reactions (15).  
PBP2 is localized at the division septum in growing cells but is dispersed in the presence of 
β-lactam antibiotics. Acylation of the transpeptidase domain of PBP2 prevents substrate 
recognition which results in its dissociation from the septum. Localisation seems to be 
substrate dependent, as blocking or eliminating the substrate also causes dislocation of 
PBP2 from the septum (90, 91, 104). 
β-lactams can have diverse, concentration-dependent effects on bacterial cells. Subinhibitory 
concentrations of penicillin have been shown to block cell growth, lethal doses to induce 
bacteriolysis in a cell cycle dependent manner and very high concentrations to result in 
nonlytic death (37, 74). Recently, Kohanski et. al. (60) provided evidence that lethal 
concentrations of all bacteriocidal antibiotics, including β-lactams, initiate a common 
mechanism of cell death. In both Gram-positive and Gram-negative bacteria, inhibitory 
concentrations of several different classes of antibiotics all disrupted metabolism, leading to 
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hydroxyl radical formation, which damaged proteins and DNA, resulting in cell death. 
Sublethal antibiotic concentrations and bacteriostatic antibiotics, however, did not induce this 
deadly pathway. 
Exposure to β-lactams also triggers global changes in transcription, most notably the 
induction of the cell wall stress stimulon (119). The cell wall stress stimulon is a set of genes 
upregulated in response to cell wall damage and disruption of stimulon induction abolishes β-
lactam resistance (63). Induction of the cell wall stress stimulon requires inhibitory 
concentrations of β-lactams (76), and is consequently strain-variable as the amount of β-
lactam required for induction depends on the strains MIC. 
 
1.2.2.3 Methicillin resistance mechanisms 
Different mechanisms have been found to confer methicillin resistance. In borderline 
resistant S. aureus (BORSA) and modified S. aureus (MODSA) low level methicillin 
resistance is expressed by hyperproduction and/or modification of PBPs, respectively (64). 
The third and by far most common and efficient method is the acquisition of the mecA gene 
encoding PBP2a, a PBP with lower affinity to all β-lactam antibiotics than the cells own 
PBPs. PBP2a, a class B, HMW, 78-kDa PBP with a C-terminal transpeptidase domain, a N-
terminal non-penicillin binding domain and a transmembrane anchor can confer high level 
methicillin resistance (Figure 4). Strains expressing methicillin resistance due to the 
acquisition of mecA, are referred to as methicillin resistant S. aureus (MRSA).  
 
 
Figure 4.  
 
Structure of the S. aureus PBP2a. The different domains are 
indicated by the colours displayed on the sample board on the left. 
Yellow: transmembrane anchor; green, N-terminal extension; orange, 
bilobed N-terminal nPBD domain; blue, C-terminal transpeptidase 
domain. The active site Ser403 is highlighted in red. Taken from Lim 
et al. (68). 
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The low affinity of PBP2a for β-lactams is caused by the inefficient acylation of the active site 
Ser403, which is distorted and would require conformational changes to be acylated, which is 
an energetically unfavourable reaction (15, 47, 68). 
PBP2a can continue cell wall cross linking in the presence of β-lactams, in cooperation with 
the uninhibited, essential transglycosylase of PBP2 (Figure 5) (88). Transpeptidation activity 
of PBP2a is very poor and only muropeptide dimers and some trimers are formed. 
Nevertheless, this is enough to maintain cell integrity (22). PBP2, which dislocates, from the 
division septum in methicillin susceptible S. aureus (MSSA) in the presence of β-lactams, is 
maintained in place in MRSA by a functional PBP2a via a proposed protein-protein 
interaction, as the transglycosylase function of PBP2 is needed for peptidoglycan synthesis 
(90, 91, 104). 
 
 
TGase
TPase
TPase
methicillin
disaccharide unit 
pentapeptide and 
crossbridge
transglycosylation
transpeptidation
PBP2
PBP2a
 
 
Figure 5.  
Scheme showing the cooperation of PBP2a with PBP2 in cell wall crosslinking. In the presence of β-lactam 
antibiotics the TPase domain of PBP2 is acylated and thereby inactivated. This prevents substrate recognition 
and results in delocalization of PBP2 from the septal plane. In MRSA strains in the presence of β-lactams the 
transpeptidase of PBP2a remains active and keeps PBP2 in place. The TPase crosslinking the peptidoglycan 
stem peptides through the pentaglycine chain and the TGase of PBP2, linking the disaccharide subunits, maintain 
cell wall synthesis. Adapted from Pinho et al. (88). 
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1.2.2.4 SCCmec   
mecA is located on the staphylococcal cassette chromosome mec (SCCmec) a genomically-
integrated resistance island with a proclivity for easily taking up and accumulating resistance 
determinants (1, 25, 50). The SCCmec integrates site- and orientation-specifically into a 
unique site at 3’ end of orfX, an open reading frame of unknown function near the origin of 
replication, called attBSCC. After its integration, via cleavage of the attBSCC site, an incomplete 
direct repeat consisting of two 15-bp DNA fragments is formed (Figure 6) (52). These 15-bp 
DNA fragments, termed ISS (integration site sequence) appear to be the site recognised by 
the SCCmec’s own recombinases ccrAB/C (cassette chromosome recombinase), which are 
responsible for insertion and excision of the element (52, 57). Composite SCCmecs might 
have evolved by sequential integration of different SCCmec elements followed by deletion or 
recombination events (45, 48, 52, 79). Multiple SCCmec excision variants in strains with 
composite SCCmecs have previously been described (27, 54). Depending on the number of 
ISS, with a consensus of 5’-GANGCNTATCANAANTNN-3’, the number of possible excision 
variants and the corresponding number of elements integrated in tandem into attBSCC can be 
predicted since each inserted element will be flanked by an ISS (Figure 7). These composite 
elements can either excise partially or as a whole. In the case of a non recombinase carrying 
element the ccrAB/C of an adjacent element can facilitate its excision. Excision and 
reintegration of different genomic elements into attBSCC is likely to result in the generation of  
new SCCmec subtypes, increasing the high variability within these elements (54). 
Spontaneous excision occurs at a very low frequency in the presence of a functional 
recombinase, therefore down regulation of ccr loci might stabilize the SCCmec within the 
chromosome (57). The conditions under which ccrAB/C are active have yet to be discovered. 
SCCmec elements are roughly divided into six main classes according to the combination of 
ccr and mec complex that they carry. They also differ in size from 21 to 67 kb and in their 
repertoire of resistance determinants (Table 2, Figure 8) (52, 53, 57, 61, 73, 84). Type I to III 
SCCmec are predominantly found in so called hospital acquired MRSA whereas strains 
carrying types IV to VI are generally community acquired MRSA (see section 1.3.1) (16, 25, 
29, 61). 
Five ccr allotypes have been described, four of which contain the two recombinases ccrA 
and ccrB and the fifth contains the single gene ccrC. The mec complex consists of the mecA 
gene and its divergently transcribed regulatory genes mecI/mecR1, which are in some cases 
deleted/truncated. mec complex A contains an intact regulatory locus (mecI-mecR1-mecA) 
adjacent to mecA; class B mec complex (IS1272-∆mecR1-mecA) and C2 (IS431-∆mecR1-
mecA), also found in S. aureus, have no mecI and a mecR1 truncated either by IS1272 or 
IS431, respectively. In addition to the mec/ccr complexes and some resistance elements, 
SCCmec DNA is divided into 3 regions, J1 to J3, termed “junkyard” regions as they mainly 
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contain truncated and nonessential genes of unknown function. Several SCCmec variants 
have been differentiated, based on differences in their junkyard regions (69, 109).  
The origin of SCCmec is unknown but it is thought to have been horizontally acquired from 
another species. The closest structural homologue of mecA was found in S. sciuri, recovered 
from rodents and primitive mammals, and shared an 88% amino acid sequence identity with 
mecA of S. aureus (21, 59, 129). Selection on increasing β-lactam concentrations was used 
to generate a resistant strain from the susceptible S. sciuri carrying the mecA homologue. A 
single mutation in the operator region of the mecA homologue was found to be responsible 
for its increased transcription and resistance levels in S. sciuri and allowed this mecA 
homologue to confer methicillin resistance in S. aureus. Because this gene was able to 
confer β-lactam resistance in S. aureus, it was suggested to be the evolutionary precursor of 
mecA (129). 
 
 SCC-chromosomechromosome-SCC
 
 
 
 
 
MSSA        agtgtatagagcatttaagattatgcgtgga gaggcgtatcataagtga
N315        agtgtatagagcatttaagattatgcgtggaGAAGCATATC TC - - - TT ACTGATACGCAgaggcgtatcataagtaa
MSSA476     agtgtacagagcatttaagattatgcgtggaGAAG TATC TT - - - GT ACC ACGCAgaggcgtatcataagtaa
attBSCC (**) AGTGTA—GAGC-TTTAAGATTATG-G-GGA                                                             GA-GC-TATCATAA-T--
ISS (**)                                       GANGCNTATCANAANTNN                                               GANGCNTATCANAANTNN
ATAAATGATGCGGTTTT AAAAAAACCTCATCATTA
CT ATAAATGATGCGGTTTT ATAAAAACCGCATCATTA GAT
 
 
Figure 6.  
Chromosome-SCCmec junction sequence. The sequences of a MSSA, N315 (MRSA, SCCmec type II) and 
MSSA476 (SCC476) were aligned. orfX, a gene of unknown function, indicated by blue shading, contains the attB 
site where the SCCmec element integrates. In MSSA476 a SCC element without mecA, was found to have 
integrated. Direct and indirect repeats are represented by arrows. Consensus sequences of attBSCC and ISS 
(integration site sequences) were taken from Ito et al. (53). 
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Figure 7.  
Excision variants of SCCmec described by Jansen et al. (54). Schematic overview of a composite SCCmec and 
its excision/circularization variants in the presence of an active recombinase. Composite SCCmec elements arise 
upon sequential integration of SCCmec and SCC-like elements. All of these elements are framed by ISSs, 
indicated by a red dot, which are recognized by recombinases, enabling excision and circularization of the 
elements. Primers used to detect circularization products are shown as arrows. The following excision variants 
were possible: 3-4, 5-6, 1-4, and 1-6; 1-2 and 3-6 were also possible but were not detected. Thick and dotted 
lines indicate the chromosomal attachment sites which are disrupted upon integration and which are reunited after 
circularization due to excision of these elements. attB is reconstituted after loss of the SCCmec element (1-4, 
yellow-green). attB’ was found after excision of the SCC-like element (blue) and attB’’ upon excision of the 
complete composite SCCmec element (green-yellow-blue), ligating 1 and 6.  
 
 
Table 2. Major classes of SCCmec, divided by their ccr and mec complexes. 
SCCmec type ccr complex mec complex Size Resistances 
I 1 B 34 kb Oxa 
II 2 A 51 kb Oxa, Ery, Kan, Tob, Ble 
III 3 A 67 kb Oxa, Ery, Tet, Mer, Cad 
IV 2 B 21-24 kb Oxa 
V 5 (ccrC) C2 28 kb Oxa 
VI 4 B ~ 22 kb Oxa 
Abbreviations: Ble, bleomycin; Cad, cadmium; Ery, erythromycin; Kan, kanamycin; Mer, mercury; Oxa, 
oxacillin; Tob, tobramycin. 
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Figure 8.  
Basic structure of all major SCCmec types. The combination of ccr complex and mec complex is the main factor 
determining the class of SCCmec element. Other attributes include insertion sequences, transposons, integrated 
plasmids and the size of the elements. Subtypes are typed according to their J-regions (J1, J2, J3). These J-
regions are indicated by arrows and dashed lines. The white bars are chromsomal regions outside of the 
SCCmec, and orfX, the SCC element integration site, is shown in black. Additional resistance are encoded by 
Tn554: erythromycin resistance; ψTn554: cadmium resistance; pT181: tetracycline (58); pUB110; kanamycin, 
tobramycin and bleomycin resistance (77). Adapted from (53, 83, 85). 
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1.2.2.5 Regulation of mecA 
mecA, the gene producing PBP2a, is controlled by the divergently transcribed regulatory 
elements, mecI, encoding a repressor protein and mecR1, a transmembrane β-lactam 
sensor transducer (49, 107). A structurally and functionally similar regulatory system controls 
the penicillinase gene blaZ, which is divergently transcribed from its regulators blaR1 and 
blaI, also encoding a sensor transducer and repressor, respectively. BlaI and MecI bind as 
homodimers to their corresponding promoter-operator regions, preventing blaZ/mecA 
transcription, as well as their own and blaR1/mecR1 expression due to the overlapping 
promoter regions (102). In the presence of β-lactams the sensor domain of BlaR1/MecR1 is 
activated and transmits a signal from the extracellular domain to the cytosolic domain, 
leading to autoproteolytic cleavage and activation of the N-terminal BlaR1 domain, which 
proteolytically cleaves the repressor causing dissociation of BlaI/MecI from the promoter-
operator region. Transcription of blaZ/mecA and their respective regulatory loci then 
proceeds. The repressor proteins, BlaI/MecI, have an amino acid sequence identity of 61% 
(33) and as homologs with structural and functional similarity they can functionally substitute 
for each other. In strains that constitutively produce mecA, due to missing or truncated 
mecR1/mecI regulatory elements the introduction of blaI/blaR1 results in controlled mecA 
expression. Reciprocally, blaZ can also be regulated by mecI/mecR1. However, while the 
repressors can replace each other, the sensor transducers, with an overall amino acid 
identity of 34% (125), are specific and only able to cleave their own repressors (78). 
BlaI/MecI, contain a DNA binding and dimerisation domain and bind specifically as dimers to 
the promoter-operator region of blaZ/mecA. In the blaZ promoter the dimerized repressors 
bind to two 18-bp palindromes (R1 and Z dyad) which are separated by 13 bp, while in the 
mecA/mecR1 intergenic region they bind to a 30-bp palindrome with two complementary 15-
bp sections (Figure 9). Each half of the palindrome contains an inverted repeat of 2x 4 bp 
(TACA/TGTA) that is protected by BlaI/MecI binding (102, 107), (18). The distance between 
the binding sites of the protein dimers determines the binding orientation relative to the DNA. 
At the single palindrome of the mecA promoter the dimers bind on opposite sides to each 
other due to steric hindrance, whereas at the blaZ promoter the dimers can bind next to each 
other on the identical DNA axis due the 13-bp gap between the two palindromes, each of 
which carries an inverted repeat (Figure 10) (102). 
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blaR1
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rbs blaZ
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pN315 TTGTAATATTATTGATTTATAAAAATTACAACTGTAATATCGGAGGGTTTATTTTG
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*
rbs blaR1 +1
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Figure 9.  
MecI/BlaI binding sites at the promoter-operator region of A, mecA and B, blaZ. MecI/BlaI binding sites 
(TACA/TGTA) are highlighted in bold. Additional features of the promoters indicated are: The ribosomal binding 
sites (rbs), -10 and -35 boxes which are framed; direct and indirect repeats are shown by arrows; start codons are 
underlayed with grey and the direction of transcription is shown by flags; transcriptional start sites of blaZ/blaR1 
are indicated by asterisks. Adapted from (18, 41, 102). 
 
 
Figure 10.  
Scheme of repressor binding to the promoter-
operator regions. The protein structure is illustrated 
as ribbons. The N-terminal helices, the β-strands 
and the C-terminal helices of one monomer are 
coloured green, orange and yellow, respectively. In 
the second monomer the corresponding secondary 
structures are coloured in blue, magenta and cyan, 
respectively. Taken from Safo et al. (102). 
A, two BlaI homodimers bound to the blaZ and 
blaR1 dyad of the intergenic region - blaZ/blaR1. 
The spacing between the protein binding sites, 
allows repressors to bind next to each other. 
B, putative MecI-mecA complex. Protein 
homodimers are bound on the opposite sides of the 
promoter DNA.  
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1.2.2.6 Signal transduction 
The sensor transducer proteins MecR1/BlaR1 sense the presence of β-lactams, which are 
not able to penetrate through the bacterial membrane, through an extracellular domain which 
transduces a signal to the cytoplasm to activate the resistance mechanism. BlaR1 consists of 
a C-terminal penicillin binding domain linked to 4 hydrophobic transmembrane domains, 
connected via 3 loops (L1-L2-L3) with L2 located extracellularly and L1/L3 in the cytoplasm. 
L3 contains a metalloprotease domain which induces the defence mechanism (46, 125, 133). 
When uninduced the C-terminal sensor domain of BlaR1 is non-covalently bound to L2, the 
loop connecting the transmembrane domains 2 and 3 (Figure 11A) (44). β-lactam then binds 
to the extracellular sensor domain of BlaR1 forming a preacylation complex which is 
subsequently acylated by Ser389, the nucleophil which is activated by the carboxylated Lys392 
known to promote acylation. A significant conformational change, interrupting the non-
covalent binding of the sensor domain with loop L2 (40, 44) results in destabilisation of the N-
carbamate of Lys392 and N-decarboxylation (115). Thus the acylation step as well as 
conformational changes are irreversible and the sensor is kept in its activated state (8, 40, 
115, 125). 
The BlaR1 zinc metalloprotease motif (H201EXXH), in its cytoplasmic domain, is essential for 
its own cleavage and for the cleavage of BlaI. Autocatalytic cleavage of BlaR1, induced by 
binding of β-lactam to its sensor domain, at the KKSLIKR293RLINIKEA of the cytoplasmic 
domain between R293 and R294 activates BlaR1 (133), which cleaves BlaI either directly or via 
an unknown intermediary chromosomal co-factor, such as the postulated BlaR2 (20).  
C-terminal cleavage of BlaI, a 14-kDa protein, generates 11-kDa and 3-kDa fragments 
carrying the DNA-binding and dimerisation domains, respectively (41). The cleavage site is in 
NH2-KSLVLN101F102AKNEELNN between N101 and F102 leaving FAKNEELNN as the amino 
acid end sequence of the cleaved C-terminal fragment. Mutational substitution of N101 or F102 
prevents proteolytic cleavage of BlaI and therefore prevents derepression of blaZ 
transcription (Figure 11B) (133). 
Signal transduction via MecR1 is similar to BlaR1, but one major difference is their 
differential interaction kinetics with β-lactams (13). Induction of blaZ transcription and 
penicillinase expression requires minutes whereas induction of PBP2a expression over 
MecR1 takes hours (78, 100). The reversible preacylation complex formed between β-
lactams and MecR1 is less efficient and the subsequent acylation reaction is slower than that 
of BlaR1. The slower sensing of β-lactams due to its poor interaction kinetics might be the 
reason for the slow derepression of mecA by MecR1 (13). 
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Figure 11.  
Schematic regulatory system of BlaR1/BlaI/BlaZ. A, mecA, blaZ and their divergently transcribed regulatory genes 
blaR1/blaI and mecR1/mecI are repressed by BlaI homodimers. B, BlaR1 undergoes acylation in the presence of 
β-lactam molecules. Acylation causes a conformational change in the C-terminal BlaR1 domain activating a signal 
transduction pathway, promoting proteolytic cleavage of the N-terminal BlaR1 domain, followed by cleavage of 
BlaI, either directly by BlaR1 or indirectly by BlaR2, resulting in derepression of mecA-mecR1/mecI and blaZ-
blaR1/blaZ. Structural genes of mecA/mecR1/mecI are coloured yellow and blaZ/blaR1/blaI orange. Adapted from 
Thumanu et al. (115). 
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1.2.2.7 fem/aux factors 
The majority of MRSA strains express methicillin resistance heterogeneously. In 
heteroresistant strains most of the cell population is capable of expressing low level 
resistance and only a small subpopulation is able to grow at high antibiotic concentrations. 
The segregation of highly resistant subclones occurs at quite a high frequency, above the 
rate of spontaneous mutations (99, 101). The genetic mechanisms controlling methicillin 
resistance levels are largely unknown. However, a factor which might contribute to the 
expression of heterogeneous methicillin resistance was described recently. The deletion of 
the postulated sodium-dependent symporter homologue SA0501 converted a heterogeneous 
methicillin resistant strain into a homogeneous resistant strain at elevated temperatures 
(110). 
Chromosomally encoded factors seem to be the main effectors determinating the resistance 
level of staphylococcal strains carrying mecA, as PBP2a expression levels do not directly 
correlate with methicillin resistance levels (5, 7, 24). Genes outside the SCCmec element 
that influence methicillin resistance levels are referred to as fem, factors essential for 
methicillin resistance or aux for auxiliary genes (7, 23, 24).  
fem/aux factors include genes involved in cell wall biosynthesis, turnover or regulation (6), 
protein kinases, ABC transporters, and the catabolite control protein CcpA (24, 106). mecA 
transcription was not reported to be altered by interruption of any of the fem/aux factor 
except for by murE. But it has not been shown whether mecA transcription is directly or 
indirectly regulated by murE. 
 
1.3 Clinical significance of MRSA  
MRSA are not only a major threat because of their β-lactam resistance but also because of 
their high adaptability under selection pressure. Penicillin and methicillin resistance were 
acquired within a short time period and other non-β-lactam antibiotic resistance determinants 
can easily be taken up by the integration of plasmids or transposons into their SCCmec 
element (1, 25). Multi-resistance has severely limited available treatment options for MRSA. 
Vancomycin has become one of the antibiotics of last resort for treating multiresistant MRSA. 
Glycopeptides, such as vancomycin disturb cell wall biosynthesis by irreversible binding to 
the D-Ala-D-Ala of the peptidoglycan stem peptide preventing peptidoglycan crosslinking. 
Vancomycin was used for over 30 years before resistance was detected in MRSA, then 
within the last 10 years both low-level vancomycin-intermediate resistant (VISA) and high 
level vancomycin resistant (VRSA) S. aureus have emerged. In VISA, resistance is 
associated with a thickened cell wall and reduced cell wall crosslinking which leads to an 
increased number of free D-Ala-D-Ala in the cell wall, which act as false targets for 
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vancomycin and prevent it from reaching its lethal target (111, 122). In VRSA, acquisition of 
the vanA operon of Enterococcus faecalis results in synthesis of an altered peptidoglycan 
stem peptide, changing the terminal D-Ala-D-Ala to D-Ala-D-Lac, which has a strongly 
reduced affinity for vancomycin (3, 72). In three of four described VRSA cases, vancomycin 
resistant Enerococcus faecalis carrying the vanA gene could also be isolated, indicating that 
horizontal transfer of vanA has occurred (3).  
MRSA strains with heterogeneous β-lactam resistance profiles have proven to be a huge 
problem for detection in diagnostics. Because their population is composed of a large portion 
of low level resistant and only a small fraction of high-level resistant subclones, they can 
appear to be MSSA, according to the CLSI guidelines (19), using traditional susceptibility 
testing. β-lactams commonly used for infection treatment, will then select for proliferation of 
highly resistant sublcones, causing treatment failure. In the Netherlands an increasing 
number of heterogeneously low-level resistant strains were detected. This might also be the 
case in other countries, and is an alarming situation which needs to be carefully monitored 
(51, 123, 127).  
 
1.3.1 Community and hospital acquired MRSA 
Community acquired MRSA (CA-MRSA) have only emerged as a major problem in the last 
few years, whereas hospital acquired MRSA (HA-MRSA) have been prevalent since the 
1970’s, soon after introduction of methicillin, probably due to their continual exposure to 
antibiotic selection pressure (1, 55). CA-MRSA are described as a class of MRSA causing 
infections in the “community settings”, where patients have not been exposed to classical risk 
factors such as recent hospitalisation, surgery, residence in a long term care facility, dialysis 
and indwelling percutaneous medical devices and catheters (82). Comparison of CA-MRSA 
with HA-MRSA showed a higher prevalence of skin and soft tissue infection due to CA-
MRSA than to HA-MRSA, in which infections of the respiratory or urinary tract were more 
frequent. CA-MRSA were generally found in younger people and had a high carriage of 
staphylococcal enterotoxins A, C, K, and staphylococcal chromosome mec type IV or in 
some cases type V (34). Panton Valentine leukocidin, previously used as an indicator for CA-
MRSA, has been shown to be present in only 20 % of all CA-MRSA analysed and can also 
be carried by HA-MRSA. HA-MRSA on the other hand were more likely to produce 
superantigenic toxins (TSST-1, enterotoxins) and typically carried SCCmec types I to III, with 
SCCmec type II being the most predominant (30, 82, 118). Another factor discriminating 
between these two MRSA classes is their growth rate. In general CA-MRSA are much faster 
growing (83).  
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1.3.2 Clonal diversity 
According to multi locus sequence typing (MLST), most successful MRSA clones belong to 
one of five main clonal complexes (CC) CC5, CC8, CC22, CC30, CC45, indicating a low 
frequency of SCCmec acquisition by only a few MSSA strain lineages (95, 118). SCCmec 
type IV has been found in twice as many diverse clonal lineages than any other SCCmec 
type. Its small size, which might elevate the transfer efficiency or reduce fitness costs upon 
its acquisition compared to other SCCmec elements, might favour type IV SCCmec 
acquisition (83, 95). Representative, successful epidemic MRSA clones spreading worldwide 
causing disease are the Iberian, Brazilian, Hungarian, New York/Japan, pediatric and 
EMRSA-16 clones (1). 
 
1.3.3 MRSA distribution/prevalence 
In a European-wide study between 1999-2002, with 27 countries participating, a north-south 
gradient was detected with low MRSA prevalence in the north and high in the south, ranging 
from 0.5 to 44 % (Figure 12). During these three years significant increases were found in 
Belgium, Germany, Netherlands, Ireland, and the UK. In the 2005 annual report from EARSS 
(European Antimicrobial Surveillance System), MRSA prevalence in Belgium, Germany, 
Netherlands, Ireland, and the UK was stable or showed only a slight increase between 2002 
and 2005. In this time period Finland and Denmark had significant increases in prevalence 
but still had low overall incidences of 2.91 % and 1.7 %, respectively. In 2002 only four 
countries had over 40 % MRSA, whereas in 2005 twice as many exceeded 40 %. 
Interestingly, the MRSA frequency decreased in Slovenia showing that the trend can also be 
reversible (2, 116).  
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Figure 12. 
Geographical region investigated for MRSA prevalence (1999-2000) taken from (116). Different proportions are 
indicated by the grey scale.  
 
 
Switzerland. In a one year epidemiological study (1997), S. aureus isolates of five University 
hospitals and some additional hospitals/rehabilitation institutions were investigated. In 
Geneva, MRSA were found to be endemic but in general the MRSA prevalence in 
Switzerland is low with an average value of 2.8 cases/10’000 admissions. Basel, Bern, 
Geneva, Lausanne and Zurich University hospitals were found to have 4, 3, 23, 3 and 6% 
MRSA, respectively. These MRSA statistics show that variation in prevalence is not only 
found between countries but also between different geographical areas within a country. Of 
four predominant clones identified, three were mainly found in Geneva whereas the 4th clone 
termed WCH, identical to the Belgium clone 2 and present in Switzerland since 1995, was 
found in various institutions. Therefore, there is a great diversity found between MRSAs but 
some clones appear to be able to spread and persist better than others (10, 11). 
West-Switzerland. In an 8 year survey from 1997-2004 in west Switzerland, changes in 
clone frequencies, clone replacements and emergence of new clones was observed. 
Although there was a rapid change in the clone population, the overall rate did not change 
over time. Four predominant clones, related to other European clones, the Japan/New York, 
Southern Germany, Iberian and Berlin clone were present in this area. The most frequent 
SCCmec types found in this study, were type IV and II, representing both CA- and HA-
MRSAs (9). 
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Zurich. The prevalence of the different SCCmec types of MRSA in the area of Zurich in 2003 
was analysed. Proportions of SCCmecs were 3.3 % type I, 10% type II, 12.2 % type III,  
45.6 % type IV, 24.4 % SCCmecN1 ((27), see section 3.1), 1.1 % SCCmecZH47 ((48), see 
section 5.3) and 3.3 % had untypable SCCmecs. In this study, strains carrying SCCmec type 
IV and N1 were the most prevalent. By multi locus sequence typing (MLST), four 
predominant clones were identified: ST217-CC22 similar to EMSA-15; ST225-CC5 related to 
the Japan/New York clone; ST613-CC8, a new clone; and ST45-CC45 found among the 
drug user community in Zurich which is the same genetic background as the Berlin clone 
((93), see section 5.3). Two clones were found to be predominant in Zurich and in the 
western part of the country, the Japan/NewYork clone and the Berlin clone. 
 
1.3.4 Emergence of new epidemic MRSA 
New epidemic heterogeneously resistant MRSA with similar phenotypes emerged from 1992 
onwards in Germany, France, Finland and Australia. These clones were resistant to β-lactam 
antibiotics but carried no other resistance markers and went on to replace multidrug resistant 
MRSA in hospital settings (66, 117, 126). In a seven years surveillance study of French 
hospitals a clear increase in non-multiresistant MRSA, gentamicin susceptible MRSA (GS-
MRSA) occurred, while the overall prevalence of MRSA remained relatively stable. Antibiotic 
resistance profiles showed increased susceptibility to kanamycin, tobramycin, lincomycin, 
pristinamycin, tetracycline, minocycline, co-trimoxazole, rifampin and fusidic acid but higher 
frequencies of chloramphenicol resistance (66). Two variants, one with high fitness and short 
generation time similar to MSSA strains and the second with reduced fitness and longer 
generation times, like multiresistant MRSA, were found, and the prevalence of the fitter strain 
was significantly higher. Decreased fitness upon acquisition of resistance and an inverse 
relationship between resistance levels and fitness, has previously been described (28, 65). 
Antibiotic resistance determinants, resistance levels and a strains genetic background can all 
determine a clones fitness and influence its predominance or disappearance (65).  
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2. Aim of this study - Project description 
 
The Swiss drug clone, represented by strain CHE482, is a low-level methicillin resistant 
Staphylococcus aureus (MRSA) found spreading in the drug user community of Zurich, 
Switzerland. Strains belonging to this clone are predestined to be misinterpreted as 
methicillin susceptible S. aureus (MSSA), due to their low and heterogeneous methicillin 
resistance, leading to treatment failure. Molecular characterisation of this strain would allow 
fast and accurate identification of this clone preventing misidentification, and should give 
additional information about mecA regulation and factors affecting β-lactam resistance. To do 
so, four projects were undertaken.  
 
Project I: Variability in SCCmecN1 spreading among injection drug users in Zurich, 
Switzerland. (published, Ender et al. BMC Microbiology) 
A commonly used multiplex PCR, used to type SCCmec elements of MRSA strains, failed in 
strain CHE482 and isolates of the same clone, indicating the existence of a novel SCCmec 
element. The aim of this project was to identify the recombinase genes, mec complex and 
additional resistance determinants of this new SCCmec and to determine the end sequences 
and create a map of this element, in order to monitor its spread and development. 
 
Project II: Impact of mecA promoter mutations on mecA expression and β-lactam resistance 
levels. (accepted by International Journal of Medical Microbiology) 
Genetic factors influencing β-lactam resistance levels, and hence potentially responsible for 
the low β-lactam resistance in CHE482, are unknown. Sequencing of the mecA gene and 
promoter sequence identified a promoter mutation in the -10 box of the intergenic region of 
mecA/mecR1, creating a perfect palindrome. The aim of this project was to characterize the 
impact of this one nucleotide substitution on β-lactam resistance levels, since the MecI 
and/or BlaI repressors controlling mecA transcription bind to this palindromic region. 
Comparison of wildtype and mutant promoters, by means of resistance testing and 
transcriptional and translational analysis of mecA/PBP2a in different genetic backgrounds, 
showed decreased resistance, lowered mecA transcription, and lowered PBP2a production 
from the mutated promoter compared to wildtype promoter. Nevertheless, expression of the 
mecA preceded by the various mecA promoter variants in two S. aureus of different genetic 
background showed that the impact of the promoter mutation on resistance levels was 
smaller than the contribution of the strains genetic background, suggesting that β-lactam 
resistance levels are mainly controlled by chromosomal factors. 
 
 
Aim of this study  35
 
 
Project III: A novel DNA-binding protein modulating β-lactam resistance in Staphylococcus 
aureus. (manuscript in preparation) 
In addition to the MecI/MecR1 or BlaI/BlaR1 control of mecA transcription, other hypothetical 
factors involved in mecA regulation have been postulated. A possible target for regulatory 
elements is the mecA/mecR1 intergenic region, where the repressors MecI/BlaI bind. A 
search for additional proteins binding to the mecA/mecR1 intergenic region identified a novel 
protein with DNA-binding capacity. Construction of deletion mutants in heterogeneously 
methicillin resistant MRSA isolates of different backgrounds resulted in increased resistance, 
while inactivation in a homogeneously resistant MRSA decreased β-lactam resistance. 
However, no changes in mecA transcription levels and PBP2a amounts were observed. This 
suggests that this newly identified DNA-binding protein affects methicillin resistance levels 
indirectly over the control of other genomic factors. 
 
Project IV: Random transposon insertion library of CHE482, a methicillin resistant  
Staphylococcus aureus (MRSA): Identification of novel fem factors. 
mecA, encoding PBP2a, is essential for expression of β-lactam resistance but the level of 
resistance is determined in a large part by the strains genomic background, by so called 
fem/aux factors. Several chromosomal factors involved in peptidoglycan synthesis, 
hydrolysis, global gene regulation, teichoic acid synthesis and genes of unknown functions, 
have already been identified as fem/aux factors. To extend this list, a random transposon 
library of the low level resistant CHE482 was constructed. The library consisting of 8064 
mutants, representing a 2.8 fold coverage of the chromosome, was screened for mutants 
with decreased and especially increased resistance. Subsequently, 17 new, and 4 already 
published orfs could be identified and confirmed to influence β-lactam resistance. However, 
only two insertions resulted in a slightly higher β-lactam resistance. 
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3 Results 
3.1 Project 1 
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3.2 Project 2: Impact of mecA promoter mutations on mecA 
expression and β-lactam resistance levels 
 
Abstract 
The reason for the extremely low-level oxacillin resistance in a so called “drug clone”, a 
methicillin-resistant Staphylococcus aureus circulating among injection drug users in Zurich, 
Switzerland, could be traced back to the mecA promoter sequence and particularly to the 
strain's genetic background. Sequencing of its mec complex identified a point mutation 
(TATACT to TATATT), creating a perfect palindrome in the -10 region of the mecA 
promoter/operator region containing the binding sites for the mecA repressors MecI and BlaI. 
Two strains with vastly different β-lactam resistance phenotypes, the low-level resistant drug 
clone type strain CHE482 and the highly homogenously resistant strain COLn, were cured of 
their SCCmec elements and subsequently transformed with plasmids containing mecA under 
the control of either the wildtype or mutant promoter. Expression studies showed that this 
mutation had significant effects on both mecA transcription and corresponding PBP2a 
production, but only small effects on β-lactam resistance levels within a given genetic 
background. A further mutation in the mecA ribosomal binding site (GGAGG to GGAGT), 
common to SCCmec type IV strains, was found to have no discernable effect on mecA 
transcription and PBP2a content, and only minimal effects on β-lactam resistance. Factors 
associated with the genetic backgrounds into which these differently controlled mecA genes 
were introduced, had a much higher impact on β-lactam resistance levels than the rates of 
mecA transcription. The tight repression of mecA expression in this drug clone in the 
absence of β-lactams, could contribute to the apparent fitness of this fast growing strain.  
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Introduction 
Methicillin resistant Staphylococcus aureus (MRSA) can express highly variable levels of β-
lactam resistance. Oxacillin minimal inhibitory concentrations (MIC) can vary from as low as 
1 μg ml-1 up to values over 1000 μg ml-1. Extremely low-level resistant MRSA strains are 
dangerous as they often evade phenotypic detection. While they appear phenotypically 
susceptible, these strains still carry the mecA gene, which encodes the β-lactam resistance 
protein penicillin binding protein (PBP) 2a, and express resistance heterogeneously. This 
means that upon β-lactam exposure they can segregate highly resistant subpopulations at 
frequencies well above spontaneous mutation rates, and cause β-lactam treatment failure. 
β-lactam resistance relies on the presence of mecA and the expression of PBP2a, however, 
several other factors are known to influence resistance. Chromosomal mutations or specific 
genomic factors are required for expression of high level resistance (Murakami and Tomasz, 
1989; Ryffel et al., 1994; Sieradzki et al., 2007). Resistance levels are also influenced by 
environmental conditions such as temperature, pH, osmolarity, divalent cations and 
aerobiosis (Matthews and Steward, 1984). The actual genetic basis governing low-level, 
heterogeneous or high homogeneous resistance is unknown.   
Expression of mecA is inducible and can be controlled by either its cognate regulators MecI 
(DNA binding repressor protein) and MecR1 (sensor/signal transducer) or by the structurally 
and functionally similar β-lactamase regulators BlaI and BlaR1, respectively. Because of 
structural and functional similarity, both MecI and BlaI can bind as homodimers to the 
promoter/operator region of both mecA and blaZ (Gregory et al., 1997; Sharma et al., 1998). 
Repression of transcription by these two inhibitors is even stronger when both repressors are 
present (Rosato et al., 2003a). In the presence of β-lactams the MecR1/BlaR1 sensor-
transducers promote the cleavage of their respective repressors allowing transcription of 
mecA. In the absence of both regulatory loci, mecA is constitutively expressed. 
High conservation of the mecA gene sequence (Chambers, 1997), promoter region and the 
preferred presence of regulatory genes (blaI/blaR1 or mecI/mecR1) (Rosato et al., 2003a) 
highlights the need for controlled expression of mecA. In strains such as N315, a so called 
pre-MRSA (Niemeyer et al., 1996; Weller, 1999) carrying both complete regulatory systems, 
mecA is repressed by both MecI and BlaI. This tight repression can prevent mecA 
transcription and lead to inhibition of β-lactam resistance and to the misinterpretation of these 
strains as methicillin sensitive S. aureus (MSSA). 
The amount of PBP2a produced has been shown to have no direct correlation with 
resistance level, however mutations in mecA, mecI, the mecI ribosomal binding site, or mecI 
deletion, can lead to increased resistance (Katayama et al., 2004; Niemeyer et al., 1996; 
Rosato et al., 2003a), whereas interruption of blaR1 results in repression and therefore 
decreased resistance (Hackbarth et al., 1994).  
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An MRSA strain with very low-level oxacillin resistance, with the ability to generate highly 
resistant subclones, is spreading among injection drug users in Zurich, Switzerland (Qi et al., 
2005). Isolates of this clone having oxacillin MICs of 0.5-4 μg ml-1 are susceptible or just at 
the breakpoint of resistance for oxacillin, according to CLSI guidelines. They fall within the 
classification of the recently described OS-MRSA (oxacillin susceptible methicillin-resistant 
S. aureus), defined as being oxacillin sensitive but mecA-positive strains with MICs of 2 μg 
ml-1 or below (Hososaka et al., 2007). A recent analysis of the SCCmec element of the drug 
clone type strain CHE482 identified a composite element carrying a mecB complex (IS1272-
∆mecR1-mecA) (Ender et al., 2007). Further investigation of the mec complex revealed that 
the mecA promoter differed from the consensus by a 1-bp substitution in the -10 region. Here 
we determined the influence of this nucleotide substitution on mecA transcription and β-
lactam resistance levels in different genetic backgrounds, using MRSA cured from their 
SCCmec element as recipients.  
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Materials and methods 
Bacterial strains and growth conditions. All strains and plasmids used in this study are 
listed in Table 1. Strains were grown in Luria Bertani broth (LB, Difco) at 37°C, with shaking 
at 180 rpm. Media were supplemented with 10 μg ml-1 tetracycline for strains harbouring the 
plasmids pME1, pME2 or pME3 and with 0.8 μg ml-1 ampicillin for those containing the 
penicillinase plasmids pBla or pI524.  
 
Table1. Strains and plasmids used in this study.  
Strain  Relevant genotype Relevant phenotype Origin, Reference 
Staphylococcus  aureus     
 CHE482  CC45, ST45, SCCmecN1, blaZ (pBla) Mcr, Apr, Far, Tmr (Ender et al., 2007; 
Qi et al., 2005) 
 ME21  CHE482∆SCCmecN1, blaZ (pBla) Mcs, Apr Fas, Tms (Ender et al., 2007) 
 COLn  COL derivative, SCCmec type I Mcr, Tcs (Katayama et al., 
2004) 
 ME131  COLn∆SCCmec  type I Mcs, Tcs (McCallum et al., 
2006b) 
 ZH47  CC5, ST100, composite SCCmec, 
aac(6’)-aph(2’’), blaZ 
Mcr, Gmr, Kmr (Heusser et al., 
2007) 
Escherichia coli     
 DH5α  restriction-negative strain for cloning  Invitrogen 
Plasmids     
 pBUS1  S. aureus-E. coli shuttle vector, tetL  Tcr (Rossi et al., 2003) 
 pME1  pBUS1-mecA and its promoter of 
CHE482 
Tcr this study 
 pME2  pBUS1-mecA and its promoter of 
COLn 
Tcr this study 
 pME3  pBUS1-mecA and its promoter of 
ZH47 
Tcr this study 
 pBla  β-lactamase plasmid of CHE482 Apr this study 
 pI524  β-lactamase plasmid Apr (Murphy and 
Novick, 1980) 
Abbreviations: Ap, ampicillin; CC, clonal complex; Fa, fusidic acid; Gm, gentamicin; Km, kanamycin; Mc, 
methicillin; ST, sequence type; Tc, tetracycline; Tm, trimethoprim. 
 
 
Curing of SCCmec. Strains CHE482 and COLn were cured of SCCmec using the method 
described by Katayama et al. (Katayama et al., 2000), resulting in strains ME21 and ME131, 
respectively.  
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Cloning and transformation. The mecA gene, together with its upstream promoter region, 
was amplified from strains CHE482, COLn and ZH47 using the primer pair (5’-
ATTAGGATCCCCAAATCTTATGTGACATAA-3’/5’-ATTAGGATCCATCCTCAATATATGCA 
TATAG-3’), and subsequently cloned into the BamHI site of the E. coli-S. aureus shuttle 
vector pBUS1. The resulting plasmids pME1, pME2 and pME3, as well as pBla, the native 
penicillinase plasmid of CHE482, and pI524 a penicillinase plasmid described in Murphy et 
al. (Murphy and Novick, 1980) were electroporated directly into ME21 and ME131. Direct 
electoporation was done as described by Katayama et al. (Katayama et al., 2003), whereby 
cells were mixed with 500 ng of plasmid DNA, incubated for 10 min on ice and electroporated 
using following settings: 25 μF, 2.0 kV and 100 Ω.  
 
Sequence analysis. The plasmids pME1, pME2 and pME3 were sequenced with  an ABI 
Prism 310 genetic analyzer (Applied Biosystems) using the ABI PRISM BigDye Terminator 
Cycle sequencing reaction kit (U.S. Biochemicals). Thermal stability of inverted repeats (∆G) 
was calculated using the DINAMelt Server (Markham and Zuker, 2005). 
 
Growth curves. Strains were grown overnight in LB (Difco) in the presence of appropriate 
antibiotics, diluted 1:200 and grown for another 3 h. This preculture was used to inoculate 50 
ml of fresh prewarmed broth at a 1:1,000 dilution. Measurements were taken every 30 min at 
OD600nm and the minimal doubling time calculated. 
 
Susceptibility testing. The MIC of antibiotics was determined by Etest (AB Biodisk) on 
Mueller-Hinton plates (Difco) swabbed with an inoculum of 0.5 McFarland and incubated at 
35°C for 24 h, according to the manufacturer’s instruction (AB Biodisk). Qualitative 
comparisons of cefoxitin resistance levels were obtained by swabbing 0.5 McFarland 
suspensions of strains across agar plates containing increasing concentration gradients of 
cefoxitin. Gradients of cefoxitin used were 0-8 µg ml-1 and 0-500 µg ml-1. The production of 
penicillinase was confirmed by nitrocefin hydrolysis of cefoxitin induced cells. 
 
Northern blot analysis. A preculture, as described for the growth curves, was used to 
inoculate 150 ml LB broth at a dilution factor of 1:1,000. Cells were grown at 37°C to OD600nm 
1.0 then induced with cefoxitin 4 μg ml-1 and sampled at time point 0’ before induction and at 
5’, 10’, 20’ and 30’ after induction. Cells were pelleted at 4°C for 3 min then snap-frozen in 
liquid nitrogen. Total RNA was extracted as described in Cheung et al. (Cheung et al., 1994). 
RNA samples (8 μg) were separated in a 1.5% agarose gel containing 20 mM guanidine 
thiocyanate in 1x TBE (Goda and Minton, 1995). RNA transfer and detection were performed 
as described previously (McCallum et al., 2006a). Primers used to amplify DIG labelled 
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probes for mecA were, mecAP4/mecAP7 (Oliveira and de Lencastre, 2002) and for blaZ, 
primer pair (5’-TGTGACTTACTTTCAACTGT-3’ / 5’-TTACGATCCTGAATGTTTAT-3’). 
 
Western blot analysis. Extraction of cell wall proteins, from cells harvested before (0’) and 
after induction with cefoxitin 4 μg ml-1 (10’, 20’), was done as described in Katayama et al. 
(Katayama et al., 2004) with minor modifications. Additionally, a sonification step (3 x 20 sec) 
was introduced after lysing the cells with lysostaphin (100 µg ml-1) and adding DNase (20 µg 
ml-1) and RNase (10 µg ml-1). Ultracentrifugation was performed at 40,000 g for 40 min. After 
washing with 50 mM phosphate buffer pH7, the pellet was resuspended in 100 μl phosphate 
buffer. 
Protein concentrations were measured by Bradford assay (BioRad) (Bradford, 1976). After 
separation of 10 μg of protein extract on a 7.5% SDS-polyacrylamide gel, the proteins were 
blotted onto a nitrocellulose membrane (Hybond) and stained with Ponceau to confirm equal 
protein loading. For detection, membranes were blocked for 1 h with 5% milk powder in 1 x 
low salt buffer (77.5 mM NaCl, 4.5 mM Tris, 0.05% Tween20, pH 7.4), washed with 0.5% 
milk powder in low salt buffer containing 40 μg ml-1 human IgG (Calbiochem) then PBP2a 
antibody (1:20,000, Denka Seiken) was added after 30 min and was incubated for another 
hour. After 3 x 5 min washing with 1 x low salt buffer the secondary antibody, an anti-mouse 
IgG HRP conjugate (1:2,500) in 1 x low salt buffer containing 0.5% milk powder, was added 
and incubated for 1 h. Membranes were washed again for 3 x 5 min in 1 x low salt buffer. 
Detection was performed using SuperSignal West Pico Chemiluminescent Substrate 
(Pierce). 
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Results  
Sequence of CHE482 mecA promoter. The low level oxacillin resistant drug clone CHE482 
carries a type B mec complex consisting of the mecA gene with a truncated, non-functional 
regulatory locus. Nucleotide sequence analysis of the mecA gene and promoter region 
revealed one single base pair mutation within the mecA promoter consensus sequence. This 
C to T substitution localized in the -10 promoter region, 33-nt upstream of the mecA 
translational start site, resulted in the formation of a perfect 30-bp palindrome encompassing 
the binding sites for MecI/BlaI surrounding the -10 box (Figure 1). The substitution increased 
the stability of the inverted repeat to a ∆G of -10.8 kcal mol-1, compared to the consensus 
promoter represented here by COLn, which had a ∆G of -8.8 kcal mol-1. Three other 
randomly chosen drug clone isolates with MICs between 0.5 and 3 μg ml-1 showed the same 
nucleotide substitution, indicating that the mutation to a perfect palindrome was apparently a 
common feature of this clonal lineage. 
 
 
 
CHE482 CACCTTCTACACCTCCATATCACAAAAATTATAACATTATTTTGACATAAAT
COLn CACCTTCTACACCTCCATATCACAAAAATTATAACATTATTTTGACATAAAT
ZH47 CACCTTCTACACCTCCATATCACAAAAATTATAACATTATTTTGACATAAAT
CHE482 ACTACATTTGTAATATATTACAAATGTAGTCTTATATAAGGAGGATATTGATG
COLn ACTACATTTGTAATATACTACAAATGTAGTCTTATATAAGGAGGATATTGATG
ZH47 ACTACATTTGTAATATACTACAAATGTAGTCTTATATAAGGAGTATATTGATG
rbs-10
-35
mecR1
mecA
MecI/BlaI binding sites
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 
mecA promoter sequence of CHE482 compared to that of COLn (consensus promoter sequence) and ZH47. 
Direct and indirect repeats are indicated by arrows. The -10, -35 regions and the ribosomal binding site (rbs) are 
framed. The start codons of mecA and mecR1 are highlighted in grey and the direction of transcription indicated 
by arrows. Binding sequences of MecI/BlaI are shown in bold. Point mutations in CHE482 and ZH47 compared to 
COLn (designated as the consensus) are highlighted in black. 
 
 
Influence of mecA promoter variants on mecA expression and PBP2a production. The 
position of the nucleotide substitution in the mecA promoter region suggested that it may 
influence induction of mecA expression and hence be a contributing factor to the low-level 
resistance of CHE482. To compare the effect of the two different promoter sequences on 
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mecA transcription, plasmids pME1, containing the mecA gene and promoter from CHE482; 
and pME2, containing the mecA gene with a consensus sequence promoter from the highly 
homogenously resistant MRSA strain COLn, were constructed. To assess mecA transcription 
and PBP2a production in both the CHE482 and COLn genetic backgrounds, CHE482 and 
COLn were first cured of their SCCmec elements, creating MSSA strains ME21 and ME131, 
respectively. Plasmids pME1, pME2, and the empty vector, as a control, were then 
electroporated directly into the cured strains ME21 and ME131 (Figure 2). 
 
 
 
 
 
 
 
∆SCCmec
CHE482
ME21
pME1 pME2 pME3
COLn
ME131
pBla pI524
pME1 pME2 pME3 pME1 pME2 pME3
∆SCCmec
pME3pME1 pME2
 
 
 
 
 
 
Figure 2. 
Scheme of strain construction. Original MRSA strains are framed by rectangles, the cured strains beneath are 
framed by hexagons. Plasmids pME1, pME1, pME3 were introduced into the cured strains. In the case of COLn, 
two different penicillinase plasmids (framed by ovals) were transformed into the cured strain ME131. The three 
plasmids pME1, pME1, pME3 were introduced into each of the three variants, ME131, ME131pBla and 
ME131pI524. 
 
Northern blots were used to compare mecA transcription from pME1 and pME2 in both the 
CHE482- and COLn-derived strains ME21 and ME131, respectively, before and after 
induction with a sub-inhibitory concentration of cefoxitin (Figure 3A). In ME21, which contains 
an inducible β-lactamase, mecA transcription is subject to repression and β-lactam induction 
over the BlaI/BlaR1 regulatory system. Consequently, both plasmids showed increased 
mecA transcription upon cefoxitin induction in ME21, although, the levels of transcription 
differed markedly. In pME1, transcription was strongly repressed before induction and 
steadily increased over the 30 min period post induction, in a similar manner to blaZ 
induction. In contrast, mecA transcription levels from pME2 were already relatively high 
before induction and only showed a small increase after 20-30 min of induction. Transcription 
of mecA from pME1 and pME2 also differed in ME131, which contains neither MecR1/MecI 
nor BlaR1/BlaI regulatory elements. While mecA was constitutively transcribed from both 
plasmids, transcription was significantly higher from pME2. Western blots, quantifying PBP2a 
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production, showed that in most cases there was a correlation between mecA transcription 
and PBP2a expression levels (Figure 3A). Amounts of PBP2a produced did however appear 
to be higher in the ME131 than in the ME21 strain background, as seen by higher overall 
PBP2a signals in both ME131 strains and a lack of PBP2a induction above the basal level in 
strain ME21 pME2. 
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Figure 3. 
Time course of mecA, blaZ and PBP2a production in different genetic backgrounds upon induction with a 
subinhibitory concentration of cefoxitin. A, strains ME21 or ME131 containing either pME1 or pME2; B, strain 
ME131 containing penicillinase plasmid pBla or pI524, and either plasmid pME1 or pME2. Sampling times after 
cefoxitin induction are indicated. Top, Northern blots probed with mecA and blaZ; bottom, Western blot of PBP2a. 
The quantitative loading of RNA is shown by 23 S rRNA. 
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Effect of mecA promoter mutation on resistance levels in different genetic 
backgrounds. The overall β-lactam resistance levels of all ME21 and ME131 transformants 
were essentially in the range of those of their respective wildtype parent strains before 
curing, irrespective of which plasmid they contained. Plasmids in the ME21 background 
yielded much lower values than in ME131 (Table 2). By Etest there were 2-4-fold differences 
in ampicillin MICs, with strains carrying pME1 being slightly less resistant than their 
counterparts carrying pME2 (Table 2). No relevant differences in oxacillin and cefoxitin MICs 
between isogenic transformants carrying pME1 and pME2 were observed in strain ME21; 
whereas in the COLn background of strain M131 all values were above 256 µg ml-1 by Etest, 
and small differences could only be seen qualitatively on gradient plates when extending the 
cefoxitin concentration over 256 µg ml-1 (Figure 4). 
 
 
Table 2. Antibiotic minimal inhibitory concentration [μg ml-1]  
and minimal doubling time [min]. 
strain AM FX OX MD 
CHE482 2 8 1.5 25 
ME21 0.75 4 0.38 25 
ME21 pBUS1 1.5 4 0.38 32 
ME21 pME1 3 12 0.75 32 
ME21 pME2 6 16 0.75 31 
ME21 pME3 8 16 0.75 28 
COLn 24 >256 >256 46 
ME131 0.19 4 0.75 45 
ME131 pBUS1 0.19 4 0.75 46 
ME131 pME1 4 >256 >256 51 
ME131 pME2 24 >256 >256 54 
ME131 pME3 24 >256 >256 47 
ME131 pBla 1.0 4 1.0 44 
ME131 pBla pME1 12 >256 >256 58 
ME131 pBla pME2 48 >256 >256 63 
ME131 pBla pME3 64 >256 >256 48 
ME131 pI524 1.5 4 1.5 42 
ME131 pI524 pME1 12 >256 >256 59 
ME131 pI524 pME2 48 >256 >256 58 
ME131 pI524 pME3 48 >256 >256 48 
Abbreviations: AM, ampicillin; FX, cefoxitin; MD, minimal  
doubling time; OX, oxacillin. 
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Figure 4. 
Cefoxitin gradient plates. Strains were swabbed across agar plates containing an increasing concentration 
gradient of cefoxitin. Gradients of cefoxitin used were 0-8 µg ml-1 and 0-500 µg ml-1. 
 
 
Role of the β-lactamase operon on mecA expression and β-lactam resistance levels. 
Although the mecA promoter mutation in CHE482 had a considerable effect on mecA 
transcription, it only had a small effect on β-lactam resistance levels, indicating that the 
genetic backgrounds of CHE482 and COLn seemed to be the major factor controlling 
resistance levels. A key difference between these two genetic backgrounds was the 
presence of a β-lactamase plasmid in CHE482, which may restrict this strain to expressing 
low levels of resistance.    
Attempts to cure the approximately 32-kb β-lactamase plasmid (pBla) from CHE482 were 
unsuccessful (data not shown). Therefore, pBla and a previously characterised β-lactamase 
plasmid pI524 (Murphy and Novick, 1980) were transformed into the ME131 isolates 
containing pME1 and pME2 (Figure 2). Northern blots confirmed that all resulting 
transformants contained an inducible blaZ gene, indicating that the BlaR1/BlaI regulatory 
elements were functional (Figure 3B). Introduction of the β-lactamase plasmids into ME131 
had a clearly visible effect on mecA transcription, especially in pME1. Transcription of mecA 
from pME1 and pME2 adopted similar patterns to those seen in ME21. In the COLn 
background plasmid pI524 appeared to exert a stronger regulatory effect than pBla, resulting 
in stronger mecA repression before induction (Figure 3B). 
Once again, Western blots were performed to show the correlation between mecA 
transcription and PBP2a production (Figure 3B). Although induction of mecA transcription did 
not always result in a corresponding induction of PBP2a expression, PBP2a signals were 
strongest in the strains with the highest levels of mecA transcription. 
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Changes in mecA expression, resulting from introduction of pBla and pI524, however, had no 
visible effect on cefoxitin resistance levels on gradient plates (Figure 4). Oxacillin and 
cefoxitin Etest MICs from all ME131 transformants remained very high, at >256 μg ml-1 
(Table 2).  
 
mecA ribosomal binding site mutation. The recently sequenced SCCmec from another 
Zurich-isolated MRSA, strain ZH47 (Heusser et al., 2007), contained a different nucleotide 
substitution. This substitution of G to T in the ribosomal binding site (rbs) of mecA, 7-bp 
upstream of the ATG, occurs more frequently in database sequences. It is also found in the 
epidemic community MRSA clone USA300 and in several other SCCmec type IV strains. To 
determine if this alteration in the rbs influenced mecA expression, PBP2a production or β-
lactam resistance levels, the mecA gene and promoter from ZH47 was cloned to produce 
plasmid pME3, and transformed into ME21, ME131, ME131 pBla and ME131 pI524 (Figure 
2).  
Oxacillin and cefoxitin MICs of strains containing pME3 were identical to those containing 
pME2 (Table 2). Ampicillin MICs were also generally the same except for in ME21 pME3 and 
ME131 pBla pME3, where they were less than 2-fold higher than their corresponding pME2-
containing counterparts. Small differences in the resistance levels conferred by the three 
plasmids in ME21 could be seen by gradient plate, with pME1 providing the lowest and 
pME3 the highest level of resistance (Figure 5A). 
In ME21, transcription of mecA from pME3 was induced by cefoxitin (Figure 5B) as was 
PBP2a expression. In direct transcript-level comparisons between ME21 strains containing 
pME1, pME2 and pME3, the highest levels of transcription were from pME2, then pME3 and 
the lowest from pME1 (data not shown). In ME131, ME131 pBla, and ME131 pI524, the 
transcription profiles of mecA from pME3 were virtually identical to those from pME2 (data 
not shown). Western blot analysis revealed a close correlation between mecA transcription 
levels and PBP2a production (Figure 5B). 
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Figure 5. 
A, Gradient plate of 0-8 μg ml-1 cefoxitin 
comparing the three mecA plasmids in the 
ME21 background. B, Northern blots of 
mecA and blaZ expression with the 
corresponding Western blots of PBP2a of 
plasmid pME3 in different genetic 
backgrounds in presence and absence of 
penicillinase plasmids as indicated. The 
time points of harvesting before and after 
induction with cefoxitin are indicated. The 
quantitative loading of RNA is shown by 
23 S rRNA. 
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Growth rate differences. Growth curves were performed to determine the minimum 
doubling times for all strains (Table 2). The minimum doubling time for strain COLn was 
significantly higher (46 min) than that of CHE482 (25 min). Minimal doubling times were not 
significantly affected by curing of SCCmec, but were increased for both strains upon 
introduction of plasmids; in ME21 by introduction of both the empty plasmid and mecA-
encoding plasmids and in ME131 only by introduction of the mecA-encoding plasmids. 
Plasmid pME3 appeared to impose the lowest burden in terms of growth rate, while pME1 
and pME2 both imposed a similar, slightly higher burden. Subsequent introduction of 
plasmids pBla and pI524 into ME131 strains appeared to result in a small further increase in 
doubling time. 
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Discussion 
Genetic factors governing β-lactam resistance levels are still poorly understood. Although it 
has been shown that there is no direct correlation between levels of mecA expression and 
levels of methicillin resistance, it has been shown that variable repressor activity, due to 
mutations in mecI and the mecI promoter can influence resistance levels (Kuwahara-Arai et 
al., 1996; Rosato et al., 2003a). Analysis of the mec complex from CHE482 revealed that it 
contained a novel mecA promoter mutation, which creates a perfect palindromic sequence 
covering the region containing both the -10 box of the mecA promoter and the MecI/BlaI 
repressor-binding operator region. Due to the location of the mutation it seemed likely that it 
could affect mecA transcription efficiency and/or repressor-binding, and hence be a 
contributing factor to the extremely low-level β-lactam resistance of CHE482. A database 
search revealed that this mutation was very rare, but was also present in strain WIS, and 
various SCCmec type V isolates from Australia, the majority of which also have low level 
oxacillin resistance levels (Ito et al., 2004; O'Brien et al., 2005). We also looked at the effect 
of a mutation in the mecA rbs, which has been previously described and associated with low-
level resistance. Shukla et al., 2004, identified this rbs mutation in 34.7% of strains 
investigated during an epidemiological screen. All strains containing this mutation had a type 
IV SCCmec and the median oxacillin MIC of these strains was lower than in strains without 
the mutation (Shukla et al., 2004). However, the influence of this mutation on resistance 
levels has never been investigated experimentally.  
A previous study in S. sciuri indicated the potential impact that promoter mutations could 
have on β-lactam resistance levels. S. sciuri contains a non-SCCmec associated mecA 
homologue, mecA1, which has an 88% similarity to the mecA gene from SCCmec in S. 
aureus. The mecA1 gene did not confer β-lactam resistance in wildtype S. sciuri strain K1, 
however, a highly resistant variant, K1M200, could be selected in vitro. Increased resistance 
was accompanied by a mutation in the mecA1 promoter. Even though mecA1 does not 
contain a mecA consensus promoter, it was interesting to note that the mecA1 -10 box in K1 
(TATATT) was identical to that in CHE482. In the highly resistant variant K1M200 the -10 box 
mutation to TATAAT was accompanied by an increase in oxacillin MIC from 1 to 200 µg ml-1. 
Promoter-reporter gene fusions showed that the K1M200 promoter had a much higher 
activity than the K1 promoter (Wu et al., 2001). This suggests that alterations in the -10 box 
can have large impacts on transcription efficiency. 
 We established a system to test the influence of mecA promoter variants in two different S. 
aureus genetic backgrounds. The mecA genes and their respective promoters from CHE482 
(-10 box mutation), ZH47 (rbs mutation) and COLn (consensus promoter) were cloned and 
introduced into CHE482 and COLn strains that had been cured of their SCCmec (Figure 2). 
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Resulting strains were then tested for mecA transcription and induction by cefoxitin, their 
corresponding PBP2a expression levels and their β-lactam resistance levels.   
Transcriptional analyses revealed that the CHE482 promoter mutation, in pME1, had a 
strong effect on mecA transcription. In the CHE482 background (ME21), which contains the 
β-lactamase regulatory loci blaR1/blaI, transcription of mecA from pME1 was completely 
repressed and induced over time after addition of a sub-inhibitory concentration of cefoxitin. 
However, transcription of mecA from the consensus-sequence promoter in pME2 was 
already strong in the absence of induction and only increased slightly upon addition of 
cefoxitin. This indicates that the pME1 promoter mutation creates a much stronger BlaI 
repressor binding site than the general mecA promoter consensus. Analysis of the two 
promoter sequences in the COLn (ME131) background, which contains neither MecR1/MecI 
nor BlaR1/BlaI regulatory proteins, revealed further transcriptional differences. As expected, 
transcription of mecA was constitutive from both promoters, however, the transcript 
abundance from pME2 was much greater than that from pME1, indicating that transcription 
may be more efficient from the pME2 promoter. Transcription levels of mecA from pME3 
were very similar to those from pME2, indicating that the mecA rbs mutation had no 
significant effect on transcription and functioned with a similar efficiency to the consensus-
sequence promoter. PBP2a levels, from Western blot analyses, revealed that PBP2a 
expression levels closely corresponded to mecA transcription profiles, indicating that the 
ribosomal binding site mutation in pME3 appeared to have no effect on PBP2a translation. 
The large effect that the pME1 promoter had on mecA transcription did not, however, result 
in a correspondingly large influence on β-lactam resistance levels. Visible differences in 
resistance could be seen on cefoxitin gradient plates, indicating that the different promoter 
sequences did have small effects on resistance. However, overall effects on MIC levels were 
negligible. All ME21 complemented strains had similar, low oxacillin and cefoxitin MICs to 
CHE482; and all ME131 complemented strains had oxacillin and cefoxitin MICs of >256 μg 
ml-1. Therefore resistance levels in these two strains appear to be mainly governed by factors 
in their genetic background. Strains within identical clonal complexes have previously been 
shown to generally have similar resistance profiles (Katayama et al., 2005). CHE482 belongs 
to multi locus sequence type (MLST) ST45 and clonal complex 45, which is one of the so 
called major MRSA strain lineages (Katayama et al., 2005; Wannet et al., 2004). The 
majority of published strains belonging to this clonal complex, regardless of the SCCmec 
type they carry, including types I, II, IV, V or a novel SCCmec type (Boyle-Vavra et al., 2005; 
Enright et al., 2002; Ip et al., 2005; O'Brien et al., 2005; Wannet et al., 2004), are low-level 
resistant (≤ 32 µg ml-1) with only a few exceptions  (Regev-Yochay et al., 2006; Wannet et 
al., 2004). By comparison strain COL, belonging to MLST ST250 and containing a type I 
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SCCmec (Enright et al., 2002; McAleese et al., 2005) is associated with higher resistance 
levels than ST45.  
Because resistance levels of the plasmid-complemented strains were very similar to the 
wildtype strains before curing, it can be assumed that no other genes encoded on the 
SCCmec elements influence resistance levels, as previously suggested by Ryffel et al. 
(Ryffel et al., 1994). These results also confirmed previous findings that mecA transcription 
levels do not directly correlate with methicillin resistance levels (de Lencastre et al., 1994). 
A key difference between the genetic backgrounds of CHE482 and COLn is the presence of 
the BlaR1/BlaI regulators in CHE482. Unfortunately, attempts to cure CHE482 of its β-
lactamase-encoding plasmid were unsuccessful, so we were unable to determine what role 
BlaI repression played in the low level resistance of this strain. We therefore transformed the 
β-lactamase plasmid (pBla) from CHE482 and another β-lactamase plasmid pI524 into 
ME131. The presence of β-lactamase plasmids, especially pI524, in most cases led to the 
repression of mecA and subsequent induction upon cefoxitin exposure. The unequal 
repression by pI524 and pBla is possibly caused by differences in the blaI sequences (data 
not shown, (Smith and Murray, 1992)), which differ in two amino acids, that could potentially 
have an influence on dimerisation efficiency/ bonding force and therefore binding intensity of 
BlaI to the mecA promoter sequence. Other factors which might be involved are the plasmid 
copy number and the transcription efficiency. These changes in mecA transcription induced 
by pI524/pBla, however, once again had little effect on altering β-lactam resistance levels.  
Another major difference between CHE482 and COLn is their growth rates. CHE482 is a 
very fast growing strain with a minimum doubling time of 25 min. It had been postulated that 
mecA is repressed in most strains by the MecR1/MecI or BlaR1/BlaI, because high levels of 
PBP2a production in the absence of β-lactams is unfavourable (Rosato et al., 2003b). 
Therefore it is likely that strains such as COLn, which constitutively produce PBP2a, have 
undergone genetic mutations or adaptations allowing it to tolerate consistently high levels of 
PBP2a. The price for these adaptations might be reflected in its relatively slow growth rate. 
The hypothesized link between methicillin resistance levels and fitness (Ender et al., 2004) 
was also supported by the decreased growth rate of in vitro-selected CHE482 isolates with 
high oxacillin resistance levels (data not shown). The promoter mutation in CHE482, leading 
to tightly repressed PBP2a in the absence of β-lactams, may have been selected as a fitness 
adaptation of this strain. 
In summary, it appears that although mecA promoter mutations can have a large influence 
on mecA transcription and corresponding PBP2a levels, they have little effect on β-lactam 
resistance levels. Resistance levels appear to be strictly governed by unknown factors within 
a strains genetic background.  
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3.3 Project 3: A novel DNA-binding protein modulating β-lactam 
resistance in Staphylococcus aureus 
 
Abstract 
Methicillin resistance in Staphylococcus aureus is conferred by the mecA-encoded penicillin-
binding protein PBP2a, which is regulated by the repressor/sensor transducer MecI/MecR1 
and/or BlaI/BlaR1. Several additional chromosomal factors are also known to influence the 
expression of methicillin resistance, including some hypothetical factors that are yet to be 
identified. A previously uncharacterized protein, SA1665, of unknown function, containing a 
helix-turn-helix motif characteristic of DNA-binding transcriptional regulators, was found to 
bind to the mecA-promoter/5'-mecA coding sequence. Nonpolar deletion of SA1665 in 
several methicillin-resistant S. aureus (MRSA) of different genetic backgrounds increased 
oxacillin resistance to varying extents in all but one of the mutants; the remaining mutant 
derived from a highly β-lactam resistant strain had decreased resistance. Deletion of 
SA1665, however, had no obvious effects on mecA transcription or its induction by β-
lactams, or on amounts of PBP2a produced, in any of the strains tested. Therefore, despite 
the proven binding of SA1665 to the mecA-promoter/5’ region of the mecA gene, evidence 
suggests that its influence on β-lactam resistance expression is not exerted via 
transcriptional control of mecA, but through the control of currently unknown chromosomal 
factors.
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Introduction 
Methicillin resistant S. aureus (MRSA) are an ever increasing threat in clinical settings and 
more recently as an emerging community acquired pathogen. Their invasiveness and 
pathogenesis depends on a variable arsenal of virulence factors, while their resistance to β-
lactams and ability to rapidly generate or take up additional resistance determinants severely 
hampers therapy and eradication. In S. aureus, β-lactam resistance can be conferred by two 
mechanisms, either by production of a penicillinase, which hydrolytically cleaves β-lactam 
antibiotics, or by production of an additional penicillin-insensitive penicillin-binding protein 
(PBP), PBP2a (19, 23, 34). PBP2a takes over the transpeptidase function of native PBPs, 
which are acylated in the presence of β-lactam antibiotics rendering them inactive. β-lactam 
antibiotics act as substrate analogs, binding to the active site Ser403 at the N-terminal 
transpeptidase domain of the PBPs (39). PBP2a has a decreased affinity for β-lactams due 
to a distorted active site, which has to undergo novel conformational changes reducing the 
acylation rate and allowing peptidoglycan crosslinking to continue (25). In the presence of β-
lactams, PBP2a maintains cell wall biosynthesis together with PBP2, a bifunctional enzyme 
containing a β-lactam-sensitive transpeptidase domain, and a β-lactam-insensitive trans-
glycosylase domain responsible for polymerization of the peptidoglycan disaccharide 
subunits (32).  
PBP2a is encoded by mecA, a gene divergently transcribed from its cognate regulators, 
mecR1 (signal/sensor transducer) and mecI (transcriptional repressor). If mecR1/mecI are 
absent or truncated, transcriptional control of mecA is taken over by the structurally similar 
blaZ (penicillinase) regulatory elements blaR1/blaI, if present. In the absence of both 
regulatory loci, mecA is constitutively transcribed. BlaI and MecI both bind as homodimers to 
two sites within the mecA promoter/operator region, inhibiting transcription of both mecA and 
mecR1/mecI (17, 38). In the presence of β-lactams, the transmembrane proteins 
BlaR1/MecR1, undergo a conformational change at the C-terminal penicillin-binding domain 
due to acylation of the active site serine. This is followed by autoproteolytic cleavage of the 
N-terminal cytoplasmic domain, leading to the activation of the cytoplasmic peptidase and 
subsequent dissociation of the repressor due to proteolytic degradation of the repressor 
dimer (13, 16, 42). However, the signal transduction cascade of this regulatory system has 
still not been completely elucidated. Cohen and Sweeney postulated that an unidentified 
genomic factor, blaR2, was essential for the regulation of blaZ, as its mutation resulted in 
constitutive blaZ production (8). A number of additional genomic factors essential for 
methicillin resistance (fem), including genes involved in peptidoglycan precursor formation 
and hydrolysis, teichoic acid synthesis, global regulators and genes of unknown or poorly 
characterised functions, have been shown to influence methicillin resistance levels (3, 9, 10, 
36). 
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To identify potential factors involved in mecA regulation we performed DNA-binding protein 
purification assays using the mecA promoter region/5’ coding region of mecA as the bait. A 
putative DNA-binding protein, SA1665, was shown to bind to this DNA fragment and 
subsequently shown to have strain-dependent effects on β-lactam resistance levels when 
deleted.  
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Materials and Methods  
Strains mutants. Strains and plasmids used in this study are listed in Table 1. Clinical 
isolates are from the IMM collection in Zurich, Switzerland. Strains were grown at 37°C in 
Luria Bertani (LB) broth or on LB agar. Media were supplemented with the following 
antibiotics when appropriate: 25 or 50 µg ml-1 kanamycin, 10 µg ml-1 chloramphenicol, 5 or 10 
µg ml-1 tetracycline, 100 µg ml-1 ampicillin, 1-2048 µg ml-1 oxacillin. 
 
Table1. Strains and plasmids used in this study.  
Strain  Relevant genotype Origin, Reference 
S. aureus    
 CHE482  clinical MRSA isolate, CC45, ST45, 
SCCmecN1, blaZ (pBla) 
(11, 33) 
 ∆CHE482  CHE482 ∆SA1665 this study 
 COLn  COL derivative cured of plasmid pT181 
(tetK), SCCmec type I 
(22) 
 ∆COLn  COLn ∆SA1665 this study 
 ZH37  clinical MRSA isolate, CC45, ST45, 
SCCmec type IV, blaZ 
(33) 
 ∆ZH37  ZH37 ∆SA1665 this study 
 ZH44  clinical MRSA isolate, SCCmec type II, aac-
aph 
(33) 
 ∆ZH44  ZH44 ∆SA1665 this study 
 ZH73  clinical MRSA isolate, SCCmec type IV, 
blaZ 
(33) 
 ∆ZH73   ZH73 ∆SA1665 this study 
 RN4220  NCTC8325-4, restriction negative (24) 
E. coli    
 DH5α  restriction-negative strain for cloning Invitrogen 
 BL21 (DE3)  F- ompT hsdSB(rB-mB-) gal dcm (DE3) Novagen 
Plasmids    
 pBUS1  S. aureus-E. coli shuttle vector, tetL  (37) 
 pAW17  S. aureus-E. coli shuttle vector, aac-aph (37) 
 pKOR1  S. aureus-E. coli shuttle vector, cat, bla (2) 
 pME17  pKOR1-SA1664/SA1666, cat this study 
 pET28nHis6  E. coli protein expression vector, with n-
terminal His6 tag, aac-aph 
unpublished D. Frey 
 pME20  pET28nHis6-SA1665, aac-aph this study 
 pME26  pAW17-SA1665 and 700 bp up- and 380 
down-stream, aac-aph 
this study 
 pME27  pBUS1-SA1665 and 700 bp up- and 380 bp 
down-stream, tetL 
this study 
Abbreviations: CC, clonal complex; ST, sequence type. 
 
 
Susceptibility testing. Minimal inhibitory concentrations (MIC) were determined by Etest 
(Solna) according to CLSI guidelines (7). Resistance comparisons were performed using 
gradient plates, whereby cell suspensions of 0.5 McFarland were swabbed across agar 
plates containing an increasing concentration gradient of oxacillin. To ensure plasmid 
 
70  Results
 
maintenance kanamycin (25 µg ml-1) or tetracycline (5 µg ml-1) was added where appropriate. 
Population analysis profiles of oxacillin resistance were determined from overnight cultures 
grown in LB. Dilutions ranging from 100 to 108 were plated on agar plates of increasing 
oxacillin concentrations (0-2048 μg ml-1) and incubated at 35°C for 48 h. 
 
Markerless deletion of SA1665. In frame markerless deletions of SA1665, from the 
chromosomes of CHE482, ZH37, ZH44, ZH73 and COLn were constructed using the pKOR1 
plasmid system as described by Bae et al. (2). Primer pairs used to amplify the DNA 
fragments flanking SA1665, for recombination into pKOR1 were: me62attB1/me51BamHI 
and me62BamHI/me62attB2 (Table 2). Deletion mutants were confirmed by Southern blot 
analysis (1) and pulsed field gel electrophoresis (PFGE) (41). 
 
Cloning of SA1665 for complementation. A 1533-bp DNA fragment, containing SA1665 
together with 690-bp of upstream and 379-bp of downstream DNA, was amplified using 
primers me94BamHI/me94Asp718 (Table 2) and cloned into the E. coli/S. aureus shuttle 
vectors pAW17 and pBUS1, creating the complementing plasmids pME26 and pME27, 
respectively. Plasmids were then electroporated into RN4220 and further transduced using 
phage 85α.  
 
Binding-protein purification. Crude protein extracts were isolated from 50 ml cultures, 
grown to OD600nm 1.5, using Lysing Matrix B (BIO 101 Systems). Cell pellets were 
resuspended in 1.5 ml PBS (pH 7.4) and shaken 3x 20 s at speed setting 6.0 in a FastPrep 
FP120 (BIO 101 Systems). Suspensions were centrifuged for 1 min at 12,000 x g, the 
supernatants were collected and centrifuged for 10 min at 20,000 x g at 4°C. Supernatants 
were transferred to Amicon Ultra Centrifugal Filter Devices (Millipore), washed with 1x 
binding buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1 mM DTT, 0.5 M NaCl) and 
centrifuged until the volume had reduced to ~120 μl. Protein concentrations were measured 
by Bradford assay (BioRad Laboratories GmbH) (5). For binding protein purification, a 
biotinylated mecA promoter DNA fragment was amplified using primers me36F/me36Rbiot 
(Table 2) and 10 pmol was bound to streptavidin coated magnetic beads (10 mg ml-1, 
Dynabeads M-280 Streptavidin, DYNAL BIOTECH) that had been pre-washed twice with 2x 
BW buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 2 M NaCl) and resuspended in 400 μl of 1x 
BW buffer. After rotating at room temperature for 30 min, the beads were washed once with 
1x BW buffer and twice with 1x protein binding buffer (20 mM Hepes, pH 7.6, 1 mM EDTA, 
10 mM (NH4)2SO4, 1mM DTT, 0.2% Tween20 (w/v), 30 mM KCl). DNA-coated beads were 
mixed with 100 μg of crude protein extract in the presence of 1x protein binding buffer, 0.02 
μg μl-1 poly d(I-C) and 2 ng μl-1 poly L-lysine, and incubated at room temperature for 30 min 
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with constant rotation. After binding, beads were washed 4 times in 1x protein binding buffer 
and bound proteins were eluted in 50 μl elution buffer (1x protein binding buffer containing 2 
M KCl). Eluted proteins were dialysed over night at 4°C against water in ElutaTubes 
(Fermentas). Samples were concentrated by evaporation, run on a 15% SDS polyacrylamide 
gel and silver stained using the Protein Silver Staining kit (Amersham Biosciences AB) 
without the addition of glutaraldehyde. 
Bands of interest were excised from gels and analysed by mass spectrometry 
(LC/ESI/MS/MS) by the Functional Genomics Centre Zurich. The SA1665 protein sequence 
[BAB42933] was analysed by Blast search (http://www.ncbi.nlm.nih.gov/ BLAST) and a motif 
search (http://myhits.isb-sib.ch/cgi-bin/motif _scan). 
 
Primer extension. RNA was extracted (6) from CHE482 cultures that were grown to OD600nm 
0.5. Primer extension reactions were performed using 20 μg of total RNA and 3 pmol of the 
5’-biotin-labeled primer me97 (Table 2) using Superscript II reverse transcriptase 
(Invitrogen), according to the manufacturer’s instructions. Primer me97 was also used to 
generate sequencing reactions using the Thermo Sequenase sequencing kit (U.S. 
Biochemicals) and a sequencing template amplified using primers me52F and me52R (Table 
2). All samples were then run on a 6 % polyacrylamide sequencing gel, contact blotted onto 
a positive charged nylon membrane and biotin-detection was performed using the Biotin 
Chromogenic Detection Kit (Fermentas). 
 
Expression of recombinant SA1665 protein. SA1665 was amplified using primers 
me65BamHI/me65XhoI (Table 2) and cloned in-frame into pET28nHis6 (unpublished, D. 
Frey). The resulting plasmid, pME20, was then transformed into E. coli BL21 and 
recombinant nHis6-SA1665 protein was harvested. To maximise the abundance of soluble 
protein produced, cells were grown in osmotic shock medium (1 g l-1 NaCl, 16 g l-1 tryptone, 
10 g l-1 yeast, 1 M sorbitol, 10 mM betaine, modified from (4)) to OD600nm 0.5 at 37°C then 
cooled briefly on ice. Recombinant protein expression was induced by addition of 100 μM 
IPTG and the cultures were grown overnight at 22°C. Crude soluble proteins were extracted 
from cell pellets using CelLyticB 2X Cell Lysis Reagent (SIGMA). HIS-Select Cobalt Affinity 
Gel (SIGMA) was used to purify recombinant nHis6-SA1665 according to the manufacturer’s 
instructions.  
 
Electro mobility shift assay. For gel shift assays, 6 ng aliquots of the biotinylated-DNA 
fragment used for binding-protein purification were incubated with 0-250 ng of purified nHis6-
SA1665 protein in 1x binding buffer (20 mM Hepes pH 7.6, 1 mM EDTA, 10 mM (NH4)2SO4, 
1mM DTT, 0.2 % Tween20 (w/v), 30 mM KCl) containing 0.05 μg μl-1 poly d(I-C) (Roche) and 
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5 ng μl-1 poly L-lysine (Roche)). For control binding reactions, 130 x unlabelled mecA 
promoter DNA (amplified using primers 36F/36R, Table 2) was used as a specific binding 
competitor and 6 ng of herring sperm DNA was used as unspecific competitor DNA. Binding 
was carried out at 22°C for 30 min and samples were run on 6 % native polyacrylamide gels 
at 70 V. Samples were contact blotted onto positive charged nylon membrane, UV cross-
linked and detected with the Biotin Chromogenic Detection Kit (Fermentas). 
 
DNase I footprinting. A 193-bp biotinylated DNA fragment of the mecA promoter was 
amplified with primers me96 and me36F (Table 2). DNA-protein binding reactions, using 40 
ng of biotinylated PCR product and 1200-1500 ng of purified nHis6-SA1665 protein, were 
performed using the LightShift Chemiluminescent EMSA kit (Pierce Biotechnology) according 
to the manufacturer’s instructions. Binding reactions were incubated for 30 min at 22°C, 
before being subjected to DNAse I digestion (0.05 U µl-1, Fermentas) for 1 min at RT. An 
equal volume of stop solution (0.6 M NaOAc, 25 mM EDTA, MS2 phage RNA 40 µg ml-1, pH 
4.8) was then added to terminate DNase I digestion (18, 21). Samples were then ethanol 
precipitated, resuspended in an appropriate volume of dH20 and separated on a 6 % 
sequencing gel. To identify potentially protected DNA regions, samples were run alongside a 
negative control consisting of 40 ng of biotinylated-DNA subjected to identical processing but 
in the absence of protein. Gels were contact blotted onto positively charged nylon membrane 
(SIGMA) and biotin-detection was performed using the LightShift Chemiluminescent EMSA 
kit (Pierce Biotechnology). The associated sequencing reactions were carried out using the 
biotinylated primer me96 and the Thermo Sequenase sequencing kit (U.S. Biochemicals). 
 
Northern blot analysis. Strains were grown overnight in LB (Difco), diluted 1:200 and grown 
for another 3 h. This preculture was then used to inoculate 150 ml (1:1,000) of fresh 
prewarmed LB. Cells were then grown at 37°C to OD600nm 1.0 and induced with cefoxitin 4 μg 
ml-1. Cultures were sampled at time point 0’ before induction and at 10’ and 30’ after 
induction. To monitor SA1665 expression over growth, separate cultures were also sampled 
at different growth stages corresponding to OD600nm 0.25, 0.5, 1, 2, and 4. Samples were 
harvested by centrifugation at 4°C for 3 min at 13,000 g then snap-frozen in liquid nitrogen. 
Total RNA was extracted as described in Cheung et al. (6). RNA samples (8 μg) were 
separated in a 1.5 % agarose-20 mM guanidine thiocyanate gel in 1x TBE running buffer 
(15), transferred and detected as described previously (27). Digoxigenin (DIG) labelled-
probes were amplified using the PCR DIG Probe synthesis kit (Roche) and the following 
primers: for mecA, mecAP4/mecAP7  (30); for blaZ, blaZF/blaZR; for SA1665, 
SA1665F/SA1665R; for mecR1’, mecR1F/ mecR1R; for SA1664, SA1664F/ SA1664R; for 
SA1666, SA1666F/ SA1666R and for SA1667, SA1667F/ SA1667R (Table 2). 
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Western blot analysis. Cells were cultured, as previously described for Northern blot 
analysis, to OD600nm 1.0 then induced with cefoxitin 4 μg ml-1. Samples were collected at 0’ 
(before induction), 10’ and 30’ (after induction), harvested by centrifugation at 13,000 g for 3 
min, resuspended in 50 μl of PBS pH 7.4 containing 150 μg ml-1 of DNase, lysostaphin and 
lysozyme and incubated for 1 h at 37°C. Suspensions were then sonicated in a sonicating-
water bath for 4x 10 sec. Protein aliquots (15 μg) were separated on 7.5 % SDS-
polyacrylamide gels, blotted onto nitrocellulose membrane (Hybond) and stained with 
Ponceau to confirm equal protein loading. For detection, membranes were blocked for 1 h in 
1x low salt buffer (77.5 mM NaCl, 4.5 mM Tris, 0.05 % Tween20, pH 7.4) containing 5 % milk 
powder and then in 0.5 % milk powder in low salt buffer containing 40 μg ml-1 human IgG 
(CALBIOCHEM) for 30 min, before PBP2a antibody (1:20,000, Denka Seiken) was added 
and membranes were incubated for 1 h. Membranes were washed 3x 5 min in 1x low salt 
buffer before the secondary antibody, an anti-mouse IgG, HRP conjugate (1:2,500) in 1x low 
salt buffer containing 0.5 % milk powder, was added and incubated for 1 h. Membranes were 
washed 3x 5 min in 1x low salt buffer and detection was performed using SuperSignal West 
Pico Chemiluminescent Substrate (Pierce). 
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Table 2. Oligonucleotide primers used in this study. 
Primer name Nucleotide sequence (5’-3’) Reference 
Markerless deletion  
 me62attB1 GGGGACAAGTTTGTACAAAAAAGCAGGCTCCACTGGCTTATTCG
CTTGA 
This study 
 me51BamHI ATTAGGATCCTTAGTACATATCTAGGCCTA This study 
 me62BamHI ATTAGGATCCACTCTGTCTATCCATTCTGT This study 
 me62attB2 GGGGACCACTTTGTACAAGAAAGCTGGGTTGTGCGACAAGGATT
GCGA 
This study 
Cloning   
 me94BamHI ATTAGGATCCTCTTCAATCACTTGGCCAAT This study 
 me94Asp718 ATTAGGTACCAAGGTGCTGATGGTTATGAA This study 
 me65BamHI ATTAGGATCCGATAGACAGAGTTTTACAGA This study 
 me65XhoI ATTACTCGAGGATATGTACTAATTCTTCTT This study 
Protein-DNA binding,  EMSA and DNase I footprinting  
 me36F TGATAACACCTTCTACACCT This study 
 me36Rbiot BIOT-AACCCGACAACTACAACTAT This study 
 me36R AACCCGACAACTACAACTAT This study 
 me96 BIOT-CTTTATCTTTGGAAGCATAA This study 
Primer extension   
 me97 BIOT-ACTCTGTCTATCCATTCTGT This study 
 me52F CCACTGGCTTATTCGCTTGA This study 
 me52R TGTGCGACAAGGATTGCGAT This study 
Gene/transcript  detection   
 mecAP4 TCCAGATTACAACTTCACCAGG (30) 
 mecAP7 CCACTTCATATCTTGTAACG (30) 
 SA1665F TTCGTATAGAGGCTGGTTAG This study 
 SA1665R AATTGGTTGGTTATCTGGAT This study 
 mecR1F TGACACGACTTCTTCGGTTA This study 
 mecR1R AACGTATATGTTCATGGCGA This study 
 SA1664F TCAGCATGTAGATAACGCAA This study 
 SA1664R ATGTCACAATTGTTCTTGCT This study 
 SA1666F GACCATTATATTGTGCGACA This study 
 SA1666R TTGTGCCTTAGGATGTATCA This study 
 SA1667F TTGTGCCTTAGGATGTATCA This study 
 SA1667R TAATACCGTGTGATGAAGCT This study 
Restriction sites are underlined; BIOT: end-labelled with biotin. 
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Results and Discussion 
Identification of SA1665. A DNA-binding protein purification assay was performed to 
identify new potential factors involved in the regulation of mecA/PBP2a. The mecA/mecR1 
intergenic DNA region including the 5’ 9 bp of mecR1 and the first 52 bp of mecA was used 
as bait against crude protein extract from Staphylococcus aureus CHE482. Proteins binding 
to this DNA fragment were analysed by SDS-PAGE. Several protein bands appeared to be 
unspecific as they were pulled down by both DNA-labelled and unlabelled beads, however 
one protein band of approximately 15-20 kDa was only isolated from the labelled beads 
(Figure 1A).  
This binding-protein was identified as a hypothetical protein of unknown function, encoded by 
the open reading frame (orf) SA1665 in the S. aureus N315 genome annotation [BA000018]. 
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Figure 1.  
A, Silver stained SDS-polyacrylamide protein gel of DNA-binding protein assay. One additional band, indicated by 
an arrow, was identified, in the positive sample (P) compared to the negative control (C). The protein size marker 
(M) is shown on the left as a reference. 
B, Organisation of the putative operons covering SA1662 to SA1667. The regions used to construct the deletion 
mutants are indicated by lines framed by arrows, which represent the primers used for amplification. The 
chromosomal organisation after deletion of SA1665 is shown underneath.  
 
 
SA1665 encodes a predicted 17-kDa protein with an N-terminal helix-turn-helix (HTH) motif 
characteristic for DNA-binding transcriptional regulators. According to the hypothesis of 
Pérez-Rueda et al., the position of the HTH motif in SA1665 indicates that it is most likely to 
act as a repressor (31). The amino acid sequence identity of SA1665 was 100 % conserved 
amongst S. aureus database sequences and 96-97 % conserved amongst other 
staphylococci, including S. haemolyticus, S. epidermidis and S. saprophyticus, indicating that 
the amino acid sequence of SA1665 is highly conserved amongst staphylococcal strains. 
There are no highly conserved homologs in other bacterial species; the most similar 
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homologs from Bacillus licheniformis DSM13 and Desulfitobacterium hafniense Y51 share 
only 64 % and 59 % amino acid sequence similarity, respectively, with SA1665. 
 
Electro mobility shift assay (EMSA) using the mecR1/mecA intergenic region. EMSA 
was used to confirm SA1665 binding to the mecA promoter region. Crude protein extracts of 
E. coli strain BL21, carrying the empty plasmid (pET28nHis6) and of BL21 containing pME20 
(pET28nHis6-SA1665) which expressed SA1665 upon induction with IPTG, were incubated 
with the 161-bp biotinylated DNA fragment previously used for protein-binding purification. A 
band shift was observed with extracts from the strain expressing recombinant nHis6-SA1665 
but not from the control strain carrying the empty plasmid. Several bands resulted from the 
shift, which is most likely due to protein oligomerisation (Figure 2A). The specificity of the gel 
shift was also demonstrated by the addition of increasing concentrations of purified nHis6-
SA1665 protein to the biotinylated DNA fragment (Figure 2B). Controls consisted of the 
biotinylated mecA promoter fragment with no protein, with 250 ng of protein in the presence 
of a 130 x excess of specific competitor DNA (unlabelled mecA promoter DNA) and with 250 
ng of protein in the presence of unspecific competitor DNA (herring sperm DNA). Band-shift 
of the biotinylated DNA was inhibited in the presence of specific competitor DNA but not by 
the presence of the non-specific competitor DNA, confirming that nHis6-SA1665 had a 
specific binding affinity for the 161-bp mecA promoter/5’ mecA coding sequence fragment.   
 
DNAse I protection assay. DNaseI footprinting, used to identify the portion of the 
mecA/mecR1 intergenic region bound by nHis6-SA1665 fusion protein, revealed a very small 
potentially protected region of only 3-bp (TAA) (Figure 2C). This region was consistently 
protected in three independent experiments. This region is much smaller than that of 
conventional DNA-binding transcription factor binding sites, but as this was the only region 
consistently protected from DNaseI digestion it potentially indicates the vicinity of nHis6-
SA1665 binding. Interestingly this protected region was not within the mecA promoter, but in 
the mecA coding sequence, 15-17 bp downstream of the translational start site of the mecA 
gene. PRODORIC (28) predicted a monomeric state for SA1665, which could explain why 
the potential binding site shown here contained neither a second protected region nor a 
palindromic sequence. 
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Figure 2. 
Electromobility shift and DNase I footprinting of the mecA-mecR1 intergenic region by SA1665.  
A, Gel shift using crude protein extract. Lane 1, DNA, negative control; lanes 2 and 3, DNA with 200 ng and 500 
ng of crude protein extract from E. coli BL21 pET28nHis6, respectively; lanes 4 and 5, DNA with 200 ng and 500 
ng of crude protein extract from E. coli BL21 pME20 expressing SA1665, respectively. 
B, Gel shift by purified SA1665 protein. Lane 1, negative control, DNA; lane 2, DNA with 10 ng protein; lane 3, 
DNA with 40 ng protein; lane 4, DNA with 75 ng protein; lane 5, DNA with 150 ng protein; lane 6, DNA with 200 
ng protein; lane 7, DNA with 250 ng protein; lane 8, DNA with 250 ng of protein, in the presence of a 130 fold 
excess of unlabelled specific competitor DNA; lane 9, DNA and 250 ng protein in the presence of unspecific 
herring sperm DNA. 
C, DNase I protection assay. A small region of 3-bp (highlighted in grey), just downstream of the mecA start 
codon (framed) was protected from DNase I digestion in the DNA sample incubated with nHis6-SA1665 fusion 
protein (+) but not in the negative control which contained no protein (-).  
 
 
Effect of SA1665 deletion on β-lactam resistance. The MRSA strains CHE482, which is 
the type strain of the Swiss drug clone, COLn, and three clinical MRSA strains (ZH37, ZH44 
and ZH73) from the IMM collection of the University Zurich, were selected for the creation of 
SA1665 markerless deletion mutants via allelic replacement using pKOR1 (2) (Figure 1B). 
Strains CHE482, ZH37 and ZH73 all contained type B mec complexes (IS1272-∆mecR1-
mecA) with a truncated mecI/mecR1 regulatory locus. In all three of these strains mecA 
transcription was regulated by the penicillinase sensor and repressor BlaI/BlaR1. ZH44 
contained a type A mec complex (mecI-mecR1-mecA) whereby mecA expression was 
controlled by its cognate regulators MecI/MecR1. COLn contained neither the mecR1/mecI 
nor the blaR1/blaI regulatory loci, therefore mecA expression was constitutive. Further 
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relevant features of the selected strains were as follows: CHE482, belongs to clonal complex 
(CC) 45 and sequence type (ST) 45, carries a novel SCCmec (SCCmecN1 (11)) and has a 
cefoxitin MIC of 12 μg ml-1; COLn has a type I SCCmec and expresses high homogeneous 
oxacillin resistance and has a cefoxitin  MIC of >256 μg ml-1; ZH37 belongs to the same 
CC45/ST45 genomic background as CHE482 but contains a type IV SCCmec and has a 
cefoxitin MIC of 12 μg ml-1; ZH73 (ST217, CC22) contains a type IV SCCmec, and has a 
cefoxitin MIC of 64 μg ml-1; ZH44 has a similar PFGE profile to ST225, CC5 strains, has a 
type II SCCmec and a cefoxitin MIC of 48 μg ml-1.  
Resistance levels of SA1665 deletion mutants (∆CHE482, ∆ZH37, ∆ZH44, ∆ZH73 and 
∆COLn) and their corresponding wildtype parent strains were compared qualitatively on 
gradient plates containing appropriate increasing oxacillin concentration gradients (Figure 
3A). All but one of the mutants had increased resistance levels compared to their parent, with 
∆ZH44 and ∆ZH73 expressing considerably higher resistance levels. In contrast, the oxacillin 
resistance level of ∆COLn was slightly lower than that of its parent. To quantify resistance 
differences between mutant and wildtype strains, population analysis profiles were 
performed. The resistance profiles of mutants ∆CHE482, ∆ZH37, ∆ZH44 and ∆ZH73 all 
showed a distinct shift at the top of the curve, indicating that the majority of the cells in the 
mutant populations expressed higher basal oxacillin resistance levels than their 
corresponding wildtype strains (Figure 3B). Strains ∆CHE482 and ∆ZH37 also had more 
highly resistant subpopulations than their respective parents. In contrast, ∆ZH73 and its 
parent ZH73 both grew to the same oxacillin concentration limit and despite the majority of 
the ∆ZH44 population having higher resistance than wildtype ZH44, the ZH44 parent strain 
actually segregated a more highly oxacillin resistant subpopulation than its mutant. This 
decrease in growth at maximal oxacillin concentrations appears to be a strain specific 
phenotype associated with SA1665 deletion. In the high homogeneously resistant strain 
COLn, SA1665 deletion also lowered resistance compared to the wildtype.  
The identical resistance profiles of CHE482/∆CHE482 and ZH37/∆ZH37 suggests that 
despite having different SCCmec elements, it is their common clonal background (CC45) that 
controls their resistance levels and the extent of resistance increase upon SA1665 deletion. 
Most of the currently known fem/aux factors reduce methicillin resistance levels when 
inactivated. Only a few genes, such as lytH, the dlt operon, norG, sarV and cidA increase 
resistance levels upon inactivation or mutation. All of these genes, except norG which is an 
efflux pump regulator, play a role in either autolysis or are important for cell physiology and 
growth (14, 26, 29, 35, 40).  
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Figure 3. 
Effect of SA1665 deletion on oxacillin resistance levels.  
A, Growth of MRSA strains, their SA1665 deletion mutants and trans complemented mutants was compared on 
plates containing the indicated oxacillin gradients. Plates were supplemented with kanamycin 25 μg ml-1 or in the 
case of ZH44 with tetracycline 5 μg ml-1 to maintain complementing plasmids.  
B, Representative population analysis profiles of MRSA strains CHE482, ZH37, ZH44, ZH73 and COLn and their 
corresponding mutants. Wildtype strains are indicated by squares and mutants by triangles. x- and y-axis indicate 
the oxacillin concentrations [μg ml-1] and the colony forming units [cfu ml-1], respectively. 
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Effect of SA1665 deletion on growth rate. Growth curve analyses showed that deletion of 
SA1665 reduced the growth rate of all strains, with minimal doubling times of the mutants 
increased by 3 to 5 minutes (data not shown). The slower growth rates could be connected in 
some way to the increased oxacillin resistance of most of the mutants (12) although it seems 
unlikely that the modest changes in resistance levels were enough in themselves to 
significantly affect growth rates.  
 
Resistance complementation. Primer extension identified two potential SA1665 
transcriptional start sites (TSS), one 76-nt and a second 139-nt upstream of the SA1665 
ATG start codon (Figure 4). 
 
CTTCATTTACTTTCGCTTCATTATAAAGTAAACTTAACTC
TTGTTGACTTGATCAAAATTTAATACAAATGTGAAATTGA
CTCTTTTCATTTTATTAAAAATATATTAAGATGTAATCTG
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Figure 4. 
Primer extension analysis of the transcriptional start site of SA1665.  
A, Lanes A, C, G, T show the dideoxy-terminator sequencing ladder. Transcriptional start sites are indicated by 
arrows and with an asterisk in the partial sequence to the right.  
B, Sequence of the SA1665 promoter region. The putative -10 and -35 promoter sequences are underlined, the 
rbs is framed and the transcriptional start sites +1, are shown in bold. The translational start of SA1665 is 
highlighted in grey. 
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Predicted σA promoter consensus -10/-35 box sequences were located upstream of both 
TSS. The -10/-35 sequences (TAAGAT/TTTTCA) for the 76-nt TSS have previously been 
described in B. subtilis (20). The predicted -10/-35 sequences upstream of the 139-nt TSS 
(TTGACT/TTATAA) were less well conserved, but still shared some similarity with the σA 
consensus (Figure 4). 
Plasmids pME26 and pME27 were constructed for complementation of deletion mutants. 
Both plasmids contained the SA1665 orf along with its own promoter and transcriptional 
terminator. Strains ∆CHE482, ∆ZH37, ∆ZH73 and ∆COLn were complemented with pME26 
and ∆ZH44 with pME27. Wildtype-like resistance levels were restored in all mutants by 
introduction of the complementing plasmids (Figure 3A). In the case of ∆ZH73pME26, 
oxacillin resistance was reduced even further than that of wildtype ZH73 containing the 
empty plasmid pAW17. Small differences in resistance could be determined by oxacillin Etest 
for CHE482, ZH37 and ZH44 derived strains but not for ZH73 and COLn as MICs were >256 
μg ml-1 (Table 3). 
 
Table 3. Antibiotic minimal inhibitory concentrations 
 [μg ml-1].  
strain OX 
CHE482pAW17 1.5 
∆CHE482pAW17 3 
∆CHE482pME26 1.5 
ZH37pAW17 1.5 
∆ZH37pAW17 2 
∆ZH37pME26 1.5 
ZH44pBUS1 96 
∆ZH44pBUS1 >256 
∆ZH44pME27 4 
Abbreviation: OX, oxacillin. 
 
Transcriptional analysis. Northern blot analysis was used to investigate SA1665 
expression and the influence of SA1665 deletion on mecA, mecR1 and blaZ transcription, as 
blaZ is also under the regulatory control of both MecR1/MecI and BlaR1/BlaI. RNA samples 
taken from different time points over the growth curve of CHE482 showed that SA1665 was 
expressed strongly in early exponential phase at OD600nm 0.25 and 0.5 then transcript levels 
decreased and completely disappeared in stationary phase at OD600nm 4.0 (Figure 5A). In 
addition to the main transcript of ~0.46 knt a weaker, larger transcript of ~0.6 knt was also 
visible, especially at later growth stages.  
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Figure 5. 
Northern blot analysis of strains sampled over growth and Northern/Western blot analysis after induction with sub-
inhibitory concentrations of cefoxitin. Relevant sampling times or OD600nm values are indicated. 
A, Transcription of SA1665 over growth [OD600nm].  
B, Transcription of mecR1, SA1665, blaZ and mecA in CHE482, ∆CHE482 and ∆CHE482pME26 before and after 
induction [min] with cefoxitin 4 μg ml-1. Ethidium bromide stained 23 S rRNA bands are shown as a comparative 
indication of RNA loading. 
C, Transcriptional analysis of CHE482 and its mutant induced [min] with cefoxitin 4 μg ml-1, probed with SA1664, 
SA1665, SA1666 and SA1667. 
D, Western blots of PBP2a protein levels in ZH44, ZH73 and their respective SA1665 deletion mutants, before 
and after induction [min] with cefoxitin 4 μg ml-1. 
 
Northerns also showed that, as expected, the SA1665 transcript was absent from the 
deletion mutant, and demonstrated that a wildtype SA1665 transcript was once again present 
in the complemented mutant ∆CHE482pME26 (Figure 5B). Polar effects were excluded by 
further Northern blot analyses of neighbouring genes SA1664, SA1666 and SA1667. 
Interestingly, a weak transcript of about 3 kb was present in all Northerns hybridised with orfs 
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SA1664-SA1667. This band was absent in the SA1665 mutant when probed with SA1665 
and decreased in size to ~2.5 knt when probed with SA1664, SA1666 and SA1667. This 
suggested that SA1665 was present on several transcripts of different lengths (Figure 5C).  
Expression of mecR1, mecA, blaZ and SA1665 was analysed from RNA of uninduced and 
induced cultures of CHE482, its mutant ∆CHE482 and the complemented strain 
∆CHE482pME26. Cells were induced at OD600nm 1.0 with sub-inhibitory concentrations of 
cefoxitin to relieve BlaI-repression of mecA and blaZ.  
mecR1, although truncated in CHE482, was still transcribed and had the same expression 
pattern as both mecA and blaZ, all of which were derepressed over time and had the highest 
transcript levels after 30 min of induction. In the mutant ∆CHE482, transcription of all three 
genes was unaffected by SA1665 deletion, indicating that SA1665 has no influence on the 
expression of mecA, mecR1 or blaZ  
(Figure 5B).  
 
Western blot analysis. Mutants of ZH44 and ZH73, which had the largest differences in 
oxacillin resistance levels, were analysed by Western blot analysis to determine if SA1665 
affected translation of PBP2a from mecA. As indicated in Figure 5D, both pairs of wildtype 
and mutant strains had the same amounts of PBP2a present both before and after induction 
with cefoxitin, indicating that SA1665 deletion did not affect translation. Therefore it seems 
that SA1665 exerts no direct control over mecA or PBP2a expression.  
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Conclusion 
β-lactam resistance in MRSA is primarily dependent on the presence of the mecA gene, 
however, resistance levels are generally governed by strain-specific factors including mecA 
regulatory elements and other chromosomal fem/aux factors which either enhance or repress 
the expression of resistance. For instance, the very low-level β-lactam resistance of the 
Zurich “drug clone” S. aureus strain CHE482 was found to be controlled by its genetic 
background (Ender 2007, accepted), suggesting that it either contained or lacked certain 
fem/aux factors involved in controlling resistance expression. Many of the currently known 
fem/aux factors are directly or indirectly involved in cell wall synthesis and turnover, or 
envelope biogenesis, however there are still several factors of unknown function.  
SA1665, a predicted DNA-binding transcriptional regulator, was found to bind to a DNA 
fragment containing the mecA promoter region and a section of the 5’-mecA coding 
sequence. This protein can be classified as a new fem/aux factor, as oxacillin resistance 
levels were increased in four different MRSA and decreased in one highly resistant MRSA 
strain, upon SA1665 deletion. However, although this protein binds to the mecA 
promoter/coding sequence it does not appear to directly control mecA transcription or 
induction. It must therefore modulate β-lactam resistance in a mecA-independent manner. Its 
helix-turn-helix DNA-binding transcription factor homology suggests that it controls cellular 
functions affecting resistance levels.  
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3.4 Project 4: Random transposon insertion library of CHE482, a 
methicillin resistant Staphylococcus aureus (MRSA): Identification 
of novel fem factors 
 
 
Abstract 
Methicillin resistance in Staphylococcus aureus is not only dependent on mecA expression 
and the amount of PBP2a produced but also on chromosomal factors outside the resistance 
island, SCCmec (staphylococcal cassette chromosome mec). Chromosomal genes found to 
influence methicillin resistance have been classified as so called fem (factors essential for 
methicillin resistance) or aux (auxiliary genes) factors, but there are still large gaps in our 
understanding of the genetic mechanisms governing the wide range of different resistance 
phenotypes, indicating that there are additional, as yet undiscovered fem/aux factors. A new 
transposon-mutant library of CHE482, a very low resistant MRSA (oxacillin MIC 1.5 μg ml-1) 
with a completely different genetic background to strains used in previous studies, was 
generated to screen for either elevated or diminished resistance levels. Seventeen new orfs 
and four previously published orfs were identified by transposon inactivation.  
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Introduction 
Inhibition of proper cell wall biosynthesis by β-lactams, leading to growth arrest and cell lysis, 
is induced by the acylation and inactivation of the native penicillin binding proteins (PBPs), 
which are responsible for the crosslinking of peptidoglycan. β-lactams act as substrate 
analogues of the D-Ala-D-Ala of the peptidoglycan stem peptide (38), which is used by the 
PBPs in the transpeptidation reaction. In methicillin-resistant Staphylococcus aureus (MRSA) 
an acquired foreign PBP, PBP2a with a lower affinity to β-lactam antibiotics than the native 
PBPs, sustains cell wall biosynthesis in cooperation with the transglycosylase domain of 
PBP2, a bifunctional protein with transpeptidase and transglycoslyase activities (30). PBP2a, 
encoded by mecA, is localized on the staphylococcal cassette chromosome mec (SCCmec), 
a mobile resistance island integrating into orfX, an open reading frame of unknown function 
(19). mecA is either regulated by the divergently transcribed regulatory genes mecR1/mecI, 
coding for a sensor transducer and repressor protein; or, due to the structural and functional 
similarity of MecR1/MecI with BlaR1/BlaI, by the regulatory elements of the penicillinase 
gene (27). In so called pre-MRSA, regulated by MecI/MecR1, mecA transcription is highly 
repressed in the absence of an inducer and is induced so slowly by β-lactams that they 
appear β-lactam sensitive (23). 
It is known that PBP2a expression levels do not directly correlate with methicillin resistance 
levels and that other factors, depending on a strains genetic background, are responsible for 
determining the strains resistance level (4, 29, 32). Several factors have been identified to be 
necessary for methicillin resistance expression (4, 6, 11). These so called fem (factors 
essential for methicillin resistance) or aux (auxiliary) factors include housekeeping genes 
involved in cell wall biosynthesis, turnover or regulation (5), protein kinases, ABC 
transporters, and the catabolite control protein CcpA (11, 35). Inactivation of most fem/aux 
factors do not alter mecA expression, except for murE coding for a UDP-N-acetylmuramyl 
tripeptide synthetase, which was postulated to either directly or indirectly regulate mecA 
(PBP2a) and pbpB expression (14).  
A method used to find new factors involved in methicillin resistance is the creation of a 
random transposon insertion library in an MRSA strain and subsequent screening for altered 
drug resistance levels. Mutant libraries were previously generated in NCTC8325-mec and 
COL backgrounds, both of which are highly resistant strains, using the transposon Tn551. In 
this study an extremely low level oxacillin resistant strain CHE482, spreading in the area of 
Zurich, Switzerland was chosen to generate a random transposon library, allowing the 
selection of mutants with either increased or decreased β-lactam resistance. A higher yield of 
mutants, especially those identifying novel genes was anticipated here because we used the 
more random and highly efficient mariner transposon, bursa aurealis (2). The new library 
generated and analysed here expands the list of factors which affect methicillin resistance. 
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Materials and methods 
Bacterial strains and growth conditions. Strain CHE482, expressing low level oxacillin 
resistance, fusidic acid and trimethoprim resistance, was used to generate a random 
transposon insertion library (12, 31). The plasmids used were pFA545, carrying a 
transposase and tetracycline and ampicillin resistance genes and pBURSA containing the 
transposon bursa aurealis which encodes erythromycin resistance (2). The strains were 
grown in/on Luria Bertani broth/agar (LB, Difco) or tryptic soy agar (TSA, Difco) at 37°C or 
43°C. CHE482 carrying pBURSA was grown at 30°C due to the temperature sensitive origin 
of replication of pBURSA. Media were supplemented with 5 μg ml-1 tetracycline or 10 μg ml-1 
erythromycin when required.  
 
Transposon mutagenesis. CHE482 was sequentially transformed by direct electroporation 
with pFA545 and pBURSA. Direct electroporation was done as described in (20), whereby 
cells were mixed with 500 ng of plasmid DNA, incubated for 10 min on ice and electroporated 
using following settings: 25 μF, 2.0 kV and 100 Ω. Single colonies, growing on selective 
plates, were resuspended in 200 μl of prewarmed (43°C) dH2O. Twenty μl of a 10-1 and 100 
μl of a 10-2 dilution were plated on prewarmed TSA plates supplemented with 10 μg ml-1 
erythromycin. Colonies grown for 2 days at 43°C were picked into microtiter dishes 
containing LB (Difco) and were grown overnight at 37°C. To screen for higher and lower 
resistance, all wells were replica plated onto LB agar plates containing 0, 5 or 16 μg ml-1 of 
cefoxitin. 
 
Southern blotting. Confirmation of integration of bursa aurealis was done by Southern blot 
as described elsewhere (1). Hybridisation was done using an ermB-DIG labelled probe, 
generated with primers ermB-fwd and ermB-rev (5’-CGAAATTGGAACAGGTAAAG-3’/5’-
TTTATCTGGAACATCTGTGG-3’) using a PCR DIG probe synthesis kit (Roche). 
 
Susceptibility testing. Qualitative resistance comparisons were done by swabbing cells 
resuspended to a McFarland density of 0.5 on LB agar plates containing an increasing 
gradient of cefoxitin (0-8 μg ml-1). Plates were incubated at 35°C for 24 h.  
 
Phenotype confirmation. Phage 85α lysates of the CHE482 mutants were used to back 
transduce the mutations into the original wildtype CHE482. All back transductants were again 
analysed on gradient plates. 
 
Identification of transposon integration sites. Transposon integration sites of mutants 
with different resistance phenotypes were determined by inverse PCR using primers Martn-F 
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and Martn-ermR, and sequenced with Martn-F (2) on an ABI Prism 310 genetic analyzer 
(Applied Biosystems) using the ABI PRISM BigDye Terminator Cycle sequencing reaction kit 
(U.S. Biochemicals). Blast searches were done using the NCBI server 
(http://www.ncbi.nlm.nih.gov/BLAST/) and sequence alignments were performed with 
MultAlin (9). 
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Results and Discussion 
Transposon library. The very low level β-lactam resistant strain CHE482 belongs to clonal 
complex 45 and sequence type ST45, has a cefoxitin MIC of 12 μg ml-1, carries a mecB 
complex (IS1272-∆mecR1-mecA) and a penicillinase plasmid (12). This strain was 
transformed sequentially with pFA545 (encoding a transposase) and pBURSA (carrying the 
transposon), and selected for integration of bursa aurealis into the genome (2). A library 
comprising 8064 mutants was generated, which assuming random integration and an 
average orf size of ~ 1 kb, every orf within the staphylococcal genome should be interrupted 
approximately 3 times; based on data from the reference strain N315 which has a genome 
size of 2.8 Mbp and 2669 open reading frames (orfs). Subtracting the number of essential 
orfs, that cannot be disrupted, further increased the probability that most non-essential genes 
were interrupted. Transposon integration and randomness were confirmed in a selection of 
mutants by Southern hybridisation using an ermB probe to demonstrate integration in 
different sized restriction fragments.  
 
Mutant screening and phenotypic confirmation. The library, grown in a 96 well microtiter 
dish over night, was replica plated onto agar plates containing 0, 5 or 16 μg ml-1 of cefoxitin, 
respectively, to screen for mutants with potentially lower or higher cefoxitin resistance, 
respectively. Two hundred and nine mutants expressing a putatively different phenotype 
were further analysed for growth on plates containing a gradient of 0 to 8 μg ml-1 cefoxitin, to 
directly compare resistance differences with their parent CHE482. This method enabled 
discrimination of small differences in resistance levels. Only 51 (24.4%) mutants with lower 
and 14 (6.7%) with higher resistance were confirmed to have differences in resistance and 
then checked for linkage of the phenotype to the bursa aurealis insert by back transduction 
into CHE482. Linkage could be confirmed in 45 mutants by back transduction (Table 1). 
Eight mutants, with only slight differences, could not be clearly discriminated from the 
wildtype and their small differences observed immediately after back transduction were 
generally lost upon further passaging, suggesting selection of adapted variants (Table 2). In 
general, mutants produced single colonies at higher antibiotic concentrations on cefoxitin 
gradient plates indicating the emergence of compensatory mutants. Transduction of the 
bursa aurealis insert of these 8 putative fem/aux factors into 2 highly resistant MRSA strains 
BB270 and COL is ongoing to clarify their influence on methicillin resistance. Preliminary 
results showed altered resistance levels and therefore evidence for their function as fem/aux 
factors. 
The number of mutants expressing higher resistance was strongly reduced after back 
transduction. Linkage of the insert to higher resistance could be confirmed in only three out 
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of the 14 mutants. Presumably, since spontaneous selection of highly resistant variants 
occurred on the screening plates, independently of the insertion. 
 
Integration sites. The insertion sites of bursa aurealis were identified by iPCR and 
subsequent sequencing. Integration sites and their distance to the next start or stop codon 
and their corresponding cefoxitin phenotype on gradient plates are shown in Figure 1. Since 
integration of bursa aurealis results in a TA duplication, the integration sites indicated are 
correct within ± 2 bp (2). The putative gene functions and cellular roles, as indicated in the 
Tigr database (www.tigr.org), are listed in Tables 1 and 2. 
bursa aurealis was shown not to have a strong bias towards insertion in certain “hotspot” 
regions, unlike Tn551 and Tn917 (2, 3, 10). Multiple identical integration sites identified 
within a single gene were counted as one event since proliferation of a single mutant prior to 
the screening procedure could not be ruled out. 
Looking at the interruption efficiency of bursa aurealis in Newman, reported  by Bae et al. (2), 
indicated that a higher number of mutants, approximately twice the number used here, would 
have been necessary to hit all non-essential genes. Nevertheless the 45 mutants expressing 
an altered resistance phenotype identified here could be attributed to the inactivation of 21 
different orfs, 19 of which generated reduced resistance and only two of which increased 
resistance. The cellular roles of these 21 orfs are mainly unclassified or are associated with 
the cell envelope and transport-binding proteins (Table 3). Of the 21 orfs found in this study 
only four orfs were identical to previously published factors known to influence methicillin 
resistance. 
 
Published factors involved in methicillin resistance. bursa aurealis inserts were identified 
in mecA (Figure 1, Nr. 1), blaR1 (Figure 1, Nr. 42-45) and alr (Figure 1, Nr. 33-35), three 
genes known to be required for methicillin resistance: mecA codes for PBP2a, whose 
transpeptidase domain is able to sustain cell wall crosslinking in the presence of β-lactam 
antibiotics in cooperation with the transglycosylase domain of PBP2. Its low affinity to all β-
lactam antibiotics allows it to avoid acylation and consequent inactivation, which confers 
resistance to β-lactam antibiotics (16, 30). 
The interruption of the β-lactam sensor transducer, BlaR1, leads to continuous repression of 
mecA transcription as it can no longer mediate cleavage of the BlaI repressor, virtually 
abolishing mecA transcription and thus the synthesis of PBP2a, the prerequisite of methicillin 
resistance (33). Four separate mutants with decreased resistance were found to have 
insertions in BlaR1. 
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The alanine racemase, encoded by alr, interrupted by bursa aurealis at 3 different sites, is 
responsible for the conversion of L-alanine to D-alanine. D-alanine is incorporated in the 
peptidoglycan stem peptide and is involved in the crosslinking reaction in bacterial cell wall 
synthesis. Other factors involved in cell wall precursor synthesis have also been shown to 
decrease resistance when interrupted (5, 21). 
The fourth previously identified orf is SA1063, a protein kinase, found both here and in an 
earlier study using a COL transposon mutant library (11) to reduce β-lactam resistance. No 
further characterisation of this gene and its function has been done so far. 
 
Novel factors. The remaining 17 orfs identified are of unknown function and whether they 
directly or indirectly influence methicillin resistance still has to be evaluated. Transposon 
insertions may also affect neighbouring genes that might be organised in the same operon, 
so polar up- or down-stream effects, in the case of SA0461/SA0462/SA0463 and SA1563/ 
SA1564, can not be excluded. Information about the putative function of these 17 orfs is very 
scarce.  
 
Factors decreasing resistance. Some information on putative function of four of these 17 
genes may be deduced from sequence homologies to published genes.  
SA0461: The mfd gene (Figure 1, 4-7), coding for a transcription repair coupling factor, was 
described to be regulated by MgrA a major global regulator, which is involved in regulating 
virulence and antibiotic resistance (25).  
SA0462: The interrupted rfbX gene (Wzx) (Figure 1, Nr. 8-16) in Gram-negatives, codes for a 
predicted flippase with 12 transmembrane domains, which may be responsible for the 
flipping of the lipid-bound O-polysaccharide subunits across the membrane to the outside, 
where polymerisation of these subunits takes place. Its function in S. aureus and influence 
on methicillin resistance has not yet been reported (24, 34).  
SA0809: mnhE (Figure 1, Nr. 19) forms part of an operon consisting of 7 orfs (mnhA-mnhG), 
encoding an Na+/H+ antiporter. Interruption of mnhE might have an influence on the internal 
pH, the export of Na+ and Li+, the cell’s internal volume or the electrochemical potential 
across the membrane (17).  
SA1463: secDF (Figure 1, Nr. 25) codes for a protein with 12 putative transmembrane 
domains and two extracytoplasmic loops, which has been shown to form part of a sec 
translocation pathway in Bacillus subtillis. Protein transport was found to be just slightly 
affected by its deletion. SecDF is postulated to improve protein secretion capacities (7, 36).  
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Factors increasing resistance. Integration of bursa aurealis into SA0756/aroD, a 
hypothetical protein similar to 3-dehydroquinate dehydratase (Figure 1, Nr. 18), and into the 
promoter/operator region of SA1054 (Figure 1, Nr. 21-22), coding for dfp, a panthothenate 
metabolism flavoprotein homolog, increased resistance slightly. Interruption of aroD, which 
together with phosphoenol pyruvate converts D-erythrose 4-phosphate to chorismate, used 
in ubiquinone, folate and siderophore biosynthesis, resulted in strongly impaired growth 
(UniprotKB/Swissprot/KEGG database). SA1054/dfp is involved in pantothenate and CoA 
biosynthesis, where it catalyses the synthesis of the CoA precursor 4’-phosphopentetheine. 
Due to an inverse relationship between resistance levels and growth rate (13), the slightly 
increased resistance might be partially due to the slow growth. Secondly, since genes of the 
coenzyme A biosynthetic pathway are essential, the bursa aurealis integration into the dfp 
promoter/operator region suggests that dfp expression was reduced but not abolished (22). 
 
Phenotypes compensated upon subculturing. The resistance phenotypes of the eight 
interrupted orfs shown in Table 2 were lost upon subculturing. Whether these mutations were 
compensated by another pathway or gene function has still to be investigated.  
One of these genes glpD (Figure 1, Nr. 48), encoding glycerol-3-phosphate dehydrogenase, 
is involved in glycolysis, converting glycerol-3-phosphate to dihydroxyacetone phosphate. A 
possible cre-site (catabolite-responsive element) recognised by CcpA (catabolite control 
protein) was found in the initial sequence of the GlpD coding region of B. subtilis but not in S. 
aureus (personal communication K. Seidl) (11, 15, 35, 28). 
trpE (Figure 1, Nr. 49) produces the catalytically functional subunit of anthranilate synthase, 
the first enzyme of the tryptophan synthesis pathway converting chorismic acid to anthranilic 
acid (18, 40). 
ribA (Figure 1, Nr. 50) is a gene in the rib operon consisting of ribG-ribB-ribA-ribH catalysing 
conversion of ribulose-5-phosphate to riboflavin (26). 
citT (yflQ), (Figure 1, Nr. 51) together with citS, encodes a two-component system. CitT 
controls transcriptional expression of CitM, a Mg2+-citrate transporter (39). 
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Region of special interest. Inactivation of SA1661, a putative membrane protein, reduced 
methicillin resistance levels (Figure 1, Nr. 31-32). The converse effect was observed when 
SA1665, approximately 3.6-kb upstream of SA1661, was deleted. SA1665 is a putative DNA-
binding protein and transcriptional regulator that binds to the mecA coding sequence (see 
section 3.3). Adjacent to SA1665 is a two component system encoded by yhcS (SA1666) 
and yhcR (SA1667) that has been shown to influence cell wall biosynthesis, as fosfomycin 
resistance was reduced upon yhcS antisense RNA expression (37). Therefore this gene 
cluster, composed of 3 operons and an additional single transcriptional unit (putative operons 
were identified using http://www.softberry.com), contains several regulatory elements/genes 
(Figure 2) affecting methicillin resistance levels or cell wall biosynthesis and is therefore an 
interesting target for further studies. 
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Conclusion 
The staphylococcal genome shows high variability with a sequence identity of 94.7 % to  
99.7 % between strains N315, Mu50 and MW2 (2). Therefore, some factors affecting 
antibiotic resistance levels might be present or active in some strains but not in others.  
In this study, certain genes affecting resistance levels might have been missed due to the 
low initial methicillin resistance in CHE482, limiting the screening for reduced resistance. The 
number and selection of fem/aux factors found depends on the genetic background of a 
strain, on the transposon, and the selection conditions used. A supplementary factor is that 
the β-lactam antibiotic used, cefoxitin, a cephamycin with high affinity to PBP4 (8, 41), used 
in this study might select for different genetic determinants than methicillin or other  
β-lactams. Further investigation of these interrupted genes is ongoing. This involves 
transducing the insertions into MRSA of different genetic background expressing high 
homogeneous (COL) and high heterogeneous (BB270) resistance, to confirm their relevance 
for methicillin resistance. Analysis of direct correlations between mecA expression and the 
interruption of the identified fem/aux factors is being done by Northern blot or RT-PCR. 
The generation of a transposon library is an interesting tool to identify new fem/aux factors, 
which are not only involved in cell wall biosynthesis but also in cell metabolism. The main 
fraction of factors affecting methicillin resistance levels are genes of unknown function, 
requiring further characterisation and functional analysis. So far a large number of genes 
have been shown to affect methicillin resistance (11), and this number is still expected to 
increase due to the high variability found in the S. aureus genus. Therefore, while the mec 
complex is essential for methicillin resistance, resistance still depends on and is controlled by 
other chromosomal determinants (32). A lot of effort is still necessary to identify all fem/aux 
factors and to determine their relevance in methicillin resistance. Genetic factors responsible 
for the extremely low-level resistance of the drug clone are still unknown and may not be 
able to be identified by mutagenesis. 
 
 Table 1. Mutants of CHE482 altered resistance phenotype. Orf numbers are from N315 (SA) , pN315 (SAP), MRSA252 (SAR).  
Nr.1 Coord.2 Strain nr. Res. level3
Gene/ 
promoter Orf number Putative gene function Tigr cellular role category
1 38H11 ME333 lower mecA SA0038 Penicillin binding protein 2 A, PBP2A
Cell envelope: Biosynthesis and degradation of 
murein sacculus and peptidoglycan
2 59G3 ME311 lower
SA0370 
promoter SA0370 Putative DNA binding protein Hypothetical proteins (Hyp. Prot.): Conserved
3 5A1 ME291 lower SA0423
Hyp. prot., similar to autolysin (N-
acetylmuramoyl-L-alanine amidase) Unclassified: Role category not yet assigned
4 23F9 ME338 lower
5 40D11 ME320 lower
6 34C9 ME312 lower
7 59F9 ME339 lower
8 23C9 ME328 lower
9 67A7 ME299 lower
10 67A10 ME293 lower
11 67B12 ME301 lower
12 66G5 ME331 lower
Membrane protein involved in the export of O-
antigen and teichoic acid; similar to low 
temperature requirement B protein
Cell envelope: Biosynthesis and degradation of 
surface polysaccharides and lipopolysaccharides
mfd SA0461 Transcription repair coupling factor DNA metabolism: DNA replication, recombination, and repair
rfbX SA0462
 
 
  
Table 1 continued. 
Nr.1 Coord.2 Strain nr. Res. level3
Gene/ 
promoter Orf number Putative gene function Tigr cellular role category
13 68EF12 ME313 lower
14 68G12 ME325 lower
15 67A1 ME332 lower
16 68EF12-2 ME314 lower
17 34G7 ME315 lower SA0463
Putative tetrapyrrole (Corrin/Porphyrin) 
methylase
Unknown function: Enzymes of unknown 
specificity
18 37D8 ME300 higher SA0756
Hyp. prot., similar to 3-dehydroquinate 
dehydratase
Amino acid biosynthesis: Aromatic amino acid 
family
19 57D3 ME298 lower mnhE SA0809 Multisubunit Na+/H+ antiporter, MnhE subunit
Transport and binding proteins: Cations and iron 
carrying compounds
20 63 E1 ME294 lower SA0931 Putative membrane protein Cell envelope: Other
21 26G9 ME281 higher
22 26H11 ME285 higher
23 80G8 ME304 lower
24 29B8 ME318 lower
rfbX SA0462
Membrane protein involved in the export of O-
antigen and teichoic acid; similar to low 
temperature requirement B protein
Cell envelope: Biosynthesis and degradation of 
surface polysaccharides and lipopolysaccharides
SA1063 Protein kinase
Energy metabolism: Electron transport; 
Regulatory functions: Other; Protein synthesis: 
Ribosomal proteins: synthesis and modification
dfp  promoter SA1054 Pantothenate metabolism flavoprotein homolog Biosynthesis of cofactors, prosthetic groups, and carriers: Pantothenate and coenzyme A
 
 
  
Table 1 continued. 
Nr.1 Coord.2 Strain nr. Res. level3
Gene/ 
promoter Orf number Putative gene function Tigr cellular role category
25 17H3 ME305 lower secDF SA1463  Protein-export membrane protein SecDF
Protein fate: Protein and peptide secretion and 
trafficking
26 10G10 ME308 lower SA1501 Conserved hyp. prot.
DNA metabolism: DNA replication, recombination, 
and repair
27 16B11 ME289 lower SA1563
Phenylalanyl-tRNA synthetase (beta subunit) 
homolog Protein synthesis: tRNA aminoacylation
28 26G1 ME340 lower
29 41A11 ME310 lower
30 46F6 ME316 lower
31 14D8 ME326 lower
32 21B9 ME317 lower
33 20A1 ME292 lower
34 10H8 ME322 lower
35 79H9 ME330 lower
Hyp. Prot.: Conserved
SA1661 Putative membrane protein Hyp. prot.: Conserved
SA1564 
promoter SA1564 Conserved hyp. prot.
alr SA1874 Alanine racemase Cell envelope: Biosynthesis and degradation of murein sacculus and peptidoglycan
 
 
 
  
Table 1 continued. 
Nr.1 Coord.2 Strain nr. Res. level3
Gene/ 
promoter Orf number Putative gene function Tigr cellular role category
36 18C3 ME302 lower
37 13F9 ME321 lower
38 3D6 ME280 slightly lower
39 59 E4 ME309 lower
40 21C8 ME327 lower manB? SA2279 Hyp. prot., similar to phosphomannomutase Energy metabolism: Sugars
41 13F12 ME296 lower cycA (dagA) SAR1775 Putative D-serine/D-alanine/glycine transporter
Transport and binding proteins: Amino acids, 
peptides and amines
42 30A7 ME282 lower
43 79F4 ME334 lower
44 5H6 ME306 lower
45 22F10 ME307 lower
blaR1 SAP011 Bla regulator protein BlaR1, pN315 β-lactamase plasmid Regulatory functions: Other
corA SA2137 Hyp. prot. similar to divalent cation; Mg
2+ and 
Co2+ transporters 
Transport and binding proteins: Unknown 
substrate; Transport and binding proteins: Amino 
acids, peptides and amines
 
1 Identical integration sites are indicated by bold numbers. 
2 Coordinates of the microtiter dishes comprising the mutant collection. 
3 Resistance level compared to parent strain. 
 
 
  
Nr.1 Coord.2 Strain nr. Res. level3
Gene/ 
promoter Orf number Putative gene function Tigr cellular role category
46 MA11 ME343 no difference SA0241
Hyp. prot., similar to 4-diphosphocytidyl-2C-
methyl-D-erythritol synthase Unclassified: Role category not yet assigned
47 70G8 ME358 no difference SA0836
Hyp. prot., similar to transcription regulator LysR 
family Regulatory functions: DNA interactions
48 35H12 ME297 no difference glpD SA1142 Aerobic glycerol-3-phophate dehydrogenase Energy metabolism: Other
49 74D3 ME344 no difference trpE SA1199
Hyp. prot., similar to anthranilate synthase 
component I
Amino acid biosynthesis: Aromatic amino acid 
family
50 64 E10 ME341 no difference ribA SA1587
GTP cyclohydrolase II; riboflavin biosynthesis 
protein
Biosynthesis of cofactors, prosthetic groups, and 
carriers: Riboflavin, FMN, and FAD
51 31 E10 ME286 no difference citT SA2486
Di- and tricarboxylate transporters, 2-
oxoglutarate/malate translocator homolog Transport and binding proteins: Anions
52 63C6 ME287 no difference
53 63C10 ME357 no difference
54 19F3 ME319 no difference
SAP031 
promoter SAP031 Hyp. prot., pN315 β-lactamase plasmid
SAOUHSC02047
Phage putative head morphogenesis protein, 
SPP1, gp7 family domain protein
Mobile and extrachromosomal element functions: 
Prophage functions
 
Table 2. Mutants of CHE482 initially exhibiting a resistance phenotype. Orf numbers are from N315 (SA) , pN315 (SAP), NCTC8325 (SAOUHSC). 
2 Coordinates of the microtiter dishes comprising the mutant collection. 
1 Identical integration sites are indicated by bold numbers. 
3 Resistance level compared to parent strain. 
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Figure 1. 
 
 
cons. hyp. 
prot.
242 bp
PBP2A sensor
transducer
SA0037 SA0038
mecA
SA0039
mecR1 CHE482
1-ME333
0                                                            8 μg ml-1
1
CHE482
2-ME311
0                                                            8 μg ml-122 bp
transposase
for IS1181
cons. 
hyp. 
prot.
hyp. 
prot. 
SA0369
tnp
SA0370 SA0371
2
similar to 
lactococcal
lipoprotein
408 bp
similar to 
autolysin
(N-actetyl-
muramoyl-L-
alanine
amidase)
hyp. prot.
SA0422 SA0423 SA0424
CHE482
3-ME291
0                                                            8 μg ml-1
3
772 bp
SA0460
pth
SA0461
mfd
SA0462
210 bp
SA0460
pth
SA0461
mfd
SA0462
peptitdyl-
tRNA
hydrolase
transcription
repair
coupling
factor
hypothetical
protein, 
similar to low
temperature
requirement
B protein
2301 bp
SA0460
pth
SA0461
mfd
SA0462
CHE482
4-ME338
0                                                            8 μg ml-1
CHE482
5-ME320
0                                                            8 μg ml-1
CHE482
6-ME312
0                                                            8 μg ml-1
CHE482
7-ME339
0                                                            8 μg ml-1
4/5
6
7
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
104  Results
 
Figure 1 continued. 
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Figure 1 continued. 
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22-ME285
0                                                            8 μg ml-1
CHE482
21-ME281
0                                                            8 μg ml-1
CHE482
23-ME304
0                                                            8 μg ml-1
21/22
23
cons. 
hyp. 
prot.
protein
kinase
664 bp
SA1062 SA1063
cons. 
hyp. 
prot.
SA1064
CHE482
24-ME318
0                                                            8 μg ml-1
24
protein-
export
membrane
protein
SecDF
1252 bp
hyp. prot. 
similar to 
single-strand
DNA specific
exonuclease
cons. 
hyp. 
prot.
SA1462 SA1463
secDF
SA1464
CHE482
25-ME305
0                                                            8 μg ml-1
25
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Figure 1 continued. 
 
 
433 bp
hyp. 
prot. 
cons. 
hyp. 
prot.
50S 
ribosomal
protein
L20
SA1500
SA1501
SA1502
rplT
CHE482
26-ME308
0                                                            8 μg ml-1
26
phenyl-
alanyl-
tRNA
synthe-
tase
(beta
subunit) 
homolog
269 bp
DNA 
translo-
case stage
III 
sporulation
protein
homolog 
cons. 
hyp. 
prot.
SA1562 SA1563 SA1564
47 bp
phenyl-
alanyl-
tRNA
synthe-
tase
(beta
subunit) 
homolog
cons. 
hyp. 
prot.
SA1563
SA1564
SA1565
thio-
redoxin
homolog
CHE482
27-ME289
0                                                            8 μg ml-1
CHE482
28-ME340
0                                                            8 μg ml-1
CHE482
29-ME310
0                                                            8 μg ml-1
CHE482
30-ME316
0                                                            8 μg ml-1
27
28-30
SA1660 
cbf1
2288 bp
SA1661 SA1662
CHE482
31-ME326
0                                                            8 μg ml-1
31
cmp-
binding
factor 1
cons. 
hyp. 
prot.
cons. 
hyp. 
prot.
2186 bp
SA1660 
cbf1
SA1661 SA1662
CHE482
32-ME317
0                                                            8 μg ml-1
32
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Figure 1 continued. 
 
 
379 bp
SAS067 SA1874
alr
SA1875
1112 bp
SAS067 SA1874
alr
SA1875
hyp. 
prot.
alanine
race-
mase
holo-
ACP
syn-
thase
102 bp
SAS067 SA1874
alr
SA1875
CHE482
34-ME322
0                                                            8 μg ml-1
CHE482
35-ME330
0                                                            8 μg ml-1
CHE482
33-ME292
0                                                            8 μg ml-1
33
34
35
134 bp
SA2136 SA2137
corA
SA2138
CHE482
36-ME302
0                                                            8 μg ml-1
36
918 bp
SA2136 SA2137
corA
SA2138
isopen-
tenyl
diphos-
phate
isome-
rase
hyp. 
prot. 
similar
to 
divalent
cation
cons. 
hyp. 
prot.
647 bp
SA2136 SA2137
corA
SA2138
CHE482
37-ME321
0                                                            8 μg ml-1
CHE482
39-ME309
0                                                            8 μg ml-1
CHE482
38-ME280
0                                                            8 μg ml-1
37/38
39
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Figure 1 continued. 
 
 
hyp. prot. 
similar to 
mutator
protein
mutT
hyp. prot. 
similar
to 
phospho-
manno-
mutase
hyp. 
prot.
946 bp
SA2278 SA2279 SA2280
CHE482
40-ME327
0                                                            8 μg ml-1
40
citrate
synthase
II 
putative 
D-
serine/D-
alanine/ 
glycine
transpor-
ter
pyruvate
kinase
31 bp
SAR1774
citZ
SAR1775
cycA/dagA
SAR1776
pykA
796 bp
SAP010
blaZ
SAP011
blaR1
SAP012
blaI
1336 bp
SAP010
blaZ
SAP011
blaR1
SAP012
blaI
1350 bp
SAP010
blaZ
SAP011
blaR1
SAP012
blaI
beta-
lacta-
mase
bla
regulator
protein
penicillin-
ase
repressor
723 bp
SAP010
blaZ
SAP011
blaR1
SAP012
blaI
CHE482
41-ME296
0                                                            8 μg ml-1
CHE482
42-ME282
0                                                            8 μg ml-1
CHE482
43-ME334
0                                                            8 μg ml-1
CHE482
44-ME306
0                                                            8 μg ml-1
CHE482
45-ME307
0                                                            8 μg ml-1
41
42
43
44
45
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Figure 1 continued. 
 
 
38 bp
hyp. 
prot.
sorbitol
dehydroge-
nase
homologue
similar to 4-
diphopho 
cytidil-2C-
methyl-D-
erythritol 
synthase
SAS008
SA0240
SA0241
CHE482
46-ME343
0                                                            8 μg ml-1
46
85 bp
ClpB
chaperone
homo-
logue
hyp. prot. 
similar to 
transcrip-
tion
regulator
LysR
family
hyp. prot. 
similar to 2-
isopropyl-
malate 
synthase
SA0835 SA0836 SA0837
CHE482
47-ME358
0                                                            8 μg ml-1
47
glycerol
kinase
aerobic
glycerol-
3-phos-
phate 
dehydro-
genase
1264 bp
SA1141
glpK
SA1142
glpD
hyp. prot. 
similar to 
lysophos-
pholipase
SA1143 
CHE482
48-ME297
0                                                            8 μg ml-1
48
hyp. prot. 
similar to 
glucanase
hyp. prot. 
similar to 
anthran-
ilate
synthase
compo-
nent I
1149 bp
SA1198 SA1199
trpE
anthranilate
synthase
component
II
SA1200
trpG CHE482
49-ME344
0                                                            8 μg ml-1
49
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Figure 1 continued. 
 
 
400 bp
6,7-
dimethyl-
8-ribityl-
lumazine 
synthase
riboflavin
biosyn-
thesis
prot.
SA1586
SA1587
ribA
SA1588
riboflavin
synthase
alpha
chain
CHE482
50-ME341
0                                                            8 μg ml-1
50
hyp. 
prot. 
2-
oxogluta-
rate/ 
malate
translo-
cator
homolog
hyp. 
prot. 
similar to 
rarD
protein
978 bp
SA2485 SA2486
citT
SA2487
CHE482
51-ME286
0                                                            8 μg ml-1
51
cons. 
hyp. 
phage
prot. 
phage
putative 
head
morpho-
genesis
prot. SPP1
phage
portal
protein
SPP1 
family
73 bp
SAOUHSC 
02046
SAOUHSC 
02047
SAOUHSC 
02048
hyp. 
prot. 
hyp. 
prot.
putative 
repli-
cation
initiation
prot. 
Rep
42 bp
SAP029 SAP031 SAP001
0
CHE482
52-ME287
0                                                            8 μg ml-1
CHE482
53-ME357
0                                                            8 μg ml-1
CHE482
54-ME319
0                                                            8 μg ml-1
52/53
54
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 
Schematic illustration of the gene/promoter interrupted by bursa aurealis and adjacent genes. The site of 
integration is indicated by an orange arrow. The distance of the insertion site to next stop or start codon is 
indicated and displayed by a black line. orf numbers are from strains N315-SA [BA000018], pN315-SAP 
[AP003139], MRSA252-SAR [BX571856] and NCTC8325-SAOUHSC [CP000253]. 
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Table 3. Number of interrupted orfs expressing altered resistance phenotypes, classified by their cellular role (Tigr 
database). orf numbers are from N315 (SA) , pN315 (SAP), MRSA252 (SAR). 
Nr. Cellular role category Orf number 
5 Unclassified SA0370, SA0423, SA0463, SA1564, SA1661 
4 Cell envelope  SA0038, SA0462, SA0931, SA1874 
3 Transport and binding proteins SA0809, SA2137, SAR1775 
2 DNA metabolism SA0461, SA1501 
2 Energy metabolism SA1063, SA2279 
2 Amino acid biosynthesis SA0756, SA1563 
1 Protein fate SA1463 
1 Regulatory function SAP011 
1 Biosynthesis of cofactors etc. SA1054 
21 total   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cmp-
binding-
factor 1 
replication
enhancer
cons.       
hyp.         
prot.
cons.       
hyp.         
prot.
cons.      
hyp.         
prot
cons.      
hyp.         
prot
hyp.        
prot.
two
compo-
nent
response
regulator
homolog
two compo-
nent
sensor
histidine
kinase
homolog
SA1660
cbf1
SA1661 SA1662
SA1663
SA1664
SA1665
SA1666
yhcS
SA1667
yhcR
 
Figure 2. 
Organisation of the putative operons covering orfs SA1660 to SA1667 (putative operons were identified using 
http://www.softberry.com). The operons are coloured green (SA1660-SA1662), yellow (SA1663-SA1664), blue 
(SA1666-SA1667), and the SA1665 single orf transcript is shown in red. Putative functions are indicated, if 
known. Genes shown to affect methicillin resistance are in bold type. 
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4. Comments – Outlook 
The variability in SCCmecN1 spreading among injection drug users in Zurich, Switzerland 
suggests that SCCmec is a dynamic structure, even within a rather small and seemingly 
localized MRSA clone. To follow the further spread and evolution of this so called dug clone 
the following questions need to be addressed: Will new variants of SCCmecN1 continue to 
arise? Will the drug clone acquire additional chromosomal resistances over time? Will clones 
of higher β-lactam resistance emerge and whether or not the elevated resistance will cause a 
fitness loss? Will drug clones spread outside the drug user community to other environments 
or regions? Is the ratio drug clone versus other MRSA clones increasing or decreasing over 
time? 
Following the evolutionary process of this clone and its SCCmec might be a complex task 
because several variants have already been detected and as continuous changes in the 
chromosome and SCCmec occur, SCCmec heterogeneity is likely to increase. 
 
Evidence that a mecA promoter mutation had only a minor effect on β-lactam resistance 
levels and that unknown chromosomal genes had a higher impact, confirms that the strains 
genomic background is of considerable importance for β-lactam resistance, not only 
determining heterogenity/homogenity but also how high or low a strains resistance levels will 
be.  
A novel DNA-binding protein (SA1665) was identified and shown to indirectly modulate β-
lactam resistance in Staphylococcus aureus. Although it binds to the mecA coding DNA it 
does not influence mecA transcription or PBP2a levels. This novel transcription factor might 
regulate several factors but those relevant in β-lactam resistance need to be identified. 
Potentially regulated chromosomal factors might be previously discovered fem/aux factor/s or 
a completely new factor/s of which the function will have to be elucidated.  
The random transposon insertion library of CHE482, a low level methicillin resistant S. 
aureus, allowed the identification of novel fem/aux factors that have an impact on β-lactam 
resistance, showing that not all genes affecting β-lactam resistance have been identified. To 
extend this list even further, screenings of strains with different clonal backgrounds and 
resistance levels would be necessary, as some genes may have very large effects on β-
lactam resistance levels in some strains but not others. Identification of the genes 
responsible for low/high and heterogeneous/homogeneous β-lactam resistance expression 
will be difficult as several factors most probably contribute to this phenotype, and resistance 
levels may not just depend on the absence or presence of these genes but also on their 
expression levels.  
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strain was grown in competition with the cured variant it only survived by segregating faster 
growing heterogeneously resistant variants. Therefore the acquisition of SCCmec, conferring 
high-level methicillin resistance imposes a fitness burden on naïve MSSA. Fitness can be 
regained in these strains but at the cost of lowered resistance. 
 
Collaboration: Molecular epidemiology of methicillin-resistant Staphylococcus aureus in 
Zurich, Switzerland (2003): Prevalence of type IV SCCmec and a new SCCmec element 
associated with isolates from drug users. 
Epidemiological analyses were performed on MRSA isolated from the Zurich area in 2003. 
Characterisation included determination of SCCmec type, resistance profile and genetic 
lineage. Typical hospital acquired SCCmec type I/II/III were found in 26 % of isolates, while 
41 % contained SCCmec type IV. Twenty-six strains carried untypable SCCmec elements, of 
which 22 belonged to a single clone with a CC45/ST45 MLST type, and low level oxacillin 
resistance. Other distinguishing features included a novel SCCmec element with a ccrAB4-
like recombinase, and trimethoprim resistance conferred by dfrA of Tn4003. This clone was 
found among injection drug users in the area of Zurich and therefore referred as a “drug 
clone”. Different variants of this clone have already been found, some containing either an 
additional sulfomethoxazole or ciprofloxacin resistance. MRCNS had a completely different 
pattern of SCCmec types and no drug clone SCCmec was identified, indicating that no 
considerable interspecies transfer occurred between MRSA and MRCNS populations. 
Contribution: Implementation of the SCCmec typing and molecular characterisation of the 
new SCCmec element of the “drug clone”. 
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Collaboration: Fitness cost of staphylococcal cassette chromosome mec in methicillin-
resistant Staphylococcus aureus by way of continuous culture. 
Integration of mobile genetic elements can often result in decreased fitness, unless 
compensatory mutations occur. Isogenic transformants containing either SCCmec type I or 
IV were investigated and their effect on fitness determined by the use of continuous cultures. 
Comparison of glucose consumption, ATP demand per gram of cells and cell yield showed a 
decreased growth yield after the acquisition of type I SCCmec whereas type IV had no 
adverse effect on fitness. 
Contribution: Implementation of the media, run of the continuous cultures, measurements of 
dry weight, glucose consumption and ATP production - together with Sui Mae Lee. A third 
measurement was performed by Sui Mae Lee. 
 
Supervision: Mosaic staphylococcal cassette chromosome mec containing two 
recombinase loci and a new mec complex, B2. 
In the epidemiological study at the Institute of Medical Microbiology, University Zurich in 
2003, a new type of staphylococcal cassette chromosome mec (SCCmec) element was 
detected, which seemed to harbour both ccrAB2 and ccrC. Cosmid cloning and sequencing 
of this element identified a new mec complex (B2) interrupted by Tn4001, conferring 
aminoglycoside resistance, and confirmed the presence of both ccrAB2/ccrC loci. Sequence 
comparisons revealed that this element had a mosaic structure and that several 
recombination events were likely to have occurred during its assembly. 
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Transformation of a type I SCCmec element into Staphylococcus aureus yielded highly oxacillin-resistant
transformants with a reduced growth rate. Faster-growing variants could again be selected at the cost of
reduced resistance levels, demonstrating an inverse correlation between oxacillin resistance levels and growth
rate.
The development of antibiotic resistance in bacteria through
either the acquisition of resistance elements or mutation often
occurs at the cost of reduced fitness and may result in a de-
creased bacterial growth rate (1). Evolution in the natural or
the clinical environment usually selects for fitter variants,
which compensate for the cost of resistance through the de-
velopment of secondary mutations or the loss of the resistance
(10).
Methicillin resistance in methicillin-resistant Staphylococcus
aureus (MRSA) is mediated by the acquisition of the SCCmec
element, which integrates in a site-specific manner into the
staphylococcal genome (7). Besides the mecA gene, which
codes for a penicillin-binding protein (PBP) with a low affinity
to -lactams, it harbors a variable set of genes unrelated to
methicillin resistance and serves as an integration site for var-
ious other resistance determinants, transposons, and plasmids.
Establishment of the SCCmec element in staphylococci theo-
retically encounters two main obstacles: one is the cost of
maintenance of a relatively large additional element, of which
only the mecA gene is essential for resistance; the second is the
accommodation of the new PBP 2a into the staphylococcal cell
wall synthesis complex. Initially, when PBP 2a enters a naïve S.
aureus strain and in the absence of -lactam pressure, PBP 2a
is not beneficial and the cells select against its production (8).
The ability of S. aureus to accommodate SCCmec and/or to
functionally integrate PBP 2a differs from strain to strain, re-
sulting in a wide range of resistance levels (3). Irrespective of
their original oxacillin resistance levels, MRSA strains are re-
sistant to all -lactam antibiotics due to their ability to segre-
gate highly resistant variants. Multiple different mutations may
lead to high levels of resistance (for reviews, see references 13
and 14), but few of them have been identified (4, 9).
Our goal was to measure the in vitro cost of SCCmec on
fitness by monitoring changes in growth rates. We transformed
naïve, susceptible strain BB255, a derivative of the widely used
strain NCTC8325 (6), by the CaCl2 method (2) with DNA
originating from an MRSA strain containing a type I SCCmec
element. The transformants were selected on plates containing
4 g of cefoxitin per ml. Resistance tests were performed
according to the recommendations of the National Committee
for Clinical Laboratory Standards (11). The transformants
were highly oxacillin resistant (MICs, 512 g/ml). The stability
of the high-level-methicillin-resistance phenotype of represen-
tative strain RA120 was tested by dilution of an RA120 culture
and subsequent regeneration from single cells in nonselective
medium, which demonstrated that the high-level-resistance
phenotype was not an induction phenomenon resulting from
selection on cefoxitin.
Interestingly, the transformants grew much slower than the
susceptible parent, with a generation time of 40  0.1 min
compared to a generation time of 29  0.1 min for strain
BB255. Strain RA120 was cured of SCCmec by transient over-
expression of ccrAB from plasmid pSR3-1, which induces pre-
cise, site-specific excision of SCCmec, as described by Ito et al.
(5). The resulting susceptible strain, strain ME23, regained the
doubling time and the chromosomal SmaI pulsed-field gel
electrophoresis (PFGE) pattern of wild-type strain BB255
(Fig. 1), demonstrating the excision of SCCmec. This decrease
in the growth rate after the introduction of SCCmec and the
subsequent increase in the growth rate upon curing confirmed
that SCCmec and/or the resulting high oxacillin resistance level
was the cause of the decreased growth rate and, thus, the loss
of fitness in vitro.
Mixed growth competition assays were performed between
strain RA120 and susceptible strain ME23 by inoculating 104
CFU of each strain into 10 ml of Luria-Bertani broth in the
absence of antibiotic pressure. Where indicated, the ratio of
RA120 to its competitor was raised to 100:1 by increasing the
RA120 inoculum to 106 CFU. Every 24 h the mixed culture was
diluted by a factor of 104 with fresh broth, and the number of
CFU of the susceptible strain per milliliter versus that of the
resistant strain was determined by plating aliquots on nonse-
lective plates and on plates containing 1 g of oxacillin per ml
and calculating the difference in the number of CFU. At an
initial ratio of RA120 to ME23 of 1:1, the RA120 population
was lost at a rate of 2 log10 CFU per day (Fig. 2a). Increasing
the ratio of RA120 to ME23 to 100:1 allowed the faster-
growing variants, represented by strain ME51, with a doubling
time of 29  0.1 min, to emerge (Fig. 2b) and to compete
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successfully with ME23 (Fig. 2d). The doubling time of this
faster-growing variant, ME51, remained constant when it was
retested 10 days later, and the strain maintained the same
restriction pattern as RA120 (Fig. 1). Subculturing of RA120
alone under the same conditions did not yield faster-growing
variants after the same number of days, indicating that faster-
growing mutants were selected only in the presence of a com-
petitor.
When ME51 was cured of SCCmec, the resulting strain,
strain ME57, was indistinguishable by its growth rate and
PFGE pattern (Fig. 1) from BB255 and ME23. The results of
competition experiments with RA120 and ME57 were identi-
FIG. 1. SmaI restriction patterns of the strains used and their corresponding growth curves. The SmaI fragments carrying SCCmec are indicated
by filled triangles, and the corresponding fragments of the cured strain are indicated by open triangles. BB255, naïve, susceptible recipient; RA120,
BB255 transformant containing SCCmec; ME23, RA120 cured of SCCmec; ME51, rapidly growing strain derived from RA120; ME57, ME51 cured
of SCCmec.
FIG. 2. Growth competition. Survival of oxacillin-resistant strains versus that of oxacillin-susceptible strains in mixed culture after daily
subculturing. (a) Strain RA120 with its cured derivative ME23 inoculated at a ratio of 1:1; (b) strain RA120 with ME23 inoculated at a ratio 100:1;
(c) strain RA120 with BB255 inoculated at a ratio of 100:1; (d) strain ME51 with ME23 inoculated at a ratio 1:1.
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cal to those of competition experiments with RA120 and ME23
(data not shown). However, when RA120 was grown in com-
petition with naïve strain BB255 (Fig. 2c), it was more rapidly
eliminated than it was in competition experiments with ME23
or ME57. This suggests that ME23 and ME57 were not as
competitive against RA120 as BB255 was; this is possibly due
to the acquisition of a chromosomal mutation, as has previ-
ously been postulated to occur in highly resistant MRSA
strains (14). However, the introduction of an accidental muta-
tion upon transformation cannot be ruled out.
An interesting observation was that strain ME51, as well as
24 of 24 other fast-growing oxacillin-resistant single colonies
analyzed from the competition of strains RA120 and ME23, all
had reduced levels of oxacillin resistance compared to that of
RA120. However, at this stage we do not know whether the
fast-growing population comprised a single clone or whether
several events resulted in faster growth. The population anal-
ysis profile revealed that RA120 had changed from a homoge-
neously, highly resistant MRSA strain into a heterogeneously
resistant MRSA strain (Fig. 3) for which the oxacillin MIC was
64 g/ml. Highly resistant subclones of ME51, isolated and
purified from plates containing 128 or 256 mg of oxacillin per
ml, again showed a reduced growth rate, with a doubling time
of 39.5 2.7 min. Analogous transformations into BB255 were
done with other SCCmec type I or type IV elements (data not
shown), and analysis of the generation time confirmed a cor-
relation between oxacillin resistance levels and growth rate.
The cost of SCCmec may be compensated for in nature. This
is reflected by the rapid rate of growth of community-acquired
MRSA strains upon which pressures other than antibiotics may
act and which, interestingly, have generally been found to
exhibit lower oxacillin resistance levels (12). We cannot ex-
clude the possibility that the experimentally demonstrated in-
terrelationship between oxacillin resistance levels and growth
rate may also be compensated for in clinical isolates. Oxacillin
resistance levels appear to have a higher impact on the growth
rate than the addition of the extra DNA comprising the
SCCmec element.
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The majority of methicillin-resistant Staphylococcus aureus (MRSA) isolates, recovered in 2003 at the
Department of Medical Microbiology in Zu¨rich, Switzerland, belonged to major clones that are circulating
worldwide. Staphylococcal cassette chromosome mec type IV (SCCmec-IV), harbored by half of the isolates, was
found in sequence type 217 (ST217), which is an allelic variant of epidemic MRSA-15 (designated EMRSA-15),
in a new local ST617 descending from clonal complex CC8 and in low-level oxacillin-resistant strains of
multiple genetic lineages characteristic of community-onset MRSA. SCCmec-I, SCCmec-II, and SCCmec-III
were in the minority, and four MRSA isolates had complex, rearranged SCCmec elements. A novel SCCmec-N1
of approximately 30 kb, associated with a dfrA gene and a ccr4-related recombinase complex, was identified in
a large number of low-level oxacillin-resistant isolates, which descended from the successful clonal complex
CC45 and are spreading among intraveneous drug users. In contrast, the SCCmec types of oxacillin-resistant
coagulase-negative staphylococci (MRCNS) were of completely different composition. SCCmec type I
(SCCmec-I) and SCCmec-II were more frequent than in the MRSA, while fewer contained SCCmec-IV. The
other MRCNS displayed 11 different, complex patterns, suggesting frequent recombination between different
SCCmec elements. With one ccr-negative exception, these strains amplified between one and three different ccr
products, indicating either new varied complexes or multiple ccr loci. This suggests the presence of novel
SCCmec types in MRCNS and no extensive interspecies SCCmec transfer between MRSA and MRCNS.
Methicillin-resistant Staphylococcus aureus (MRSA) is a ma-
jor cause of hospital-acquired infections and has also recently
established itself as a significant community-acquired pathogen
(7, 9). Community-onset MRSA (cMRSA) differs from noso-
comial MRSA in that it does not generally belong to the major
clonal groups of epidemic MRSA, is susceptible to most non-
-lactam antibiotics, contains the type IV SCCmec (for staph-
ylococcal cassette chromosome mec, the mobile genetic ele-
ment encoding methicillin resistance), and frequently carries
genes responsible for the production of Panton-Valentine leu-
kocidin (PVL) (13, 22, 26). In contrast, nosocomial MRSAs
are generally multidrug resistant and contain SCCmec types I,
II, or III.
Besides the five major allelic types of SCCmec elements,
epidemiological studies paired with molecular characteriza-
tions suggest the existence of additional, different SCCmecs
(16, 28, 36). The origin of the SCCmec element is still unclear,
with the closest mecA homolog found in Staphylococcus sciuri
(43). Methicillin-resistant coagulase-negative staphylococci,
which are more frequently carriers of SCCmec than S. aureus,
are postulated to be the reservoir for the transfer of methicillin
resistance to S. aureus (2). SCCmec has the attributes of a
mobile element, such as the ccr genes, encoding recombinases
that were shown in vitro to be responsible for the precise
excision and integration of SCCmec into the chromosome.
However, the type 1 and type 3 ccrA and ccrB genes are
dysfunctional. This, plus the larger size of nosocomial SCCmec
types I to III, may have been the reason that they have spread
only into a restricted number of genetic lineages, whereas the
smaller type IV SCCmec seems to be more mobile and to be
associated with more diverse strain lineages (29, 32).
The ability of MRSAs to segregate a highly resistant sub-
population in the presence of -lactams makes them resistant
to virtually all -lactams and their derivatives. The level of
oxacillin resistance reached is strain specific and can vary over
a 1,000-fold concentration range, depending upon the genetic
background of the strain. On the one hand, it depends upon
the ability of MRSA to rapidly induce the synthesis of penicil-
lin-binding protein 2a (PBP2a), which is indispensable for re-
sistance; on the other hand, it is the genetic background of the
strain into which the SCCmec element has entered which de-
termines the final resistance level (for a review, see reference
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5). Some clinical MRSA isolates have such a low level of
resistance to oxacillin that they are difficult to identify pheno-
typically. Interestingly, an inverse relationship between resis-
tance levels and growth rate has been observed (10).
The recent appearance of vancomycin-intermediate-resis-
tant MRSA (VISA), which is due to alterations in gene ex-
pression caused by gene induction and/or the accumulation of
multiple mutations which finally lead to intermediate levels of
glycopeptide resistance (17), is a further challenge for the
diagnostic laboratory. VISAs may go undetected by conven-
tional resistance tests, since they produce only a small number
of cells within a culture that express resistance. VISAs are still
regarded as a rare cause of clinically relevant infections (35),
but the evolution of their prevalence needs to be monitored.
The aim of this study was to examine the SCCmec types, the
associated resistances, and clonal composition of MRSA iso-
lates in the Zu¨rich area and to search for a correlation between
low-level oxacillin-resistant strains, which are increasingly be-
ing isolated, and the genetic background and/or SCCmec type.
A comparison of the SCCmec elements occurring in methicil-
lin-resistant coagulase-negative staphylococci (MRCNS) with
those in MRSA should show if the distribution of SCCmec in
MRSA is a reflection of that in MRCNS.
MATERIALS AND METHODS
Bacterial strains. Ninety independent MRSA isolates and 88 randomly se-
lected coagulase-negative, methicillin-resistant staphylococcal isolates (MRCNS)
sampled between November 2002 and January 2004 at the Department of Med-
ical Microbiology of the University of Zu¨rich, Zu¨rich, Switzerland, which serves
the university hospitals of Zu¨rich, were analyzed. All strains were unique isolates
from different patients. Identification of S. aureus and of the coagulase-negative
staphylococci was by standard methods: colony morphology, Gram staining,
catalase test, and confirmation with Staphaurex (Murex Diagnostics) and API
Staph (bioMe´rieux), where required. Oxacillin resistance was confirmed by mecA
PCR and with the MRSA screen from Denka Seiken (Japan) using -lactam-
induced bacteria growing around the amoxicillin-clavulanic acid inhibition zone
for the detection of PBP2a (PBP2) by latex agglutination (44). The strains were
stored in skim milk at 80°C. Reference strains were S. aureus NCTC10442 for
SCCmec type I, S. aureus N315 for SCCmec type II, S. aureus 85/3907 for
SCCmec type III (19), S. aureus WSPP for SCCmec type IV (1, 25), and S. aureus
WBG8404 for SCCmec type V (20). The Panton-Valentine leukocidin-positive
WSPP strain and Swiss strain 497 (22) were used as references for lukS-PV. Mu3,
a hetero-VISA (hVISA) strain, and susceptible strain N315 (18) were used as
comparisons for glycopeptide intermediate resistance in population analysis pro-
files. The quality control strains for antibiotic resistance testing were S. aureus
ATCC 29212 and Enterococcus faecalis ATCC 29213. Curing of SCCmec from
clinical isolates was done by ccr overexpression, as described by Ito et al. (19).
Susceptibility testing. Oxacillin, cefoxitin, tetracycline, gentamicin, ciprofloxa-
cin, erythromycin, and clindamycin susceptibility were determined by disk diffu-
sion according to CLSI (formerly NCCLS) (7a) on Mueller-Hinton agar (Difco).
Inducible macrolide-lincosamide-streptogramin B (MLSB) resistance was iden-
tified as a D-shaped inhibition zone by the clindamycin-erythromycin double-disk
test (21). Oxacillin and linezolid MICs were determined by Etest (AB Biodisk,
Solna, Sweden) on Mueller-Hinton agar (Difco) with an inoculum of 0.5 Mc-
Farland standard as recommended. Rifampin, cotrimoxazole, and fosomycin
MICs were determined by agar dilution according to the CLSI (7a). Vancomycin
and teicoplanin resistance were determined by macro Etest on brain heart
infusion plates (BBL), using a inoculum consisting of a 2 McFarland standard as
recommended by the manufacturer (AB Biodisk, Solna, Sweden). Production of
a penicillinase was shown qualitatively by nitrocefin hydrolysis from -lactam-
induced cells growing around an amoxicillin-clavulanate disk. The hVISA phe-
notype was confirmed by population analysis profile, by plating aliquots of an
overnight culture on brain heart infusion agar containing increasing concentra-
tions of either vancomycin or teicoplanin and reading the CFU after a 48-h
incubation, using strain Mu3 as a control (15). The growth temperature was
35°C.
Molecular typing. (i) PFGE. The MRSAs were genotyped by pulsed-field gel
electrophoresis (PFGE) of SmaI-digested chromosomal DNA, following the
protocol of Wada et al. (39). The banding patterns were analyzed visually, by
scanning with a Fluor-S MultiImager, and by digital analysis with a Multi-
analys/PC (Bio-Rad) (28).
(ii) MLST. Multilocus sequence typing (MLST) was performed with selected
isolates as specified by Enright et al. (11). The sequences obtained were com-
pared with the sequences at the MLST website (http://www.mlst.net/) to assign a
sequence type (ST).
(iii) SCCmec typing. Determination of SCCmec types I to IV was done by
multiplex PCR (30). Untypable strains were further analyzed by ccr typing using
a PCR screen with primers to identify ccr types 1, 2, and 3 (19); the SCCmec type
V ccr complex ccrC gene (20); and primers C1 and C2 (23) to detect the ccr4
locus of the pediatric clone (31).
(iv) PVL. The primers lukSF (5-ACAGAAGATACAAGTAGCGA-3) and
lukSR (5-TAATTCATTGTCTGGCACAA-3) were used to detect the pres-
ence of the lukS-PV gene, which is specific for Panton-Valentine leukocidin, by
PCR.
(v) Colocalization of dfrA-mecA. Sequential Southern hybridizations (4) of
SmaI-digested chromosomal DNA separated by PFGE with a mecA (30) or dfrA
probe, amplified with the primer pair dfrAF-Tn4003 (5-AATAGACGTAACG
TCGTACT-3) and dfrAR-Tn4003 (5-AAGAATGTATGCGGTATAGT-3),
showed whether dfrA mapped in the same SmaI band as mecA.
RESULTS AND DISCUSSION
Oxacillin resistance and -lactamase production. The Uni-
versity Hospital of Zu¨rich, a 920-bed hospital, had an incidence
of 1.1 cases of MRSA per 1,000 admissions in 2003. Ninety
independent isolates were collected from November 2002
through January 2004 and characterized to determine their
resistance profile, clonal distribution, PFGE pattern, and
SCCmec types (Table 1). For comparison, 88 MRCNS clinical
isolates were sampled randomly during the same time span to
see if there was any correlation between the SCCmec types of
MRCNS and MRSA. Methicillin resistance was confirmed in
all strains by mecA PCR. The frequency of nonmultiresistant
MRSA with low-level oxacillin resistance was rather high in
this collection. Thirty percent of all MRSA strains had an
oxacillin MIC below the breakpoint of 4 mg/ml (Fig. 1). In disk
diffusion tests, the 30-mg cefoxitin disk was found to be supe-
rior and easier to interpret than the oxacillin disk and correctly
identified all low-level resistant MRSA, with only one strain
displaying intermediate resistance. The PBP2a agglutination
by the MRSA latex-screening test using induced bacteria was
as reliable as the mecA PCR, even for the phenotypically ox-
acillin-susceptible MRSA.
While MRSAs displayed oxacillin MICs over the entire
range measured, the MRCNS formed two distinct clusters,
consisting of 39 strains with oxacillin MICs of 32 mg/ml and
49 isolates with oxacillin MICs of 256 mg/ml. One MRCNS
had an oxacillin MIC below the breakpoint for coagulase neg-
ative staphylococci of 0.5 mg/liter. Interestingly, penicillinase
production was more frequent in MRSAs (90%) than in
MRCNS (74%).
PFGE and SCCmec typing of MRSAs. PFGE indicated that
there were four epidemiologically dominant genetic lineages
and a number of sporadic isolates of MRSAs isolated from the
University Hospital of Zu¨rich (Fig. 2). The genetic back-
grounds of representatives of each of the larger groups were
investigated by MLST and determined to be ST217-MRSA-IV,
a single-locus variant (SLV) of the pandemic epidemic United
Kingdom strain epidemic MRSA-15 (designated EMRSA-15);
ST225-MRSA-II, an SLV of the Japanese/America clone;
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ST613-MRSA-IV, a new ST so far reported only in Zu¨rich; and
ST45-MRSA-N1, the drug clone, so far predomantly found in
isolates from intraveneous drug users and their contacts in
Zu¨rich. The ST217 and ST255 isolates have the characteristics
of nosocomial MRSAs, while ST613 and ST45 have the char-
acteristics of cMRSA (Table 1). The predominance of SLVs of
pandemic isolates, the new ST, and the unique drug clone
suggest that these MRSAs have evolved locally and are dis-
seminating in the geographical region.
The classic nosocomial SCCmec types I, II, and III formed a
minority in this MRSA strain collection with only 3, 9, and 12
isolates, respectively, representing 26% of all isolates. Two
MRSAs produced a composite pattern consisting of a partial
SCCmec type III lacking region C but with region D, otherwise
found in types I, II, or IV SCCmec elements (Table 2). These
two strains contained the ccr type 3 recombinase allele and
clustered in the PFGE-based dendrogram within the SCCmec
type III clusters (Fig. 2). They may therefore represent MRSAs
with a new, composite SCCmec element, listed here as
SCCmec type N4. Forty-one MRSAs carried SCCmec type IV
and could be divided according to their PFGE pattern into
three major groups (Fig. 2). The predominant clone, consisting
of 18 strains with generally high levels of oxacillin and cipro-
floxacin resistance, belonged to ST217 of CC22, differing from
the ancestral clone EMRSA-15, a strain epidemic in the
United Kingdom (12), at the tpi locus. The second major group
of 10 strains belonged to a new sequence type, ST613, so far
only found in Zu¨rich and originating from clonal complex CC8.
The remaining type IV strains formed a heterogeneous group
with various PFGE patterns, which is common for the small
community-onset-type IV SCCmec elements with enhanced
mobility. PVL, reported to be associated with cMRSAs, was
not frequent in this MRSA collection; the lukS-PV gene was
present only in five SCCmec type IV strains. Interestingly, one
of the PVL-producing strains was found during an outbreak in
a dermatological ward.
Characterization of the “drug clone.” Twenty-four MRSAs
amplified only the mecA band with the SCCmec multiplex
PCR. All isolates, except for three, carried none of the ccrAB
alleles types 1, 2, or 3 or the ccrC gene, but with the primers
specific for the ccr4 complex they yielded a band very closely
related to that of the pediatric clone reported by Oliveira et al.
(31; M. Ender, unpublished results). Curing the SCCmec de-
terminant from a representative of these strains showed, ac-
cording to the SmaI PFGE banding pattern, that the element
had a size of approximately 30 kb. Interestingly, the SmaI band
which carried the mecA gene also harbored a copy of the
Tn4003-associated dfrA gene, which was lost upon SCCmec
curing. PCR mapping and sequencing showed that the dfrA
gene was integrated into the SCCmec determinant (Ender,
unpublished). The association of dfrA with the SCCmec, the
lack of any characteristic bands of type I to IV SCCmecs other
than mecA by multiplex PCR, and the presence of a ccr4-like
ccr complex suggested that this was a new SCCmec element,
termed here SCCmec type N1. All of these strains belonged to
an MRSA clone, which is spreading among isolates from in-
jection drug users (14) and which is referred to as the “drug
clone.” It is characterized phenotypically by a very low level of
oxacillin resistance, the presence of a penicillinase, and a high
maximal growth rate of 1.8 h1 in LB broth. All drug clones
were trimethoprim resistant and generally either sulfomethox-
azole or ciprofloxacin resistant. The drug clone appeared in
1994 and peaked in 2001 (Fig. 3), but it still represents a
FIG. 1. Distribution of oxacillin MICs. Black bars, MRSA (90
strains); white bars, MRCNS (89 strains).
TABLE 1. Characteristics of the MRSAs grouped according to SCCmec type
No. of strains
No. of different
dendrogram
profiles
SCCmec
type
No. of strains containinga MIC50/MIC90
Oxab
No. of strains in each group resistant to:c
dfrA-mecA dfrA pvl blaZ SXT Tet Cm Gen Cip Erod Clid Rif
3 3 I 256/256 3 3 3 3 3
9 4 II 8 4/256 1 9 9 6
11 11 III 11 256/256 6 9 1 8 7 7 2 1
41 13 IV 2 5 36 4/128 3 1 23 17 7 2
22 3 N1 22 22 1.5/4 11 11
1 1 N2 1 256 1 1
1 1 N3 0.5 1
2 1 N4 2 256 1 2 2 2 2 2 2
a dfrA-mecA, dfrA integrated into SCCmec; dfrA, dihydrofolate reductase gene not associated with SCCmec; pvl, Panton-Valentine leukocidin; blaZ, penicillinase.
b Oxa, oxacillin.
c SXT, cotrimoxazole; Tet, tetracycline, Cm, chloramphenicol; Gen, gentamicin; Cip, ciprofloxacin; Ero, erythromycin; Cli, clindamycin; Rif, rifampicin.
d All clindamycin-resistant strains had constitutive erythromycin resistance, all erythromycin-resistant but clindamycin-susceptible strains had an inducible erythro-
mycin resistance.
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substantial part of the MRSA isolates in the Zu¨rich area. It has
also spread in a few cases to isolates from non-drug users,
probably as a result of nosocomial transmission. MLST showed
that the genetic background of the drug clone belongs to allelic
profile ST45. The drug clone is thus similar to the epidemic
Berlin MRSA clone, with low-level resistance to oxacillin (42),
except for carrying the novel SCCmec type N1 element.
Two isolates, that like the drug clone only amplified the
mecA band in the multipex PCR, had novel SCCmecs, N2 and
N3, that were otherwise unrelated to N1 of the drug clone.
They both lacked the dfrA gene; moreover, the strain contain-
ing SCCmec type N2 amplified products specific for the ccr2
and the ccr5 complex, whereas the strain containing SCCmec
type N3 amplified a ccr2 complex. The strain containing
SCCmec type N2 was highly oxacillin resistant and also genta-
micin and rifampin resistant, very unlike the drug clone. The
FIG. 2. Dendrogram. a, number of PFGE pattern; b, SCCmec type; c, number of isolates of the same PFGE profile and SCCmec type; d;
sequence type and clonal complex. Light gray shading, SCCmec-IV; dark gray shading, SCCmec-N1 (drug clone).
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strain containing SCCmec type N3, a ciprofloxacin-resistant
strain of low-level oxacillin resistance, was one of a cluster of
ST45 isolates that harbored at least three different SCCmecs
(types N1, N3, and IV) (Fig. 2), indicating that there have been
three genetic events during which ST45 isolates found in this
region have acquired methicillin resistance.
SCCmec typing of MRCNS. The distribution of SCCmec
types in the MRCNS showed a completely different pattern.
Among the MRCNS, we identified 14 strains with SCCmec
type I, 12 strains with type II, none with type III, 8 strains with
type IV, and a large number of untypable variants, which
produced 11 new patterns by multiplex SCCmec and ccr typing.
None of the MRCNS strains was a carrier of the new SCCmec
type N1 found in the drug clone, since isolates amplifying mecA
alone carry no ccr4 complex and no dfrA gene, suggesting that
MRCNS were unlikely to have been the donors of the SCCmec
type N1 for the drug clone. The marked difference in the
distribution of SCCmec profiles in MRSAs and MRCNS sug-
gests that there has not been extensive interspecies SCCmec
transfer. However, it would be interesting to search for and
analyze commensal MRCNS in isolates from drug addicts who
are carriers of the drug clone to see if there is SCCmec type N1
transfer in that collective of patients.
The degree of multiresistance was clearly higher in MRCNS
than in MRSAs (Fig. 4), when resistance to trimethoprim-
sulfamethoxazole (SXT), tetracycline, chloramphenicol, genta-
micin, ciprofloxacin, erythromycin, and rifampin was deter-
mined. The high number of MRSA isolates with no or only one
additional resistance determinant was mainly due to the high
proportion of SCCmec type IV and drug clone MRSA isolates
in our strain collection.
Antibiotic resistance in MRSA. (i) SXT. The SXT combina-
tion blocks the synthesis of folate derivatives (33). Resistance
to trimethoprim in S. aureus is formed by mutations in the
chromosomal gene for dihydrofolate reductase or by acquisi-
tion of the transposon Tn4003-borne dfrA gene (8, 34). Sul-
fonamides, competitive inhibitors of dihydropteroate synthase,
block folate biosynthesis. Resistance to sulfonamides in staph-
ylococci is due to mutations in the chromosomal dihydrop-
teroate synthase gene (38). The use of the inexpensive SXT
combination in the treatment of infections in intravenous drug
users may have been one of the driving forces for the associ-
ation of dfrA with the SCCmec type N1 element. Although all
drug clones amplified the dfrA gene, only approximately half of
them were resistant to the SXT combination (Table 1). Inter-
estingly, the SXT-susceptible drug clones were generally cip-
rofloxacin resistant instead, with two exceptions: one isolate
was susceptible to both drugs, and one isolate was resistant to
both drugs.
The integration of the dfrA gene was unique for type N1
SCCmec and has not been found in any of the other SCCmec
types of MRSA and MRSCN analyzed so far. Two STX-resis-
tant isolates with SCCmec type IV carried a dfrA gene unlinked
to SCCmec, and 10 SXT-resistant MRSAs did not amplify any
dfrA gene, suggesting that their SXT resistance was due to
chromosomal mutations.
FIG. 3. Number of drug clones isolated at the university hospitals
of Zu¨rich from 1994 through 2004.
FIG. 4. Number of additional resistances besides mecA and blaZ.
Additional resistances counted were trimethoprim-sulfamethoxazole,
tetracycline, chloramphenicol, gentamicin, ciprofloxacin, erythromy-
cin, and rifampin. White bars, MRCNS; black bars, MRSA.
TABLE 2. SCCmec types and ccr complexes identified in the
MRSA collection
Amplified region
SCCmec type New SCCmec type
I II III IV N1 drugclone N2 N3 N4
Locus, genea
A, pls 
F, Tn544-orfX  
G, IS431-pUB110 
D dcs    
B, kdp 
E, pl258-Tn544  
C, mecR1  
mecA        
ccr complex
ccr1 
ccr2    
ccr3  
ccr4 
ccr5 
No. of isolates 3 9 11 41 22 1 1 2
a Loci F, G, and E are located between the orfs/elements indicated, as de-
scribed by Oliveira and de Lencastre (30).
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(ii) Glycopeptides. Glycopeptides sterically inhibit cross-
linking and polymerization of the cell wall peptidoglycan by
binding to the D-Ala-D-Ala of the nascent peptidoglycan pre-
cursor at the cell membrane. VISAs have been found to be the
cause for glycopeptide therapy failure in several instances,
especially in infections with high bacterial load, but their fre-
quency and relevance have been questioned (35, 41). All
MRSAs were screened for glycopeptide resistance upon isola-
tion from patients and prior to storage at 80°C, by using the
macro-Etest method that is indicative for potential hVISA
(40). A few strains showed elevated teicoplanin and/or vanco-
mycin MICs of 4 mg/ml. However, upon retesting after some
months’ storage at 80°C, resistance values had dropped, sug-
gesting that glycopeptide resistance was unstable or that lower-
resistance variants survived storage at low temperatures better.
Only three strains out of all potential hVISAs could be con-
firmed by population analysis with vancomycin to be similar to
that of strain Mu3 (data not shown). One of them belonged to
the epidemic ST217 clone, one belonged to a multiresistant
type IV isolate, and one belonged to the multiresistant
SCCmec type N4 isolate.
(iii) Fosfomycin. Fosfomycin inhibits the MurA enzyme,
preventing the formation of N-acetylmuramic acid, a precursor
of the cell wall peptidoglycan. All MRSAs were susceptible to
fosfomycin with MICs below the lower fosfomycin breakpoint
of 16 mg/ml (24). However, the distribution of fosfomycin
MICs suggested the presence of two populations of fosfomy-
cin-susceptible strains in the MRSA collection, namely, iso-
lates with a fosfomycin MIC of around 0.5 and a slightly more
resistant population of strains with an MIC of 4 (Fig. 5). The
increased fosfomycin MIC correlated with elevated initial
teicoplanin MICs (Kendall’s rank correlation coefficients: k-
tau-a  0.3346 and k-tau-b of 0.4083; P  0.001). This may be
due to upregulation of the murA gene, which upon overexpres-
sion can confer some fosfomycin resistance. Whether the fos-
fomycin MIC can be used as indication for upregulated cell
wall synthesis in hVISA has to be analyzed further.
(iv) MLS. The structurally different, but functionally similar
MLSB class of drugs binds to the 50S ribosomal subunit, block-
ing protein synthesis (37). The erm-encoded methylases are the
most frequent resistance mechanisms against macrolides in
staphylococi (3). The inability of lincosamides to induce MLSB
resistance results in clindamycin susceptibility, while constitu-
tive expression of erm genes confers resistance to all MLSB
antibiotics. Over 30% (34/90) of the MRSAs had an interme-
diate level of erythromycin resistance. Inducible MLSB resis-
tance was found in 17/91 isolates, and constitutive expression
was found in 20/91 MRSA isolates.
(v) Linezolid. Linezolid is the first representative of oxazo-
lidinones, a new class of antibiotics which inhibits the assembly
of a functional initiation complex for bacterial protein synthe-
sis. It shows no cross-resistance with existing antibiotic agents
with the same target (6); in our collection, all MRSAs (MIC at
which 50% of the isolates tested are inhibited [MIC50]  0.5;
MIC at which 90% of the isolates tested are inhibited [MIC90]
 1) and MRCNS (MIC50  0.75; MIC90  1) were suscep-
tible to linezolid.
CONCLUSIONS
The rather high prevalence of the drug clone, a phenotypi-
cally oxacillin-susceptible MRSA, in the Zu¨rich area is chal-
lenging, especially since it belongs to the same genetic back-
ground as the successfully spreading Berlin clone (42). Because
of its low MIC, the drug clone is difficult to detect. The evo-
lution and spread of this clone have to be monitored closely to
prevent the clone’s escape into other patient populations,
where it may pick up other resistance determinants and in-
crease its resistance spectrum. ST45 can harbor different
SCCmec types. Here, it has acquired a new SCCmec type N1,
which differs from those previously reported (type II and type
IV) to be associated with ST45. The core genetic background
of the drug clone is related to the epidemic Berlin clone. Two
of its interesting characteristics are its rapid growth rate and
the extremely low level of oxacillin resistance, the cause of
which is under investigation. Interestingly, we found in this
small survey no MRCNS with an SCCmec type N1 like that of
the drug clone, suggesting that there may be not such a high
rate of SCCmec exchange between MRCNS and S. aureus.
Unexpectedly, the MRCNS seemed to harbor multiple new
types of SCCmec and were more likely to amplify more than
one representative of different ccr complexes, suggesting that
the MRCNS may nevertheless be the breeding ground for new
SCCmec elements.
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We examined the effect of introducing type I or IV staphylococcal cassette chromosome mec (SCCmec)
elements on the growth yield of Staphylococcus aureus in glucose-limited continuous culture. Type I showed
increased glucose consumption and ATP demand per gram of cells synthesized and decreased cell yield
compared to those of the parent strain. In contrast, type IV SCCmec elements had no adverse energetic effect.
New strains of methicillin-resistant Staphylococcus aureus
(MRSA), have emerged in the community, causing infections
in young, otherwise healthy people, such as children and mil-
itary personnel (15, 16), and these strains can achieve a higher
infection burden than nosocomial strains (10). In New Zealand,
a community-acquired MRSA (CA-MRSA) strain designated
Western Samoan phage pattern led to a 15-fold increase in
MRSA cases between 1993 and 2000 (14).
The origins of CA-MRSA strains remain elusive. Compared
to hospital-acquired MRSA, CA-MRSA strains appear to have
higher growth rates, but the basis for this is unknown (11).
These strains compete in an environment that is largely devoid
of antibiotic selective pressure, and therefore, the selection for
factors that contribute to ecological fitness may outweigh the
need for multiple resistance determinants. Moreover, genetic
factors seem to determine the permissiveness of S. aureus
strain lineages to accommodate mecA and maintain methicillin
resistance (8).
In this study, we sought to determine the fitness cost of the
staphylococcal cassette chromosome mec (SCCmec) elements
by measuring various physiological parameters between three
isogenic S. aureus strains carrying either SCCmec type I or
SCCmec type IV elements or no SCCmec element, by way of
glucose-limited continuous culture.
The susceptible parent strain BB255 is of NCTC8325 back-
ground. Strain RA120 is BB255 transformed with an SCCmec
type I element (4). Strain RA2 was constructed in this study by
transformation of strain BB255 with chromosomal DNA
obtained from ST92/398, a CA-MRSA isolate harboring a
SCCmec element type IV (1), as described earlier (4). In vitro
transformation frequencies were extremely low (4 101/g
of chromosomal DNA). One representative transformant from
eight analyzed, designated RA2, was chosen for further study.
Figure 1 illustrates that the SmaI-G fragment of strain BB255
harboring orfX, the integration site for SCCmec, shifted by
about 25 kb in the transformant RA2 due to the integration
of the SCCmec type IV element, which was confirmed by
Southern blotting with a mecA probe and by SCCmec typing
(5, 12, 13).
Growth experiments were performed in a medium contain-
ing the following: Na2HPO4  2H2O, 6.0 g/liter; KH2PO4, 3.0
g/liter; NaCl, 0.5 g/liter; NH4Cl, 5.0 g/liter; CaCl2, 15 mg/liter;
MgSO4, 247 mg/liter; MnSO4, 1.0 mg/liter; citric acid, 0.06
mg/liter; tryptone, 1.0 g/liter; and glucose, 0.9 g/liter. The cell
yield for all strains was proportional to the glucose concentra-
tion, indicating that this medium was glucose limited. The
doubling times for each strain at 37°C were as follows: 39  3
min for BB255, 41  3 min for RA2, and 54  5 min for
RA120. On the basis of these results, the SCCmec type I
element appeared to have a negative effect on the growth rate
of BB255 compared to SCCmec type IV in batch culture.
To study the roles of the different SCCmec elements on
bacterial fitness at precisely controlled growth rates, all strains
were grown in glucose-limited continuous culture, with a work-
ing volume of approximately 350 ml at a dilution rate of 0.1
h1 (doubling time of 6.9 h). The growth medium was inocu-
lated with exponential-phase cells and permitted to undergo
batch growth to densities of approximately 0.3 to 0.8 (optical
density at 600 nm) with constant agitation at 200 rpm. Con-
comitant with the initiation of continuous growth, agitation
was then increased to 400 rpm to provide adequate aeration
during steady-state conditions. The desired dilution rate was
maintained for at least four residence times to allow the cul-
ture to reach steady state prior to sampling. At each steady
state, 90-ml samples were removed and analyzed for residual
glucose (UV method; R-Biopharm), end products (3), total
viable CFU on LB agar plates, and cell weight (dry weight).
After each sampling, the culture was again maintained for at
least four residence times to reach steady state prior to repli-
cate sampling. The values reported are the means of two to
four independent experiments with triplicate determinations
performed per sampling for each parameter measured. The
standard experimental error of the mean associated with these
determinations is shown.
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At a dilution rate of 0.1 h1, cells reached a steady-state
optical density at 600 nm of 0.39 to 0.56 (data not shown) and
the CFU ranged from 5.75  107 to 5.86  108 (Fig. 2A). To
determine the cell yield on glucose (Yglucose), the dry weight
and glucose consumption rate of all strains were measured
(Fig. 2B and C). Strain RA120 had the lowest dry weight but
exhibited the greatest rate of glucose consumption, resulting in
the lowest Yglucose for the three strains studied (Fig. 2D). In
contrast, strain RA2 had the highest dry weight and the lowest
rate of glucose consumption, resulting in a relatively high
Yglucose. Strain BB255 was intermediate for both parameters.
End product analysis from glucose consumption for each strain
indicated that glucose was oxidized to CO2 at each dilution
rate, i.e., no incomplete oxidation to acetate or lactate was
detected.
When S. aureus is grown on glucose as the sole carbon and
energy source under aerobic growth conditions, the theoretical
ATP yield is 9.4 mol of ATP produced per mol of glucose
consumed (6). On the basis of this value, we calculated the
weight in grams (dry weight) of cells produced per mole of
ATP utilized (YATP) for each strain (Fig. 3A). For example, at
a dilution rate of 0.1 h1, the average Yglucose value for strain
BB255 was 38.4 g (dry weight) of cells/mol glucose utilized
(Fig. 2D) or 38.4 g (dry weight) of cells/9.4 mol of ATP utilized,
which is equivalent to a YATP value of 4.10 0.3 g (dry weight)
cells/mol ATP utilized. The calculated YATP value for strain
RA2 was 5.64 0.45 g (dry weight) cells/mol ATP utilized, and
for RA120, it was 3.24  0.2 g (dry weight) cells/mol ATP
utilized (Fig. 3A). These values are equivalent to an ATP
demand per gram of newly synthesized biomass for each strain
as follows: BB255, 244  18 mmol ATP/g cells synthesized;
RA2, 177  22 mmol ATP/g cells synthesized; and for RA120,
308  25 mmol ATP/g cells synthesized (Fig. 3B).
A number of studies have suggested that the size of the
SCCmec element plays a major role in the fitness of S. aureus
strains (2, 7, 16). Our data suggest that the SCCmec type IV
FIG. 1. (I) Pulsed-field gel electrophoresis patterns of Western
Samoan phage pattern strain ST92/398 (lane 1), recipient strain BB255
(lane 2), and transformant RA2 (lane 3) after SmaI digestion. (II)
Southern hybridization of the pulsed-field gel in panel I with a mecA
probe. The sizes of the fragments (in kilobases) are shown.
FIG. 2. Glucose-limited continuous culture of S. aureus strains at a dilution rate of 0.1 h1. Strain BB255 is the susceptible parent, RA2 is the
BB255 strain transformed with SCCmec type IV element, and RA120 is the BB255 strain transformed with SCCmec type I element. (A) Log
CFU/ml, (B) cell weight (dry weight), (C) glucose consumption rate, and (D) Yglucose. The values reported are the means of two to four independent
experiments with triplicate determinations performed per sampling for each parameter measured. The standard experimental error of the mean
(error bars) associated with these determinations is shown.
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element from CA-MRSA did not impose an energetic cost to
its naı¨ve host in terms of the maximum growth rate, cell yield,
and the amount of cells that can be produced per mole of ATP
consumed. However, the SCCmec type I element reduced the
fitness of its host in terms of growth rate and cell yield. It is
unlikely that the difference in size of the SCCmec elements is
responsible for decreased fitness. Genes expressed from this
DNA, such as pls coding for the plasmin-sensitive cell wall
protein Pls, located on type I but not on type IV SCCmec
elements, may affect the performance of MRSA. Notwith-
standing this, the most likely factor may be the ease at which
PBP2a was integrated into the existing cell wall synthesis com-
plex, and the possible secondary compensatory events accom-
panying this event. Naı¨ve cells, such as strain BB255 used here
as a recipient for SCCmec, represent a host barrier for PBP2a,
and were postulated to have to adapt in order to accept PBP2a
(9). The altered ribosome binding site of mecA in the type IV
SCCmec element (unpublished results) predicts lower PBP2a
production compared to type I mecA, the latter of which is
known to produce large and constitutive amounts of PBP2. It
is possible that differences in the levels of PBP2a may have
triggered different compensatory events and that these have
caused the negative effect of SCCmec type I elements on
growth yield.
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FIG. 3. (A) YATP and (B) ATP consumed per gram of newly syn-
thesized biomass for S. aureus strains BB255, RA2, and RA120 grown
in glucose-limited continuous culture at a dilution rate of 0.1 h1.
Calculations are based on data presented in Fig. 2D and a theoretical
ATP yield of 9.4 mol of ATP produced per mol of glucose consumed (6).
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Mosaic Staphylococcal Cassette Chromosome mec Containing Two
Recombinase Loci and a New mec Complex, B2
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A novel staphylococcal cassette chromosome (SCC) mec from a clinical methicillin-resistant Staphylococcus
aureus isolate (ST100/CC5) had a mosaic structure, composed of SCC DNA from several different backgrounds.
It harbored two complete ccr loci and a new variant of mec complex B, with mecR1 interrupted by the
aminoglycoside resistance transposon Tn4001.
Methicillin resistance in Staphylococcus aureus (MRSA) is
facilitated by the acquisition of the staphylococcal cassette
chromosome mec (SCCmec), which integrates site specifically
into the staphylococcal genome and carries mecA, encoding
the alternative penicillin-binding protein PBP2a, a -lactam-
insensitive transpeptidase (6, 11, 13, 22, 26). The precise exci-
sion and site- as well as orientation-specific integration of this
element depend on the action of cassette chromosome recom-
binase genes (ccr’s) located within the element (13).
Five main types of SCCmec have been described so far, each
differing in size and composition and characterized according
to its type of ccr locus and mec complex (3, 7, 25). mec com-
plexes differ in the extents of insertion sequence (IS)-mediated
deletions in the mecA regulatory genes mecR1 and mecI and
the presence and location of insertion sequence IS431, IS1182,
or IS1272 (23). Apart from the ccr and mec complexes, and
some common mobile resistance elements, SCCmec subtypes
harbor variable J (junkyard) regions containing truncated and
nonessential genes and genes of unknown functions (8). In
addition to the major types, a number of new SCC elements,
including non-mecA-carrying cassettes, have recently been dis-
covered (4, 5, 9, 14, 15, 17, 19).
An epidemiological study of methicillin-resistant staphylo-
cocci from Zurich in 2003 identified several strains which con-
tained multiple ccr loci (21). Here, we describe the SCCmec of
one of these isolates, MRSAZH47.
MRSAZH47 is of multilocus sequence type 100 and belongs
to clonal complex 5, a genotype previously identified in Argen-
tina (1, 24). In addition to its -lactam resistance, it was resis-
tant to aminoglycosides and carried a blaZ-encoded penicillin-
ase. Its SCCmec type could not be determined by standard
multiplex PCR (20), and additional ccr typing indicated that it
contained both ccr2 and ccrC loci (21).
Southern hybridization of SmaI-digested chromosomal
DNA, separated by pulsed-field gel electrophoresis, showed
that mecA- and ccr2-hybridizing sequences were colocated on
a separate SmaI fragment from the ccrC-hybridizing sequence
(data not shown).
Transient overexpression of ccrAB2, facilitating the precise
excision of all major SCCmec types (10, 12, 13, 18), was used to
cure MRSAZH47. Southern hybridization showed that the re-
sulting oxacillin-susceptible clone MRSAZH47c had lost mecA
and both ccr loci, indicating that all three were present on a
single excisable SCC element containing an internal SmaI re-
striction site (data not shown). The susceptibility profile of
MRSAZH47c showed that aminoglycoside resistance had also
been lost.
A cosmid library of MRSAZH47 DNA, consisting of over 600
clones with estimated inserts of about 45 kb, was constructed
using a SuperCos1 cosmid vector kit (Stratagene, La Jolla,
CA). Screening of the library by colony blot analysis using ccr2-
or ccrC-specific probes identified 11 clones that hybridized to
ccr2, 7 that hybridized to ccrC, and 2 that hybridized to both
probes. Cosmids were end sequenced and the sequences com-
pared to the genome sequence of S. aureus Mu50, revealing
that the two cosmids hybridizing with both probes each con-
tained one end of the SCCmec element and together com-
pletely covered it (data not shown).
Primers specific for known orfX, ccrC2, IS431, and mecA
nucleotide sequences were used to synthesize long-range PCR
products that were subcloned into either pUC19 or pBluescript
SK(). Inserts were end sequenced and the obtained se-
quences assembled. The double-stranded nucleotide sequence
of the 33.7-kb element was completed by primer walking.
This SCCmec proved to be unique, containing elements and
properties not previously described. GeneMark.hmm (16) and
BLASTX (2) identified 33 open reading frames (ORFs), all of
which were identical or highly similar in sequence to previously
annotated staphylococcal genes (Table 1 and Fig. 1).
The orfX insertion site and the characteristic terminal in-
verted and direct repeats, generated upon insertion, were al-
most identical to those of other, previously described SCCmec
elements (12). However, the left-end (proximal) direct repeat
sequence contained a nucleotide transition of an adenine to
guanine (Table 1), which has not been found elsewhere and
increased the identity between the junctional direct repeats.
This mutation did not impede the excision of the element, as
demonstrated by the precise curing of SCCmecZH47 from the
chromosome of MRSAZH47. It could, however, possibly influ-
ence the stability or transfer frequency of the element.
SCCmecZH47 contained a new mec complex that we have
* Corresponding author. Mailing address: Institute of Medical Mi-
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TABLE 1. ORFs encoded on SCCmecZH47
Coding
sequence
no.
Namea Position (bp) Identity(%)b Homolog(s)
c Informationd
DR-L 754–771 Integration site sequence of SCCmec, A3G substitution
at position 16 of left direct repeat
IR-L 757–764 Integration site sequence of SCCmec; left inverted repeat
1 ZH02 1017–1322 98 CZ078 (85/2082) Hypothetical protein, predicted restriction endonuclease
domain (COG 3183)
2 ZH03 1887–2384 100 CZ077 (85/2082) Conserved hypothetical protein (COG 3680)
3 ZH04 2468–3967 100 CZ076 (85/2082) Hypothetical protein
4 ZH05 4193–5293 100 CZ075 (85/2082) Hypothetical protein; DNA polymerase A family domain
(Pfam 00476.12)
5 ZH06 5286–5657 94 CZ074 (85/2082) Hypothetical protein (DUF 1092)
6 ZH07 5654–7273 100 3 half: CG008 (85/3907) Hypothetical protein; POX_D5 domain associated with
viral DNA replication (Pfam 03288.11)100 5 half: unnamed ORF
(TSGH17)
7 ccrC 7498–9174 94 ccrC2 (TSGH17) Cassette chromosome recombinase C
89 ccrC3 (85/2082)
8 ZH09 9280–9618 98 SSP0034 (ATCC 15305) Hypothetical protein
9 ZH10 9714–10025 90 SSP0032 (ATCC 15305) Hypothetical protein, contains SmaI restriction site
10 ZH11 10041–10547 90 CZ068 (85/2082) Conserved in gram-positive and -negative bacteria but
of unknown function (COG 4333)
11 IS431 10696–11370 99 IS431 (SCCmec types I–IV) Insertion sequence IS431
12 ZH13 11628–11795 100 ORF CN041 (N315) and in
SCCmec types I–V
Putative HMG-coenzyme A-synthase (cholesterol
biosynthesis)
13 ugpQ 12712–13455 100 ugpQ (all SCCmec types) Glycerophosphoryl diester phosphodiesterase
14 ZH15 13552–13980 100 SA0037 (N315) and in SCCmec
types I–V
Hypothetical protein, MaoC-like domain (Pfam 01575.11)
15 mecA 14026–16032 100 WIS (SCCmec type V) and
TSGH17 (SCCmec type VT)
Penicillin-binding protein PBP2a
16 mecR1 16132–16958 100 mecR1 from mec complex B First 826 bp of mecR1, truncated signal transducer
MecR1 from mec complex B
DRTn4001 16951–16958 Repeated region generated by transposon integration
IRTn4001 16959–17059 Repeated region generated by transposon integration
17 IS256L 17060–18232 100 Tn4001 IS of Tn4001
18 aac 18235–18681 100 Tn4001 Putative N-acyltransferase, GNAT family
19 aac(2)–aph(6) 18682–20121 100 Tn4001 Aminoglycoside-(2)-acetyltransferase-aminoglycoside-
(6)-phosphotransferase
20 IS256R 20251–21423 100 Tn4001 IS of Tn4001
IRTn4001 21424–21524 Repeated region generated by transposon integration
DRTn4001 21525–21532 Repeated region generated by transposon integration
21 mecR1 21533–21692 100 mecR1 from mec complex B Remainder of mecR1, interrupted by Tn4001 insertion
22 ZH22 21595–21924 100 hsdR (MW2) Truncated hypothetical protein, similar to type I
restriction endonuclease
23 ZH23 21915–23438 100 IS1272 transposase from mec
complex B
aa 1–102: transposase and inactivated derivatives
(COG 3666)
aa 185–459: transposase DDE domain
24 ZH24 23574–24083 100 Various type IV SCCmecs Hypothetical protein
25 ZH25 24095–24406 100 Various type IV SCCmecs Hypothetical protein
26 ZH26 24493–24843 100 Various type IV SCCmecs Hypothetical protein
27 ccr2B 25365–26993 100 ccrB SCCmec type IVd
(JCSC4469)
Cassette chromosome recombinase B
28 ccr2A 27015–28364 100 ccrA SCCmec type IVe (AR43) Cassette chromosome recombinase A
29 ZH29 28598–30391 100 R004 (MR108) aa 1–382: superfamily II helicase and inactivated
derivatives (COG 5519)
30 ZH30 30391–30687 100 Different type IV SCCmecs Hypothetical protein
31 ZH31 30880–31926 100 Different type IV SCCmecs
(ATCC 12228)
Hypothetical protein
32 ZH32 32381–33535 100 CR008 (MR108) aa 1–122: abi alpha protein, predicted transcriptional
regulator (COG 2865)
33 ZH33 33565–34365 100 Different type IV SCCmecs and
SE0042 (ATCC 12228)
Hypothetical protein, abortive phage resistance protein
IR-R 34423–34430 Integration site sequence of SCCmec; right inverted
repeat
DR-R 34432–34449 Integration site sequence of SCCmec; right direct repeat
a ORFs of known functions are named accordingly; putative and hypothetical ORFs have been assigned ZH numbers.
b Amino acid sequence identity.
c The name of the homologous gene is indicated, and the strain in which it was found is indicated in parentheses. If homologous ORFs were unnamed, the SCCmec
type in which they were found is indicated.
d Information about the element, e.g., about the encoded protein. Positions and reference numbers of known protein domains are indicated. aa, amino acids; HMG,
3-hydroxy-3-methylglutaryl; COG, cluster of orthologous groups of proteins.
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named B2 because of its similarity to mec complex B. The new
B2 complex differed in that the 987-bp mecR1 fragment was
interrupted by insertion of the aminoglycoside resistance trans-
poson Tn4001 at base pair position 820 (Fig. 1), and while the
mecA promoter region was identical to that of mec complex B,
the mecA gene sequence was identical to that of SCCmec types
V and VT.
In addition to a ccrAB2 locus at the usual position down-
stream of mecA, the element possessed a ccrC locus between
orfX and the dru element (Fig. 1). The ccrA2 sequence was
identical to that of SCCmec type IVe, while the ccrB2 sequence
was identical to that of SCCmec type IVd. Comparison of the
ccrC sequence to published variants revealed high levels of
similarity to the ccrC2 and ccrC3 sequences of SCCmec types
VT and III, respectively (Table 1).
The element as a whole appeared mosaic in structure. The
presence of both a ccrAB2 locus and a variant ccrC locus and
of regions with strong similarity to several different SCC ele-
ments, including the typical hospital-acquired MRSA type III
SCCmec, the community-associated MRSA SCCmec types IV
and VT, and SCCmec from the non-S. aureus species Staphy-
lococcus saprophyticus, suggests that SCCmecZH47 had been
assembled via several recombination events (Fig. 1).
Most of the new SCC and SCCmec elements recently dis-
covered, including the SCCmecZH47 described here, appear to
have acquired regions from other SCC elements, suggesting
that significant intra- and interspecies exchange and recombi-
nation of SCC DNA occurs.
Nucleotide sequence accession number. The nucleotide se-
quence newly determined in this study was deposited in the
EMBL database under accession number AM292304.
This study was supported by Swiss National Science Foundation
grant NF31-105390/1.
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